var title_f26_1_26640="C ANCA";
var content_f26_1_26640=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F66748%7ENEPH%2F78968&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F66748%7ENEPH%2F78968&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    C-ANCA pattern on indirect immunofluorescence",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 243px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Demonstration of cytoplasmic antineutrophil cytoplasmic antibodies (C-ANCA) by indirect immunofluorescence with normal neutrophils. There is heavy staining in the cytoplasm while the multilobulated nuclei (clear zones) are nonreactive. These antibodies are usually directed against proteinase 3, and most patients have granulomatosis with polyangiitis (Wegener&rsquo;s).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    P-ANCA pattern on indirect immunofluorescence",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Demonstration of perinuclear antineutrophil cytoplasmic antibodies (P-ANCA) by indirect immunofluorescence with normal neutrophils. Staining is limited to the perinuclear region, and the cytoplasm is nonreactive. Among patients with vasculitis, the antibodies are usually directed against myeloperoxidase. However, a P-ANCA pattern can also be seen with autoantibodies against a number of other antigens including lactoferrin and elastase. Non-MPO P-ANCA can be seen in a variety of nonvasculitic disorders.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_1_26640=[""].join("\n");
var outline_f26_1_26640=null;
var title_f26_1_26641="Spiculated carcinoma CT";
var content_f26_1_26641=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F51731&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F51731&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Spiculated solitary pulmonary nodule",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 364px; height: 353px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Irregular border in a poorly differentiated bronchogenic carcinoma presenting as a solitary pulmonary nodule in the left lower lobe.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_1_26641=[""].join("\n");
var outline_f26_1_26641=null;
var title_f26_1_26642="Coal tar and salicylic acid: Drug information";
var content_f26_1_26642=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Coal tar and salicylic acid: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?25/36/26180?source=see_link\">",
"    see \"Coal tar and salicylic acid: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F154060\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Tarsum&reg; [OTC];",
"     </li>",
"     <li>",
"      X-Seb T&reg; Pearl [OTC];",
"     </li>",
"     <li>",
"      X-Seb T&reg; Plus [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F154061\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Sebcur/T&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F154066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Topical Skin Product",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F154062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Psoriasis:",
"     </b>",
"     Scalp:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel: Apply directly to plaques; may leave in place for up to 1 hour. Apply water and work into a lather; rinse.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Shampoo: Apply to wet hair; massage into scalp; rinse.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F154063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F154054\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel [shampoo] (Tarsum&reg;): Coal tar solution 10% [equivalent to coal tar 2%] and salicylic acid (120 mL, 240 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Shampoo, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     X-Seb T&reg; Pearl: Coal tar solution 10% [equivalent to coal tar 2%] and salicylic acid (120 mL, 240 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     X-Seb T&reg; Plus: Coal tar solution 10% [equivalent to coal tar 2%] and salicylic acid (120 mL, 240 mL) [conditioning shampoo]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F154045\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F13817651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid contact with eyes, nose, mouth, and genitals. Wash hands after each use. Discontinue if use causes irritation.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F154055\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of symptoms of seborrheal dermatitis, dandruff, and psoriasis",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F13817540\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Photosensitivity: Use is associated with increased sensitivity to UV light; avoid sunlamps or excessive sunlight exposure. Daily sunscreen use and other protective measures recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pediatrics: Children and teenagers who have or are recovering from chickenpox or flu-like symptoms should not use this product unless instructed by physician. Risk of Reye syndrome may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Self-medication (OTC use): For external use only; avoid eyes, nose, mouth, and genitals. Apply only to affected areas; do not apply to healthy skin. Do not apply to irritated, infected, or red skin; open wounds; or moles, birthmarks, or warts (genital, facial, or with hair). Talk to your healthcare provider  before applying to large area of body. Do not use this product with other forms of psoriasis therapy such as ultraviolet radiation or prescription drugs unless directed by doctor. Do not use more often or longer than recommended by your doctor; overuse may make condition worse.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299072\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6219455\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13817538\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The amount of coal tar and salicylic acid available systemically following topical application is unknown.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F13817539\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/ not recommended",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323075\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Shampoo",
"     </b>",
"     (Tarsum External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-5% (120 mL): $15.74",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F154058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Ionil-T Shampoo (SG);",
"     </li>",
"     <li>",
"      Soritas (IN)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F154057\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See Salicylic Acid monograph.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8879 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-89.32.226.102-9F539080E8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_1_26642=[""].join("\n");
var outline_f26_1_26642=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154060\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154061\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154066\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154062\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154063\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154054\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154045\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13817651\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154055\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13817540\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299072\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6219455\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13817538\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13817539\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323075\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154058\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154057\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8879\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8879|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?25/36/26180?source=related_link\">",
"      Coal tar and salicylic acid: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_1_26643="Treatment for Bennett fracture of the thumb";
var content_f26_1_26643=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F70853&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F70853&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 530px\">",
"   <div class=\"ttl\">",
"    Treatment for Bennett fracture of the thumb",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 510px; height: 360px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFoAf4DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD334leO9N+H2iW2qavbX1zDcXItUSzRGfcUd8neyjGI27+leYv+1H4MQ4bSPEgP/XC3/8Aj1W/2t4jN4A0ZF+8dXUj8LW5NYOr2vh7w18FfA93pXgjwzq3irWbXT7W0ju9Nik8+aSJWd3OATxnJLDlgSaANL/hqXwX/wBAnxJ/4Dwf/HqP+GpPBf8A0CPEn/gPB/8AHq5rxtb+FfEP7L934q0zwtoGmasy26TNZ2EcTwTC6jSQKQNyg88ZztbvXy4KAPsj/hqTwZ/0CPEn/fiD/wCPUv8Aw1H4M/6BHiT/AL8Qf/Hq+OBS0AfY3/DUfgz/AKBHiT/vxb//AB6j/hqPwZ/0CPEn/fiD/wCPV8c0GgD7G/4ak8Gf9AjxJ/34g/8Aj1H/AA1J4M/6BHiT/vxB/wDHq+NzRmgD7I/4ak8Gf9AjxJ/34g/+PUf8NSeDP+gR4k/78Qf/AB6vjgVasLCa9f8AdjbHnBcj+VAH15/w1J4L/wCgT4k/78Qf/HqP+GpfBf8A0CfEn/fi3/8Aj1fM1roECL8ybz3Lc1Zk0iErjylx9KAPpH/hqTwZ/wBAjxJ/34g/+PUf8NSeDP8AoEeJP+/EH/x6vlPUNF8sFrfg/wB09KxSCCQRgjgigD7G/wCGpPBn/QI8Sf8AfiD/AOPUn/DUngv/AKBHiT/wHg/+PV8cZooA+yB+1H4MJ40jxJ/34g/+PU//AIae8H/9AfxJ/wB+Lf8A+PV8aA1ejbcoNAH17/w094P/AOgN4k/78W//AMeq9oX7RnhTWdd03SrbSvEEc9/dRWkbywwBFeRwilsSk4ywzgGvjY10Xw3/AOSkeEf+wzZf+lCUAfeHiHxI2karYabbaNqWrXt5DNcLHZNAuyOJolYsZpYx1mTABJ6+lVf+Eo1f/oRPEn/f/Tv/AJKrlPjV/wAxH/sTNf8A/bOuM+KC6L4c8eQ6Do3gnwf5L6PJqO5/C7X0jyK7AJthK7VOB8xGB3oA9e/4SjV/+hE8Sf8Af/Tv/kqj/hKNX/6ETxJ/3/07/wCSq4HwjZaDeWnwu8SaZ4d8P6VqF/fyec+lW8Sgf6BebkDoMkblGRk4I55Fe0UAcr/wlGr/APQieJP+/wDp3/yVR/wlGr/9CJ4k/wC/+nf/ACVXVUUAcr/wlGr/APQieJP+/wDp3/yVR/wlGr/9CJ4k/wC/+nf/ACVXVUUAcr/wlGr/APQieJP+/wDp3/yVR/wlGr/9CJ4k/wC/+nf/ACVXVUUAcr/wlGr/APQieJP+/wDp3/yVR/wlGr/9CJ4k/wC/+nf/ACVXVUUAcr/wlGr/APQieJP+/wDp3/yVR/wlGr/9CJ4k/wC/+nf/ACVXVUUAcr/wlGr/APQieJP+/wDp3/yVR/wlGr/9CJ4k/wC/+nf/ACVXVUUAcr/wlGr/APQieJP+/wDp3/yVR/wlGr/9CJ4k/wC/+nf/ACVXVUUAcr/wlGr/APQieJP+/wDp3/yVR/wlGr/9CJ4k/wC/+nf/ACVUnjjxlYeEbFZbqK5u7qT/AFVpaoGkfkDPJAVQWUFiQBkVxD/EbxfLPm28L6XHEGwY59SbzAO/Kxlc/nSbSNIUZ1FeCudn/wAJRq//AEIniT/v/p3/AMlUf8JRq/8A0IniT/v/AKd/8lVJ4K8XW3iaO7i8iSy1Sxfy7yxlILRE8ghhw6MOQw4PsciujlkSGJ5JXVI0BZmY4CgdST6UyGrOzOY/4SjV/wDoRPEn/f8A07/5Ko/4SjV/+hE8Sf8Af/Tv/kquduvikbsBvDGh3Go2zf6u8uJRbQyjsyZBZl6/NtAPbNW9K+I6i+s7PxLpcmlNdsY4bpZRNbFwM7WbgoT23AA+tK5bozUeZrQ1/wDhKNX/AOhE8Sf9/wDTv/kqj/hKNX/6ETxJ/wB/9O/+Sq6qimZnK/8ACUav/wBCJ4k/7/6d/wDJVH/CUav/ANCJ4k/7/wCnf/JVdVRQByv/AAlGr/8AQieJP+/+nf8AyVR/wlGr/wDQieJP+/8Ap3/yVXVUUAcr/wAJRq//AEIniT/v/p3/AMlUf8JRq/8A0IniT/v/AKd/8lV1VFAHK/8ACUav/wBCJ4k/7/6d/wDJVH/CUav/ANCJ4k/7/wCnf/JVdVRQByv/AAlGr/8AQieJP+/+nf8AyVR/wlGr/wDQieJP+/8Ap3/yVXVUUAcr/wAJRq//AEIniT/v/p3/AMlUf8JRq/8A0IniT/v/AKd/8lV1VFAHK/8ACUav/wBCJ4k/7/6d/wDJVH/CUav/ANCJ4k/7/wCnf/JVdVRQByv/AAlGr/8AQieJP+/+nf8AyVW14e1WDXtA0zV7NZUttQtYruJZQA6pIgYBgCRnBGcE1oVyvwn/AOSWeDf+wLZf+iEoA4b9p8bvCPh8eusD/wBJLmuE03xX8Jb/AEfwE3jXWbiS98P6TFanSrnTppLbzTCqOXQwneQV4IOPlB5rvf2nOPCnh7/sMD/0kua+OvFcBa4adf4ePwoA9s8e+KfhlZfCjxhoPgXXrqebWbyG9i097SWOKF/PiZxFmJQi7U6En7oAr51FNpQaAHinUwU6gBaaaWmmgAozzSZp8EbTzJFH95jj6e9AFvS7Fr6fHIiU/MR39q7mws1ijVVXAAwAKraPYpbwqqjgfrW3GgBxQAiRjA4p4tZZIy6Quy/3gOK09FsBfahHEwLRj53AOMgdq6O6jZoLjn7Pbwjdu28BemAKAPMLxNu5XUhh1BHSuJ1TZ9ul2AD1x611/irVAZbm5QkgnbGD+QrhSSeWOWPJPvQAtFFFABVi2bgiqxp8LbXH5UAXs10Xw3/5KR4R/wCwzZf+lCVzgro/hv8A8lI8I/8AYZsv/ShKAPsD4v2095dXVrZwyz3M/g/Xo4ookLPI7GzAVQOSSSAAKpeJU8P634sg8RxX3jzS9Uhsm08PY+HbrBiZix4ks35yeox0rs9S/wCSp+Hv+wLqf/o+wrqqAPJvD1to1hJ4B8PeEtN16Ox0rUZp3e80m8gVENndgu8ksSrkySqMZ6twK9ZoooAKKKKACiiigAooooAKKKKACiiigAooooAKDRQaAPNZNMHiO38XyH/j51GSWwtpHwfLSEbY9p7KZdzfU5pNDCanpVnfImwzxhnQ9UccOp9wwYfhWj4UIWzvoFBUW2pXcIHsJSw/R6jFlqel6jePpdnBf6feSm58l7jyHtpmxvwSCGRiN2OCrZ6g8c8tWzspy5FddTD1iG40PxTZ6zp8ZeZ7Zw0a9ZhD8zxe+6Ill9GiHqa6vxRcQ623h7ToJFlsNTk+1TFTxLbxp5mPdWYxg+oJHeq8Flq1/rGm3upRWmn22nyPNFbwymeWV2Qp874CquGPABJ45FZWgwDTviCmjLjyLOyuZ7RSOVgmeM7R7K4dfpitIvSxhP3pXFtNMSx8RatpgQCJm/tG1GOkcpxIo9lkB49HFWde0Nr/AES4ihjR7mMefArrlWkXkIR3VhlCPRjWz4i0q6vJbK/0mWCLU7EuIxcAmKaNwA8TkcgHCkMM4IBwelQJfeIHUrB4ZWG4HAe5v08kH1yoLEfgD9KSWt0ae1fLysg+H2r7Ug0qaSSS2ltxd6XPKctJbnGYmPd4iQp9QVPXNdvXDXXh680/wlZGzkS41nSZWvoTGhRZGLM0kKryQrKzIB9PSuv0u+g1PTbW+tG3W9zGsqH2IyK0RzFqikdlRGd2CqoySTgAV5DqHiLX/Ft1dx6bdy6LpMRXyxAB9puo3GUmLnPlowB2hRu4OSOlNuxdODnLlR6/RXi8S+IvDdxb39v4ivZrZnEFzHqbm5hXccRyHkMgDkKxB6MDzivS/DuvNqM1xY6jaNp+sWoDTWrOHBU9JI3H30JBGeCCCCAaSdwqU3Tlys3aKKKZAUUUUAFFFFABRRRQAUUUUAFcr8J/+SWeDf8AsC2X/ohK6quV+E//ACSzwb/2BbL/ANEJQBxH7Toz4U8PD/qMj/0kua+VtZtg5dSMj+dfVf7S/wDyLHh3/sMj/wBJLmvmbUo90h4oA8yljMMrxN1Q4/CkBrX8S2pjnWdRwflb+lY9ADwaWmA06gBTSGimk0ALW74WtfMkknYcZ2L/AFrB5JAXqTgV3ug2ogtI0A6D9aANm3jAUYq0nHqKiiBxgVf061a8u44F4zksw7AdaAOn8Fwm207UdSm4WQLbQg9znLH6CqfxBvDZeGLW3XK3F45Z+eRGP8TWxeNG8FrY2/yRx42pjjnqT61xnxSuhLqcqKcpaoka+2BzQB5Tr1z5t0sQPyx8n61m5pGkMsjyN1c5pBQA8UtNFLQAGgUUlAF6JtyA103w2/5KR4R/7DNl/wClCVyVu+CQa6v4an/i5HhH/sM2X/pQlAH3RqX/ACVPw9/2BdT/APR9hXVVyupf8lT8Pf8AYF1P/wBH2FdVQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHFWKm18WeIrJjxI8OoRjGAFdPLb/AMejz+NbKdazfEqfZPF+h3wB2XUc2nyHdxuIEkfHrlGH41NqM17DbKdMskvLl2ChZJhFHGP77tgnaPRQSf1rnmveOmEvdNFe4rk/Gcbaf4o8JeIYh8kF02l3hAPMFyNqk+wmWP8AM1fi0bUrkBtU8QX2/r5WnqtrEp9BwznHqTV6fQ7W70G50i/mur21uFZXe5k3yc8g7sfwnBHoRVR0JldmyBjg9qzNR8R6Zp961nNNJLfKu77NbwPNJg9OFB/WoPCV/c3WnyW+pEHVNPlNpdnGBIygFZB7OpVvxI7U6Tw6JZ3c6zrih2LFFu9qjJzgYGQKpEMlh8SWqWjXWpxT6VBvWOI34WNpmPZVyW68YIz7VV8Kn+yNb1Tw+/ywq32+xHT9zIx3oP8Adk3fgy1a0zwxpVhffbVhkuL4DC3N3K08iD0VnJKj6Yqt42SS0t7TXrVGafSZDLIq5JktmGJlx3+XDD3QVaIZN8RAx8FasFdkUxYcqcEpuG8fiuR+NZnjK0i0i8sNeiQR2dvH9iv1ReFtmIKyYHaNsH2VnrptRtbXXtCntmcSWl9AVDoeqsvDA/jms3wjdvqnhxYdTVJLy3L2N6jAFWkT5WyO4YYb6NQwTs7jJtKgvLaa1uohNb3EbRSJ/eRhg/oetcvZfb7nw7BqlszXms+HLia1W4XpqMCHEi57llA+kiVuxeC4UtVsn1rW30xF8tLMXOxVj7JuUByoHH3s4GM10VlaW+n2kNrYwx29tCoSOKJQqoo6AAVK0LlJy3JdNvbfUtPtr2zkEltcRrLG47qRkVZrkfDeNC8RXmgk7bK5DX+ngnhQW/fRD/dYhgPR/auuqzMKKKKACiiigAooooAKKKKACuV+E/8AySzwb/2BbL/0QldVXK/Cf/klng3/ALAtl/6ISgDi/wBpX/kWfDn/AGGR/wCklzXzbqCDzDmvpP8AaV/5Frw5/wBhkf8ApJc1836jxJ8x5oA57WbUXFq6EdR+tcLyOG+8ODXpNwu5SPWuD1qDyNQfH3X+Yf1oApilzTRS0ALmkoNJmgC7o0Pn6jGMZVPmNehWabUA/GuO8KRbpZJPfANdxAuFoAtRjIHrXVeCbcST3spH3IwPw6muZgQuVCjLHoPU133hq1OmaPeNOCJbpc9Puovf86AKEEnnapE5wcOOPauC8Vyme/1BmOd0rfzruLRDFcbyTwcjPI+tcDr+VvrpD1EjfzoA8ykXy5ZF64Yimipb0bb2cf7ZqIUAOFOFNFOoAWkpaKABTg11fwxY/wDCyvCA7f21Zf8ApQlcpXUfC4/8XL8ID/qM2X/pQlAH3hqX/JU/D3/YF1P/ANH2FdVXK6l/yVPw9/2BdT/9H2FdVQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHMfEZCvhW4vEIWawkivI3IztMbhj+mR+NXSAJG2/dzkfTtS+NLT7d4Q1q2HWWzlUfXYcVT0q5F5pdjdL92e3ikH4oDWVU2pPdF9akWolqVKhFswL0/2T4wsb37trqyCxnPYTrloWPHcb0/75rqB1rJ8QaZ/bOi3ViG8uZ1DQyf885VIaN/wYA0/w1qn9s6Ja3rL5czqUnj/AOecqnbIn4MCK0Mma4pwAIIIBBGOaatOWqRLOW8MMdC1e48NTZFrtNzpbHoYcjfD9Y2PH+yy+lPgzpfjy6tzkW2r24uY+uBPFhXA9yhQ/wDATV7xXpM+pWUM2nPHFq1jILizkf7u8DBRsc7HUlT7HPYVg6xqi6z4Xj12yt5I9R0W48+W0bHmxOnE0LYz1RmxjrlSOMVRJ195cwWdtJcXc0cEEYy8kjBVUe5NYP8AwmOiyRmS2mu7pextrGaUN/ulVwfzrdR4Ly1jkQpNbyqsiEjIZTyDz+FZeo6BbX98bm5utTwVC+RFfSxRYH+ypFSUZ2tx3GtaLDqWl2lzb6pYTfabNLqPynkKghkI6hZFLLzjqD2ro9F1K31jSrXULJibe4jDrngj1BHYg5BHYg1HZWkFhZxWtonlQQrtRQScD6nmsLScaF4uuNPHyafq+67th2S5H+uQf7wxIB676Ewa6nXUUUVRIUyeaO3gkmndY4o1Lu7HAVQMkk+lPrlfHOLybQ9HYt5V/ejz0xkSQxqZGVvYkKD6g470AcpL8T9Q1Exz+G9CSTTZBvhur6cxG4XsyRqCQp6gtgkdq6Hwf43bWtWfSNV0uTS9UEBuY185ZYp4wwUmNxgkgkZBAIyK5vwpZ7tDjDqN0c9xEeP7szgfoKq6rp80viKeSxVf7R0/TEvbJsciUTnKg+jqpQjuG5rFVHfU7qlKn7O8VqexUVT0fUINV0q01C0O6C5iWZOezDOPrVytjhCuV+E//JLPBv8A2BbL/wBEJXVVyvwn/wCSWeDf+wLZf+iEoA4z9pT/AJFvw5/2GB/6SXNfN+oklzxX058fYRcaV4Yibo+rsP8AySu6+ZtTjaKaWNxhkYqR7igDNfkVyniiD92so6qefpXVsOKydWhEsLqehGKAOIpaQgqWU9VOKKAFpKDTT0NAHW+Fo9ltGc/e+b6V2EAGxa5Tw0f9FhGOdvSutt87RQBs6Eim+iDDLc4HvXostuZ4QnnRx/LjBbrXAaBbyG+t5duYt2Ce+O5r0aJNOskV7ydHlbogPX8KAMG6014F3KwbPJKmvOvF1t5OoNIVIWYBhx0PevWNQ1HShbsrvLDkcOYjgV5d4puVu7xPLkEkUS7VYHO4nqaAPKtdi8vUCccMM1QFb3iuHDRSjscH8awKAHinCminCgBaKKWgBMV03wv/AOSneD/+w1Zf+j0rmq6b4Yf8lN8H/wDYasv/AEelAH3jqX/JU/D3/YF1P/0fYV1VcrqX/JU/D3/YF1P/ANH2FdVQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFADJo1mheJ+UdSp+hrivAr7/COlJggwxG2IPX92zJ/7LXcVxXhr9zNrdi20Pa6lNhB/CkuJU/PefyrOotDSk9TeWpUqJalQZOByfSs0aslTrXPWX/Eo8Z3dp9201hDeQjsLhAFlUf7y7H/Bq6AkIRvZVJ/vMBWX4s0ufUdLV7AhNTs5Bd2Tnp5q5+U/7LAlT7NWiMpG6KctZ+halDrGk2uoWwZY503bG6oejKfcEEH3FJrOtWGiQxSajP5Zmfy4o1UvJK391EUFmP0FUiWahrkPEca6FrcXiFFAsZwtpqq4+Uxk4jmI/wBgnaT/AHWP92rDeINWnXfp3he/kj5Aa6mitySP9kktj6itvy/tun+Xf2yATxbZrdiHXkYZSehHUUyTD8DK1ppt5pLbgNLupLWPcRnyeHi/8ccD8K6ButcH4St5vD/jzUtDlYS2U9jFcWU7uDIyxsyGJ+ckorIA3ddueQa7xutJloaaxfFOmSappTJZsqajbutzZyN0SdOVz7HlT7Ma2jUbd6kq1xnh3VYta0a11CFSgmX5426xuDh0PurAg/StGuOs3Hh/xe0R+XTddcunpFeBfmHsJFG4f7St612NWnczasFcjrjN/wALA0Zcnaun3bAdgd0Qz9cV11chrn/JQdH/AOwbd/8AocVKWzHHdGYLHV9MubxdOj068srid7lFuJHhkgZzlkyqsHXOSDwRnBz1p+j6fepq8+papLbfaZ4o7Zbe1DGOGNWLffbl2Jbk4AHQDvV/VdQltZlht9Nv72Vl3ZgRRGvs0jEAH25pmmXxvJDvsr6zeN1BW7h2Z91IJDD6GuWVzsjba5b+GeB4LsUGAI3mjAHYLM4/pXUVyfwyJHhuWNuDFf3aY9P37/411lda2OKW7CuV+E//ACSzwb/2BbL/ANEJXVVyvwn/AOSWeDf+wLZf+iEpiOe+OLBLTwmzdP7ZOf8AwCuq+fvHll5F8LlB+6m4JH94V758ezjTfCx6f8Tn/wBsrqvJb5IruCa3uAXibj/dPtQB5cxODgVSuYtynPNdDqmmPYzbH+ZDykg6MP8AGs148gqetAHn2uW5hu94GFk6/Ws6ux12z863dcc9QfeuOOQSDwRwRQAE0h6GjNKoyyj1IFAHb+Hk2WsKt94Ac+tdTbHgZ61gaWu2NQPat236dc0Adh4TZvKZFTzJHfbGOmD/AId666OG30kIkSb7hgN8pHLZ9M9BXFeELtbeaQNjI5T6muw1Alyk2T867uuOnagC2LrzFZbhVliPDRyLnj+leW+L9MXS9UkjhJa2lHmxZ6gHqp+ld8ZywIVCeCS2evtXF+ObkTahAueUiyR6ZoA808VLus2I7EHNcnXX+JjizkGflI4rkKAHCnimCnCgB1LSUtAC10vww/5Kb4P/AOwzZf8Ao9K5qum+GH/JTfB//Yasv/R6UAfeGpf8lT8Pf9gXU/8A0fYV1VcrqX/JU/D3/YF1P/0fYV1VABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcfqSnTvHsMhyLfV7Qwk548+Ell/Eoz/APfNdhXM/EWI/wDCK3V9EQtzphGoQMezxfNj8RuU+zGk1dDTs7l9ASeB05rmvEFzoU96I9X8TxwW4UA6fHerCrHnJcp85z6ZA4rZvLGy1ixjivrZZ7V9swhkJxyMgHB5xnoeKrTvYeH44IrHQ5mRwQE06wVwgH97GMfjWUTaWpT0vRfBWpIPsFpol8OmVZZWz6ckmui0vSrHSI5I9NtY7aORt7LHnGcY6dvwrmr9dP1Jg994GvrluoeS2tw3578ijTbTU4/Og8OaJaeHLKRsyT3YEkrnGMrEjY/Fm/CrRncv6Kh0jxbqWmqCLPUFOpW3HCSZCzIPxKP/AMCak1e+0PSvEn2lopr7xFLCI47e3UzTJFn+FekSk8ljtBxyTimeKkfTotB1WWUzy6ddJHcTFAC8co8pzgcDllbj+7XR3yXEVtcy6ZBbPfso2iZiiuR03MATjr2NUiWY39oeKLrH2bRLOyXJBa9vNxA9dsYI/wDHqjbTPEt6Smoa7bWkB6jTbXbIfbfIWx+Az7083PjD/oG6H/4Gyf8AxuopNO8R6uDHquowaVaHhodLJaVx7zOBt/4CoP8AtUxGZqej6ZZaRdz+Ggkur6Pci9lYSmSaSUL86SucsWeMsMH1HTArsbS5hvbOC6tXD288ayxsP4lYZB/I03StNstIsY7PTLaO2tY+kaDuepJ6knuTye9YngqM2VtqelbSsenX0kUCk8iFgJEH0AfA9hUspHQmoz1qHU9QstLtXudSu4LSBBuZ5nCjH41z0E+t+IczWztomkMf3TvCGvLhf7+G+WFT2yC3chelTYq5q6/pkWs6TPYyyNEZMNHMv3oZFO5JF91YA1P4S1WXVtGSS8jEWoQO1tdxDokyHDY9jww9mFZ2n6C1ldxT/wBs61dbMjybi6DxtkY5XaM1V8P3ttH461WG0njmgvolkLRncq3MOElQkHG7aYiR7GnF9Akup2lchrn/ACULR/8AsG3f/ocVdfXIa5/yUHSP+wbd/wDocNOWxMd0XparScZx9atSdKqyd645HoQG+AG2t4ith0g1aXA9mVH/AJsa6yuP8GPs8SeJrcDjfbXH4vCAf/QK7CuyGsUefNWkwrlfhP8A8ks8G/8AYFsv/RCV1Vcr8J/+SWeDf+wLZf8AohKok5f4/HGleFz/ANRn/wBs7qvHJW+Yqo4PPWvZPj6u7S/Cw9dZP/pFdV5BcwiNnLfO+MgCgCNkWWIxTIHjPY1y2vaX9heN0bfBJnYfQjtXXxFmgBbliOmOD71Q8SoraQUOA8Th1Ht0oA86voQQeK4bXLbyLneB8r8H616JdJkH8q5fxBbeZbOMc9R9aAORqS2G65hHq4qHPFT2I3XkIH97NAHfafwo9K27c4UZrCsm+VexrYt2ymAelAF+OVosuhww716jIxn8LaddIAHbGe4ryZmwh+lesWJ8vwlZRMDkouPyoAZp8RlUgdBya8u12YTavfOeV80qMeg4r1jScLa3TDsnrXjMjF2lY9SxP60Ac14oXdYSZPTB/GuTzXYeIV3WE49q44dKAHinCmLTxQA6nCminCgArpvhh/yUzwf/ANhqy/8AR6VzNdN8MP8Akpng/wD7DVl/6PSgD7w1L/kqfh7/ALAup/8Ao+wrqq5XUv8Akqfh7/sC6n/6PsK6qgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACqWt2S6lo99YyDKXMDwkf7ykf1q7RQByfhK7e+8L6Tcy4857ZBKB2dRtYfmprZWue8MILG71zSQABZ3rSxqFwBFOPMXHrhjIPwroV71i9GdCd0SrUtQpU1UiGUfEdiupeHtSspEDie2kTb7lTj9cU7wvdSX3hvSrqcgzTWkUjkf3ioJ/WtBeornPhySvhS2tncNNZyTWsmDnaySMuPyxVIhnUGmGnmmHrTEhprmbYiw8f3sTcDVLOO4jJbq8J2OMf7rofwrpT1rmfHH+hwadrS8HS7pJZTk/wCof93L07ANu/4DSGVX8ILbaq99pJ02GQ4ZTdWJuJA2ck+aX3dfyqvNq95HPLBd+LfDNtJGxVwsPzqR2IaXg/Wu0bgkVRk0+yeRnksrVnY5ZmhQkn1JxSv3Kt2Obs7SHWxJFP4un1IKP3kOnTR26bTx83l5fHvup/iG2t9D03Sb7T7eO3t9GuEYRxIAEt3/AHcoH4Nu/wCA5roobW3t9xt7eCEsMExxqufrgVFqNnFqNhdWM4BhuongfIzwwI/rU31K5dDcrkNZ+b4haWB/Bpl0x+heICtPwReSX3hXTpbnP2lI/ImyMHzIyUfj/eU1mTsZfH+oHHy2+mQoD7vK5P6IKufwmcPiRflqtJVmSqsneuOR3xKnhuUReOr+Ef8ALzp0MxPukjp/JhXa1w2mHZ49sNuB5mn3Ct7gSREfzP513NdVJ+4jjrK02Fcr8J/+SWeDf+wLZf8AohK6quV+E/8AySzwb/2BbL/0QlaGRz3xyKiz8KFxlf7ZOR/25XdeYzXFruIEYOD1J/SvT/jgA1p4TDDcv9snI/7crqvOLl0RvkRQD0AUCgCri0l+dWCBfU8VyXia9huZvKs23RL99+zH0HtW5qkcd0NjgBO23iuY1C0e3JP3kBwT3H1oAxLhOMVh6ggINb9ycDmsO9DMSAM9+KAOA1KD7PduoGFY5FGmDN9F7ZrX1y0d18zbyvIrM0cf6auewNAHa2fAFakLHPt1rKtj0x+lakHUEGgC5HGZpUjUZLsFA+pr1XUpPIitbZcYijGfrXB+D7QXWtxM/wDqoMysfTHSunvLprieSTsTwPagDY0x82l76mI149jKE9+a9Y0Y5FwpHJjce3SvKFyFbHv/ADoAwtWG63mB6bTXEL0Fd1qn+pkP+ya4VelAD1p4pi08UAOFOFNpwoAK6b4Yf8lM8H/9hqy/9HpXNCul+GH/ACU3wf8A9hqy/wDR6UAfeGpf8lT8Pf8AYF1P/wBH2FdVXK6l/wAlT8Pf9gXU/wD0fYV1VABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHI6mv2L4gWcvSPU7GS3Y7uskLeYnHrtaT8q2171l+O4ykGkX6bQ9nqUDFiM4R28pv0krUHBIrOe5rDYkSpqiWpRQgY9a5zw6xs/F3iTTWJCytFqMKkYGJF2Pj1+aMn/gVdGK5rxrHJYi08R2cZe40skzogyZbVseavuQAHHunvVIhnVmmHrSW80dzbxTwOskMqh0dTkMpGQR+FKetMSGHrUF5bxXdtNbXKCSCZGjkU9GVhgj8jU5601utSUc34JuJv7Kl0y+ctfaTKbKVj1kUAGKT/AIFGVP1zW8e9c5rZ/sXxNZawoxZX2zT7444RiT5Ep+jEoT6OPSujbqaTKQxulRmpG6VG1QzRGZ4PPkax4lsQm1EvVuU56iWNWP8A48GqrpLefrviW7Dbla8S3X2EUSgj/vpzUlu32L4gI7HEeqWHlrz/AMtYGJxj3STP/ATVbwg6z6PNdqu37Xe3Vxj6ysB+iiqk/dM4L3xPFOr/ANkWsUgm02JpGIzfXBjUD1CqCznPGB+dYNl4ljmuohN4l8OlCcvFHDJGSO4V3bH4muuaztkvHvEt4VvXTyzcbAZMDoN3XA9OlYl1beITC0b6ppN9G3BS604qD9dr4P5Vi7WOhc17ljTHSTx1pbxuro2n3JVkYMCN8XII4Nd3Xn2nqLPxn4dSGOKKJrW6gKRKFRSPLbCqOg+U16DW1H4DCvfndwrlfhP/AMks8G/9gWy/9EJXVVyvwn/5JZ4N/wCwLZf+iErUxOd+OTbbPwoT0Gsn/wBIruvMbuZMsSTjtn1Nel/Hkkab4Wx1/tk/+kV1Xj99cuCy5G/jBx0x/OgDVt7eN4mVjuBH6/4VkatCVhOAZMHaOOop9pdz/dUqwOQcnpW1DYpc2UsSkGUjOfUigDza408RyMHO7uB2qjdQALwBiuo1G2aO48twQ6jkEYqhLZbh2FAHCalbgqwI4NcdBE1vq4jHQk4+leo6jpTMGAYZ7Vyl9os8UpuzFlU+XK8gCgC1ZAcZrWtwAOayrIfdx0rpNCtftN2oPKLyfegDrPD8A0/RXd/9ddHJ9Qop6Bfl3dQe1WbrnCgfKFC4zVeNfmPOR0xQBraOQjEbgchh6HkV5g6bWcehI/WvSbeTZhzwFH4CuA1Bdt7c46eY386AOX1o4gm9lNcKv3RXc68D9lnx/dNcMv3R9KAHrTxUa1IKAHCnCminCgB1dL8Mf+SmeD/+wzZf+j0rmq6X4Y/8lM8H/wDYasv/AEelAH3fqX/JU/D3/YF1P/0fYV1VcrqX/JU/D3/YF1P/ANH2FdVQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBzHxMDHwTqLJndH5UnH+zKjf0rWb/WP/ALxpviezOo+G9UswdrT2ssYPoSpANUPDl4NR8P6XfBi32i1ikJPXJUZ/XNRM0gaa1KKiWpR1pIbJFp4GQQeh7UxeoqRapEM5Lwwx8P6zP4YmyLQq11pTnoYc/PD9Y2PH+wy+hrrD1NZHirRn1ewjNnMLbU7SQXFlcEZEcoBGGHdGBKsO4J9qd4c1STVtME1zaS2V5G7Q3NvIP9XKv3grdGXuGHBBH0pkmketNbrTj1pp61JaKWr2FvqmmXVheLut7mMxOB1wR1HuOoPqKyPCuo3M0dxperMDrGnFY52HAnjI/dzr7OBz6MGHauiboa5fxjDJZfZ/EVlGXutMBM6L1ntD/rU9yMB1919zSKOgamNSxyRzwxywSLJDIodHU5DKRkEfUUhqGWjn/Gky2GkprTEqNHlF85HXylBWX8NjMfwqTwnAbbwrpEbD5/sqO3uzDcT+ta8iJLG8c0ayROpR42GQ6kYII9COKwPB7Nb6dPpMrl5dImNmCerRYDQt+MbKP+Amk3pYaVpXNiSq0nerMlVpO9YyOmBjamzRa74XmXjbqJjY+zwyL/PFehivOPE5ZLOymThoNSs5M+g84Kf0avR66KD905cSvfCuV+E//JLPBv8A2BbL/wBEJXVVyvwn/wCSWeDf+wLZf+iErY5zmPj423S/Cx441k9f+vK6rx6/uHJ4wSfboa9g+Pw3aV4XH/UZP/pHdV5DLFl8EEkHj/GgAtJXXGVTA56VtafPmQNt6c8dqyY1Pl/MuR3q/bYUHOfQA0AXtctYr2JZCAJVXO6uXMO5ccV1F0SthIT124rCVCBkD/8AVQBhX8HXGfwFV7Syk8rlflbkkiuhmh3KR696gMZAxyMUAcre+HQjGW3AGeSq9K2PBenB3myWEmdvpjAzWgeVx+tSWEqw3A+YIc53dPagDQmt2LKCBycfWlTTH3EhSecjFbdhqGlQx5kkWacdo0zn8TV9bxpSWtdLYRn+J3xQByd1bvFDgrnnr6Vw2rx7byX/AGjn9K9S1y6UQs93aNbKBw55X8a8y1R/PuZZezHjHoKAOS1iPdHIvqDXnoG3I9CRXp2pR5QnFecX6eXfTp/tZoAhWpBUYp4oAcKeKYKeKAFFdN8Mf+SmeD/+w1Zf+j0rmRXTfDH/AJKZ4P8A+w1Zf+j0oA+79S/5Kn4e/wCwLqf/AKPsK6quV1L/AJKn4e/7Aup/+j7CuqoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooADXC+AruFLG40TzA13pU8sMqKDiNDK/lAnpkrggdcc13VcX4KhgWLXLm3RAt3q91KXXrIQwTJ/wC+MfQCplsVDc6VKlHWokqXvUotki9RT1pi09apEMeaYetPNMPWmJDD1pppx601utSUhrd6jPXoD9aeehqNqllIytA0v+xtONik5mto5HNspGDDETkRZ7hckA+mB2q+aeelMNSy0MNc/ODZ+N7aRTiHVLJ4pBn/AJawEMhHuUdx9FFdAap3VpBcXFpPNHultHaSFs42MylT9cgkVJdrj5KrSd6syVWkrKRvA53xoSvhfUmHDKiMD6ESpg16ZXmXjf8A5FPVj6Qq35SIa9NHIBrbD7M5sV8SCuV+E/8AySzwb/2BbL/0QldVXK/Cf/klng3/ALAtl/6ISug5jmvj0M6b4WAGf+Jyf/SK6ry+SEdMZ5xjNenfH2XydM8KyD+HWufp9juq89kjAOQTg8rigDPSMB/lYjn04+lWxH0GOBSbSHG3BB65q1FGSARQAt4uNNkJz0rEHOa6C8Uf2fIo9OtYIXOOPrQA3BxTXTK9smpgD/jSFcdKAJbCwRtryKWzyo7Yp+p2EQtHfaVcHCn3qzY3kUUYjmU8cbh6VIWTUboIfls4jz6yH0HoKAKeiaQkMUd3MoNw/wA0eR/qx649a3Ud0UhmJPXJOabcTjcCOp/u0sTCRdzsNvQ4oAjmEkqsr7WQjlD0P1rz7xFpy2VwDEMQyZ2r/dPcfSvRWkDHbkAE9BXOeLrUNbTEAfKFZD/OgDzS/jyrcV5tr6bNVf8A2lBr1C+A2mvNfE2P7TGP7n9aAMoU4U0U4UAOFPFMFOFADhXTfDH/AJKZ4P8A+w1Zf+j0rmRXTfDH/kpng/8A7DVl/wCj0oA+79S/5Kn4e/7Aup/+j7CuqrldS/5Kn4e/7Aup/wDo+wrqqACiiq95e2tjF5t7cw28ecb5pAgz9TQBYornrvxr4atdvm61YsT0EUglP/juagPjnR8/u11KVOzx6dOVP0OyldDszqKK5b/hOdJ/546r/wCC2f8A+Io/4TrSP+eWq/8Agtn/APiKLoLPsdTRXNDxxoB+9dToe4ezmXH5pVJPiR4cu5DFo1xcaxOrbWj063ebYf8AabG1fxIougszsqK4mbXvEV6MWmnWmkxEffvZPPm/COM7Qfq9Z82mXl5n+1td1W6BGGjhkFrGfwjAP/jxrOVaKNY0JyO71DU7DTk36he2tqmcbp5VQfqawH+IPhdHZf7WRiDjKRSMPwIXBrCtdA0m0dnttNs1lb70jRiR29yzZOa0vnHAdsem41k8R2RvHCd2aFp468M3TlE1m1jYf89yYf8A0MCujikSWNZInV42GVZTkEexriJY/OTZMolQ/wAMgDr+R4rHkhl8L+dq2gAwwxZmvNNT/UXEY5dkXpHKFywK4DYwR3DhiLuzRNTCuKvF3PUaKitp47m3ingcSQyqHRh0ZSMg/lUtdJyBRRRQAy4kEMEkrchFLH8BXJeAoyng3SHddrzw/aXH+1Ixc/8AoVbPjGdrXwlrU6fejspmH12HFQ6NF5GkWEOMeXbRJj0wgFRMuG5eSpR1qNakFJFMkXqKetMXqKetUiGPNMPWnmmHrTEhh601qcetNapKQw9KjapD0qNqllIY3SmGnt0phqWaIYaiapTUbVDLRFJVaSrMlVZKzkbQMDxinmeFtYT1tXP5c/0r0e3YPBGw6MoP6V534r58N6tjn/RJf/QTXoFiQ1lblSCDGpBHfitsPszDFbonrlfhP/ySzwb/ANgWy/8ARCV1Vcr8J/8Aklng3/sC2X/ohK6DkOU/aE50bwx/2Gf/AGzuq4HRX+02TRt/rIzt/wAK9A/aAGdJ8Lj/AKjP/tndV5loMvlantPCyDHPqKALsgO7mrMHQE5zT72MJLwDjqPcUyH5cZ6UATXChrVwo6gg1z6rhcV0zIfKIOORmudcbZGGOQTQAgBFDDH1pegpDmgCMgCrNjIEZP4hnketVm4PtUYdo33pwQc80Ab1wD5z9MYyO2RTg4SBV7An8/U1O8Ky+TKn3Hi4+tVplKNzgc4PoKAIZZwWVcY3DmqHjGfybXG7LS/Ig/ma0IoGknwyjIPy896wPiJJjXIrZT8tvCM4/vNyaAOGvzhSK8v8QSb9XmH9wBa9L1Fsh68pvnMl/cuepkNAEQp4pi08UAOFOFNFPFAC103wx/5KZ4P/AOw1Zf8Ao9K5qul+GP8AyUzwf/2GrL/0elAH3fqX/JU/D3/YF1P/ANH2FdVXK6l/yVPw9/2BdT/9H2FdVQBk+JtZj0PSzdNC9zO7rBb20ZAeeZjhUBPAyep7AE9q5ey0ESzPqHiFbbUtYm/1kjxh4oF7RQKwwqD1xuY8nsBOZj4g8Wy3a86Zo++2tz2luiMSuPUIvyA/3mf0ra21jUl0RvSit2VYYEgXbbxpCPSNQg/So7y7t7MgXt7b2xIziedYyR9GIrOuYdU1i/lg33Wk6PCxUyROEub0/wCy3PlRe4+Zu20dbNn4c0azB+z6XZ7idxkljEsjH1LvlifxrLlXU2530Kb+KtDDlI9WjuZB/wAsrRXuH/AIDmk/tTVL5f8AiUaROkR6XOqMbZD7iMZkb8lro0yi7U+RfReB+lI64VnfhR1djgfiTRZdgu+rObOhS3x3eIdRn1Af8+cWbe0H1jU7n/4Gx+grXihSGFYYUSKFeFjjUKo+gHFVbzxFoVm2261nTo3PRPPVm/Jc1APE+lyNttE1O8Y9Ps+nTMD9GKgfrQ4tgpRiaWz2pNlZ/wDauoSgi18Napu7NdPFbp+ZYn9KPsviC6z51/YaZH6WUJnlx/vyYUH6Kank7l+17F6VViiaWVljiXlndgqj6k8CsY+IdPlkMWlpdavMDgpp8JkUEdQZDiMf99Vbj8L6Z5omvIptTuAcibUZTOQfZT8i/QLWxswgQcIowFAwAPpRyoOeT8jnC+vz/wCrsNNsV9bm5adsf7sYAB9i1J/ZWqzAi78QzoD1Wys4ofwywYmuiKe1JspWHvuc/aaFJZWsVtaa9rsVvCoSOMXCHYo6AEpnApx0Zwxki1rXo7jp5v24v/44wKfpW8UpPLJOAM0+aXcOSHYyodV8Q6O5kuCdfsBy6RxLFdxgd1UfLL7qNregPSuw0jU7PV9PhvtNuEuLWUZWRP1BHUEHgg8g8GuS1LV9O02dYLq4zdt9y1gRpp2+kagkfU4rP0O61ux1nVrix0Aw2N+Y7jF9dpC3mhdrny03EFgFOT3zmtqc39o5qlON/cOq8f8A/Ila1/16uP0q6OPyH8q4zxR4p+0+G9V0zVNPn07U5bZvJjZhJHOuQpMUi8NjcMrww9Mc12hGHYenFXLUzhpcetSCokqahDY9eop60xaetUiGPNMNPNMPWmxIYetNanHrTWqSkMPQ1G1SHoajapZSGN0php56Uw1LNEMNRtUhqNqhloikqrJVqSqslZyNoFK8gW6t57Z/uTRtEfoykH+da/w+uze+CdFmZSri2SNgf7yDYf1U1mMdrZHY5qT4bv5NrrOnZY/YtSmC5/uyYlGPb95j8K0w71aMsUtEzsK5X4T/APJLPBv/AGBbL/0QldVXK/Cf/klng3/sC2X/AKISuo4jl/j/AP8AIK8L/wDYZ/8AbO6ryPcYrpJAfuNmvXfj7/yC/C3/AGGf/bO6ryK4ALEUAdlOBcWscgPTuPSoI0XPPNN8Oy+fpojJyV+WrBTYxH4UATFd0Y4x2rnLwbbmQe9dLEuY2B9K5/Vl23IOMZFAFM9vWkz2pw5pp9aAGmoiCTzUvUUygDqdJw+kW5P8GQKgvl+UNjqeasaRxo8YHpTLyPMQYngdR60AR2ER+0RntuFcL40l87xNqT9drhfyFegaagE8JzgFs15p4gbdqt++fvTN/OgDldTbCP8ATNeVOd0jt6sT+tena022CdgeNp/lXl6/dBoActPFMWpBQAop4ptOFADq6X4Y/wDJTPB//Yasv/ShK5qul+GP/JTPB/8A2GrL/wBKEoA+79S/5Kn4e/7Aup/+j7CpPGmp3Mcdvo+kSbNX1LcqS4z9mhGPMnP+6CAPVmUetVNeuobL4j6LdXcixW8GhapJJI3RVWaxJJ+gFN8KW890bnxBqKOl9qgUpE/W2tlyYovY4Jdv9pvak3YcVdmnpun2+mafbWNjH5dtboI41JycDuT3JOST3JNWNvFS4NGKwsdCZFik21LijHtRYdyhqa3xsnGlG1W8JARroMY0GeWIXliB0GRn1FZUHhSwZ/P1kvrN8fvXF78w+iRD5EX0AH1JNdJikxQLfVlWzs7axTZZWtvbJ/dhiVB+gqcs56uxHpmnYo20rD0Itgo21LtpMUWHcixRtqXFBwFYkgBRkknAA9Se1KwcxEV9qjneOCCSaeSOKCMbnlkYKiD1JPAFYzeIJdTZovCtquoYO1r+UlLJD7P1lI9EBHqwp8HhqKaaO61+4fWbxDuXz1C28Tf9M4B8o+rbm96fL3Fz32IE12bUv+Rb09r2E8C+uXNvak/7JILyD3Vce9SHRr69OdZ1mdo+9ppw+yw/QsMyN/30AfSuhPzHJPNJgUbbBa+5n6ZptlpcBh021htY25YRJtLH1J6sfck1Z8v0qfbSbalotO2xyvjy1guNL01bkZA1ex2YOCGMwH6jIPqK7InLse5Ncd4lB1TxX4a0CDkpONYu2/55xQnEYP8AvSEAf7p9K6Hw/qY1jTFvhCYVeWWMKW3ZCSMm7Pvtz+NaJaGUndmolS1EtS1aIY9eop60xakWqRDHGmHrTzTD1piQw9aa3WnHrTW61JSGnpUTVK3SomqWUhjdKYaeelMNSzRDDUbVIajaoZaIpKqyVakqtJWcjaBVk6mo/CDiHxnrEJbH2qztrhV90Lxsf0WpJO9UdMkFt4/0ptuftVlcWxPptZJB/wCzUUXaaDEK9NnoVcr8J/8Aklng3/sC2X/ohK6quV+E/wDySzwb/wBgWy/9EJXceacx8fP+QZ4W/wCwz/7Z3VeSXAwxzXrnx7/5Bnhb/sM/+2d1Xklx9859aANPwzN5V06Z4YZrprhOcjoRmuL0+TybuJ/fFdvH88AI5x60AJAONo6YrC15NpRh64Nb0B2vjOKzfEMf+jEgcqc0Ac9SE/nSZ/Omk+tADieKY3elz8vJpYV8yZE9WAoA6q2Aj02FPYUk+PJ5OfanOSFVR2GKglYHCmgCfT8B95GVUE5rynUTvmlbrudiT+Nep7/I0u7mP8EZrymfG059KAOQ8SNs065I7Ka83X7o+leg+LXxpNyR3GK8/HSgBy08UxaeKAHCnLTRThQA6ul+GP8AyUzwf/2GrL/0elc1XS/DH/kpng//ALDVl/6UJQB9reOtIXW/iT4UtZ5StmunahLcxAf8fCLNZERn2L7CfUKR3rtipPJ5zXPawM/FHw7/ANgbU/8A0fYV0mKiWpcSLbRtqXFBFKxVyLbSbamx7UhApWC5FijFS4pMUWHcixSYqbbSbaLBcp3tzbWFpLdX08VtbRDLyysFVe3JPvxWMPEn2pd2jaRqmpL2lEQt4jzjhpSufwBqddClvNcOo65LHcx20hOn2iA+VB6SsD9+U88nhRwvOSeZ8TfFbTND1e+sToXijUhYEC7u9P04ywQcA/M5I4APOM9DQkJyOh+3eIpYyYPDtrE3/T3qQH/oCNUI8OTaowl8V3a6gAdy2EKmOzjPbKdZSPVyR6KK2PD+rWWv6LZ6rpU4nsbuMSxSYI3KfY8g+xrQxQMhVAqqqqFVRtVVGAB6AdhRtpmp31jpNjJe6reW9laR8vNcSCNF+pJArzWf4zaZqE0tt4G0HXPFU6HaZbK2KW6n/alfGPrjFLluPmR6bigiuH8Jat4+1PWYm8Q+F9N0XR2Vt6/b/tFwDj5fujb1613mKVh8xFtFQ3txBY2dxd3sqwWtvG0ssrdERRkk/hVptqqzOQqgZLE4AHck151qN5qHjueBdAgtf+EWgl3ve3pYR38qnK+XGvMkCsMkkqHYAAlQSWog5Fc6rLpGk6rrcsL/APCT69A1zBan71naRoRF5n91UB3N6u5UZNdl4G0j+wPBuiaUc77SzjjfOc7sZbr7k1zx0mCbVxosckt7M8kd9r1/PgvKF+aGA44Xc2CI14VFP97J7sHJJPU802SkSLUoqvJLHBDJNPIkUMal3kdgqqoGSST0AHesDwj450Lxdq2t2Hh66+2/2SYhNcxlWgkMgYgRsD82NhyenoTTQmbWvammjaNdalLDNPFap5kiQjLbAfmYDvgZP0FVH8QZwYIFZSMqxfIIPQjHatpkSRWSRVZGBDKwyCO4IrzjQITYx3ukMxZtKuWtUJ6mEgPD9fkYL/wGvPzKrWpQU6Tt0Zrh4wlK0ka/iHX9Vj0O/n0/ykuoIWmjUJu3FfmK8+oBH411tncJeWcFzCcxTxrKhBzkMMj+dcvDGufnG5Dww9Qeo/Kp/hzKU8NJpspH2jSpXsZB7IfkP0KFDn3qMsrVKnMqjuPEwjFrlR0p601uBkkAepOKcetcFcBh4z8QK7MVK2jqCxIH7twcDt0rsxVf6vTdS1zKlDnlynYzXtrHkPcR59Ac/wAqpW2sWd1qsunRM/2lIFuMMuA6FiuVPfBGD6ZHrWPFHntVDxBu0w2WuxAk6ZIWuFGcvavhZR/wH5X/AOAV59DMKlWolJJJnTUoKEbp6naN0php5wQCrZUjII7j1pjV6jMUMNRtUhqNqhloikqtJVmSq0nes5G0CrJ3rI1F2t9Z8OXSHaItSWJz/syo6Y/MrWvJ3rB8U5GmRSA48m+tJifQLOmf51EXaaNJq9No9SrlfhP/AMks8G/9gWy/9EJXVVyvwn/5JZ4N/wCwLZf+iEr0TyTmfj3/AMg3wt/2Gf8A2yuq8lnGGOa9a+Pf/IN8K/8AYZ/9srqvJ7j7x9KAIh6iu20eTzrVT1ytcSprqPDD77YqOqsfwoA1XO09elN1KLzrR/l6qaLhsOQfXmrCDfb9M46/SgDggeMfhQ3tU19F5N5Mnoxx+NVz15oAX6Vd0ZN94G/hQZNUVJJwBzWtpyCGMZ++/JoA03Yu+B7moM7pMk4pysMls++RUZYsc8Y6Y6UASa4/keFrzH8eF+ua8wuejY6V6P4zfytAtYRwZpM9eoArzm55U0AcH4zbGlSj1IH61wtdr40P/Eub3YfzriqAHrThTFp4oAcKcKaKcKAHV0vwx/5KZ4P/AOw1Zf8ApQlc1XS/DH/kpng//sNWX/o9KAPu3Vf+SpeHf+wNqf8A6PsK6fFczqYz8U/Dv/YG1P8A9H2FdRikxpjMUmKkxRilYdyPFGBUmKQiiwXGbaTbUmPajbRYdyPbSbakxRtpWC5HiuG8XeJ7m/uLnwv4NjjvddZfKurhubfTEYY3ynu+Puxjk9Tgc13mK851z4KfD/XNXu9U1TQPPvruQyzS/bbhd7HqcLIAPwFMGzqPBnh218J+FdM0KwZnt7GERK7/AHnPVmPuSSfxrnviP8QU8MT2mjaJZNrPi3UOLPTYj0H/AD0lP8KDB574PQAkV/El5ofwb+Hnk+HtOwWl8jTdOEjyNcXMh4UFiWIzknnoOO1S/CfwJJ4atrjWfEMgvvGOq/vdRvWOSpPPkp2CLwMDg49AAFYLmPo3wmfWr6LXPirqB8Rat9+OwGVsLT/ZSP8Aj9Mt17gnmvU7eGK1gjgtYY4YIxtSONQqqPQAcCpsUYoBEZFQX1zbWFnNd308VvawKZJZpWCoijqST0FM1rVLDQ9LuNS1e7is7G3XdJNKcBR/UnoAOSeBXCW0d54vvoNX1+3ktdKhYTaZo8y4bI5W5uR3k7pH0TgnLfdTaSuyopydkS3EVx46kV9QimtPCQIaKykBSXU/R5h1SD0jPL9WwPlPXxgIFCgKqgBQAAAB0AHp7VChJJLEknqT3qdaycrm6gokdhZW1ikq2kIjE0zzyckl5GOWYk8kn+QA6Crq1SvIpp7OeK3uWtZ3Qqk6qGMbEcMAQQcHnBr5dvfj/wCOfBXiG90PxZpWmX9xZymN3VWgdx1DAgldpGCPl6Gqirmcmon1i8MdxFJDcRpLDIpR43UMrqRggg8EEdq8x+Fum2OkfF34o2Wk2VtY2cf9l7ILaJYo0zbuThVAAyST9TXGaR+0v4T1yzk03xDoeq2ovEaB0gxOjKw2kZUq/OccLmu+8I/CP4eafdadr+heHp7S8iInt3nnukeM/wC1HI/B9mFaJWMm7npo61xWuQ/Y/HcUowI9TsSpGeskDZHH+5If++a7YVy/j8C3ttK1THFhfRmUhcnypMxP+Hzgn6VjiaftKUolQlyyTJYY+KoA/wBj+MbO7zttNXQWU/oJ0BaFv+BLvT8FrZii2kq3UHBqDxDpT6rod1a27+XdFRJbydNkyENG34MB+tcOEhyNNG9Z3R0B61w+q4Hjy9QdX023kP4SyL/Wum8O6qmtaJaagiGNpU/eRnrHIDh0PuGBH4Vz2toE8ewN/wA/Glsv18uZT/7PXTj482HkvT80ZUHaaZet484qy1ukkbRyoHjdSrqRwykYIP1GaW1TpWgIvkrhw9C8TepPU5zwVK8Nhc6NcuWutIk+zZPWSEjdC/4phfqhreaud8RQ3Gm6hDr2nxSTvCnk3ttEMvcW2c5Qd3jJLAdwWHcVtWF7a6lYw3mn3EdzazDKSxnKn/A+oPIr0oS5kYrTQlphqQ1GaGaIhkqtJVqSqsnes5G0CrJ3rnvGx2+EtXYfeWDcD6EOpFdDJ3rnvG//ACKOs/8AXt/7MtZdUbP4WeqJyik9cCuW+E//ACSzwb/2BbL/ANEJXUx/6tfoK5b4T/8AJLPBv/YFsv8A0QlemeOcz8e+NN8Lf9hn/wBsrqvJbk/OecV618ezjTPC3/YZ/wDbO6ryO5I3HPWgBqnHWuh8IyfvJk6/xVzinI+lbvhYZubg7tvygUAbV222Y4PXkVZ0+UfdY9eKzr8SeYcODjHGabbSurAEEgN1FAFPxRb+TfJKBxIMceorEJ9K7jU7ZNT09o1OJ1+ZAfWuW0u0We6H2gmKNGw5xnafpQAW8Hlx7mGW7/4VJaTHzcdiOBXQ/wDCPLdJ/wAS/VbKcnorNsaqZ8MaxauXaxkdOm6IhwR+FAFd+nGOnao4iAwLA0lyjQNtuEkiYckOpXFEJDMMHPPHv6UAV/HznztPg/55wbyPrXC3ONpz1rrvG0xk1uVf+eaKnH0rjb59uPegDz/xsMWTj/bH864uu18afNZyZ7MP51xVADlp4pi08UAOFOFNFPFAC10vwx/5KZ4P/wCw1Zf+lCVzVdL8Mf8Akpng/wD7DNl/6PSgD7u1Pj4p+Hf+wNqf/o+wrqs1ymqf8lS8O/8AYG1P/wBH2FdTmkMdmjIpuaM0XCw/ijimZozQA7FGKQGjNAhcUm2lzRmgBNtePftAfEPVPhtdeFdUsY1udOmnmhvbViB5q7UIwezDDEH8+tex5r5y/bbiVvA/h+bncmolB6YMTH/2UUDKukfEjwn43+LKeJdb1m00/wAP+H7RRpltfOI3luZVzJLsPUpjbxnkKRX0LoerWOu6XBqOk3C3VjOCYpkBCuAcZGRyMivi79nT4My+Ob9Nb8QRSxeGbd/lX7pvXB5RT12D+Jh9Bzkj7fghit4Y4YI0ihjUIiIAqqoGAAB0AHaiwrht9qwPG3iAeGtEN1HAtzfTypa2VqX2efPIcImcHA6knHABPauglkjhieWZ1jjQFmdjgKB1JPYV5da3T+JtbXxHcKyWcaNFo8LDBWJuHuSOzyDhfSP3Y1FSagrs1pQdSVkSWuiT3epRap4pvRq+qQtugjCbLOyPrDEc5Yf89Hy3pt6V0qEkkkkk8kmqkXFW464+Zyd2ehyRgrRLMdTrUEdTrWqMJEmOteC/tU/Dwa94eHinS4c6npaYuVUczW3Un6oST9C3oK9u1bUU0qxe7mguZ41YBkto/McL3YL1IA5IGTjoDU1hcWeqafHc2c0N3ZXC5SRCHSQdD/UEVcZa6GUkmrM+U/gh4T8QeEvDmm/EXStDs/EVvdCRZ7Bo8XluiyMvm25Ock4OQBkjAGc5H0/4I8Z6F420kX/h68WZVIWaF/llgb+7InVT19jjgmr+gaXaaHpNrpumRCCytk8uKMHhV9K4vxx8M49T1Y+JPB96fDvi5OReQD91dd9s6dHB7nBPrnAFa3uY2selLWR4ys/t/hHWbXvLaSgfXaSP1qh8PtR8R6hoTHxjpMWmatBM0DiCUPFcAAfvU7qpyeDzxW/qX/IMvP8Ari//AKCaaEzK0W4W902yu1+7PBHKPxUGtmJAVrmPBJx4T0Mf9OUP/oArpY5MCuKhZaGs72OZSUeHfFcsUo2aVrUgeKT+GK8xhkPp5gAI/wBoMOrDMXiMY8daKT3sLsf+PRVu6xZ22p2FxZX0SzW067JEPGR7HsQeQRyCAa8+1y9vvD+p6NPrsrXtjatJapqQGGaOVQP3wHR1Kg5HDjJGCMF15qdOUFuKCaaZ3tp2rVUjy6xrZ+ByCPUcg1fEvy1jhaiUTSrG7ILrqTmuRniTSPE+n39kvkx6jcfZL6KPhZmcHy5SvTerAAsOSG5zgV1Ny4Oa5jxAcXWhFiADq1sBnjJyeB61zSqNV48vVo0UfcdzrTUZqVlZfvKR9RUTV6bJRFJVWTvVqSq0neokaxKsneud8b/8ihrX/Xv/AOzLXRSdDXP+Ml8zw1qEA4e4Edumf7zyKo/nWPVG7+BnqUf+rX6CuW+E/wDySzwb/wBgWy/9EJXUqMKB6DFct8J/+SWeDf8AsC2X/ohK9M8cwfjZALm38Jwt0bWGH/kjd147q1tNZXDRzKR6MOjCvYvjYcW/hI88ayTx/wBeV3XE3pWe3fzlDITgqeoPtQBwyvjrjmun8ORmMFmHzSHpWVcWAt72MoCYX5U46GtzTiu9fmAY8+tAFi5Kbdynnoc1UjchlZs/QVNNIoO1VyPeqRmB659jQB0lhq00AhglhjuIjkAMMMB7GrtxpmmagN1tMbSZjuIblWP1rA09pJQG2fdHBz1rYSTBXbCTgcmgDP1Pw/e2sXmi385Af9ZD8w+pxzUVjNc2iD7Nczo3s5GPwq9qWq3Gmy2v2WSS2LNlmB4x6Grn9uQ3aldW09Js9ZYPkk+voaAIE8UatGoSSaC5Q8eXcwhvwp0Ot6ZdTxrqPh62EhIxJayGPHvimTaLY6ln+xNVh88ji2vB5b/QNWPNpepaXPnVLWWAr0bG5D/wIcUAQ6lD4H1W9uJDqur6RM7neZovNjz7YrIuvAA1BN3h/wAUaFqJz8sbzeTIfwOa564lB3sDkEk59a5/UjGwLOinA6kUAQ/ED4beN7OCQt4avbiHr5lnidcf8Byf0ryS7triyl8q9tp7aUcFJoyhH4Guu1DxRrug3yPomt6nYuecQXLqPyzitux+OfjeOBLfVbnT9ctlP+q1SyjlB+pAB/WgDzJSD0IP0qQV6gfiB4H1fcPE3wzsI3Y5a40a6a2YH1CdP1p66T8IdZcfYvEviLw3K44j1K0FxGp9Mpzj6mgDy4U4V6mvwan1JA/hLxl4V14E8RLd+RMf+AN0/OsHWvhV460VmOoeF9RMSnBktlFwv1yhNAHF10vwx/5KZ4P/AOw1Zf8ApQlYl3ZtaymOffBIP4J4zGw/AgVvfDSJ0+Jfg8kfL/bNlyOR/wAfCUAfdOrf8lS8O/8AYG1P/wBH2FdPk1y+sf8AJUfDv/YG1P8A9H2FdLn3qWUh+aM03PvRupDsPzRmmbqXNO4WH5ozTM0Z96LisPopmaWi4WH5rifit4CtviJpekaXqMzRafa6kl7cqhw0qLFIuxT2yXXJ9M45xXZ0ZouFiLTbK20zT7ex0+CO3tLeMRRRRrhUUDAAFWM03JrkdQvbrxRfT6Roc8lvpsDmPUdSiOGyOsEB/v8AZn/g6D5vusRgfEHWzrOLCNXHhSK6Ftq98v3ZHzxAD/zz34WRx0zt/vEaSZDEMACOMYxj2rsodI0+DRhpMVpCumiHyPswX5PLIwVx6Yrz61t5tD1Q6BfO8gRDJp1y/W4gHVGPeSPgHuVw3rXLiYN2kjswdWMbwfU2oqtR1Uiq3H1rCJ1TLMdTr1qCOpsEqwDMpIIDLjKn1GeOK3RzSM3UZjJchUPEXAI9e5rHfSrm1u5dR8PTx2eoSndPFICba8P/AE1Ufdb0kX5vXcOKia9utCkWPxP5Qty21NWhG2Byenmr1hY+pyh7EdK6iGKvHUK0a7qS0b/r5mjlCUOVDPD+vwarLLaSRSWWq26hp7GYjegPR1I4dD2dePXByK3RWFqmhWerRRC8ibzYSWguInMc0DHujjlf5HuDVeO08TWhVINZsbyJeB9usyJCO2542Az77R9K9qFVNXlocUlY6kVW1VgmlXrN0WByf++TXnOga/rPiVbx5tei0eeC8ntGsreOJjGYm2k7pOWBxuzgcEVrawviaz0i8K3sOr2z20ivG8CwzAFT88bKdrEddpAz2NEcTBycddPLQTg7FvwflPC2iq3BFlDn/vgVvLJxXMeEdQgv/Dmm3Fr/AKowIm3+6VG0j8CP5VuCQ15cKri2mdThdKxYlfNZGsWkGpWE9ldAmCddjEdR3DD3BAP4VceTNVZXycDrWNet1RpCF9DnPh9qEyW97oWoH/iYaPJ5JH96E8xsP9nsPwFdiJeOtef+InXQ/Geia3MRDBcRPYXTsdvyfeVj64PfoADXSa/rVtoGjXWp6hIqwW8ZkAJ5lIHCqP4iTjp60lWbtJfa/PYnlSun0MzxL4g1F9Z/sLwxFayaoIhJPcXKs0VopPBYDGTjnGe4Hc4q23gyMXP23WdX1TWNR2lfOmkECKD1VI48BFPoDn3NaHw+0a4stHa71RT/AGvqTfa7vPVC3Kp+APPuTXTSxcVpUUvsO3n/AMEUEt5HE31pH4atjqmiBrU2rK08AldoriEsA6urE4IBLBhggjuCRXfSrtdlHIB4Ncr4qtxL4d1eI5AezmXj/cNdFYymfTrKZuslvE5/FAa2y+pKUZRm72f5jqJKSt1HSVWk71ZkqtJ3rtkOJVk71ia2onutDs3GVudVgz9I90n/ALJW5J3rLG2Txl4agcZAluJx9VhIH/odRDWaNKrtTZ6NXK/Cf/klng3/ALAtl/6ISuqrlfhP/wAks8G/9gWy/wDRCV6B5Rz/AMbyRbeEyOo1k/8ApFd1wYnAcBuRnBHT867v44f8enhP/sMn/wBIruvNZ95c7eD3I9KALEkRYMu4EsePZu2Kj0z5J8YPoR71Z3b7PeeBgE+3vTzHtuklUcMDu+tAFW6DAEc4z0pltbtNcKhwF6sT6Vdltw+CT90544zUljZsbhSCVU9fcUAX7KKGLaSxPoMcVrRuAuV4xzweapTCOL5STu7HHahGwgwQc8cdqALVw6XhEMy7gehxyK5+cS2N00BXcg5Cnpj1Bq9HMTqEa8tg9jnH41H4rnSK6t1I5UZPrQBzc+pWUpzMhwOMD7w5q0nj3UNNtxDpLN5X8S3X7xSPTBrm9TURXkuDlW+dfoayppB2oA6y71vwjrYK69o02jXTHm80k5Qn1MZ7fnWRqnw8u9RtXm8G6vp3iOEZJhikEVyo942rmbqT5C2e+K5vUJjFMbiKR4Z0GVkjYoy/QjmgDjfGFpfafrkltqtldWNxGNpiuYyjfkaxRXpGk/GTxIlqLHxHHY+KdJ5/0bWIRKyj/Zk+8D75NW/J+Ffi1v8AR59S8Dak+fkm/wBMsS3oG++v48CgDy8U8V6Drvwe8V6dZHUdLhtvEWkYyL3RphcKR15UfMPyrz9lMcrRyKySqcMjghgfQg0AJsQ9VGfUcV0vh3xl4k0CQHSvEOrWkYGNkdyxT/vk5H6VzgpwoA9hsvjj4pliWHWU0TX4AMeVqVipz+K4/lV/QPFnhjXfFXhxI/AVlpGtvrWnmK+0+5IiU/aoi2Y8AYK7h35IrxCun+GMj/8ACyfCK7jtOs2Qwf8Ar4SgD7o1nj4o+Hf+wNqf/o+xrpMiua1v/kp/h3/sD6n/AOj7GugzUS3NIrQlyKOKjzRmlcdiWkqPdS7qLhYkzRmmbvejd70XCw/NGaaGpc+1FwsOzS5pm6kd1RGeRgqKCzMegA6mgVjn/E97dXl3F4d0eV4r+7TzLi5TrZ22cM+f77cqg9ct0Wui0uwtdL0+3sdPgSC0t0CRxoOFA/z1rB8BRNc2N3rk8ZSfWJvtChhgrABthX/vgBvqxrqKtEMKyPE+hw6/phtpJHgnjcTW1zH9+3lX7rr9OhHQgkHg1r0UxHnejXstwbi2v4lt9Vs2Ed3AvQE/dkT1jfGVPblTyDWzHVrxR4dGqtFe2Ews9ZtlIgutu5WU9Y5F/jjPcdR1BB5rD0nVRcXZ0+/h/s/WUH7yykfJb/biY/6yM9iOR0IBrjnS5XdbHdTr86tLc246nWoEyCQcgjsanWmgkSFVdHR1VkcFWVhkMD1BHcVzR0688MMZdCgkvNFHMmlqcyW3q1tnqvcxH/gJH3T0y96lFXZPRmUkM0W/stVsY7zT7iO4tpPuyJ6jggg8gg8EHkHrVicAdK5zUdGuLa/l1fw40UOoSYNzayHbBfAf3sfckx0kH0YEdOe8T/Fvwr4d0aS71a8eC8QmNtMZf9KWQdU2f+zH5Twc80pq0bIzW+pN448F6Jq+k6zL/YlncapcQSMkmz53l28HrjPAqhpXinXtH03RrHV/DBs7KOOO1E8d4s0pdVAH7pR3xwu4k9BzgHhPhT8Utb+JPj/UGES2Hh+xtSUtU+ZndmAUyP3OA/AwPr1r1DxZtfw7qIYZAiDD2IZSD9Qea8ytiJUp+yl1t+JvGmpR50cf4e1uHRLy6nWG5i8PaheuFd4zstn7HPudwZewA5JDAekLKCoYEFSAwIOQQehB7isvw3YQX/hWK3uohLBMJVdDxn96/fsQeQR0PNc5qNlqfg7TdRk+2Xv9iW8Dzi4tbeOaSFFBZ8IzLsfGcFdyE87VPWKlF1G3HRrTXr5+vfuVGfItdUaviDxBcRX8ekaBAt5rEmdxb/VWyjGS59eRx2yM9QDXPhfWr0E6r4mvEB6x2I8sfTPT8QK0PAukR2enrdGNUnvEWXaHL+XGfmVNx5Y/NuZjyzsT6Y7NLb5M4pwpc2lP77b/AH7CcrayPPrHwhbadO0trf6mLllKefcSpcsAeCP3ing9xwDWR4H0LTtTvLi9u7dZW02YaekJZvIimi/1pRCSApYjCj5R2Fek3EP7xR/tD+dcX8L8NoupzqMC41vUZB7jz2XP/jtY89WF4SlpoW4xbTSO/t03deTUlxFhaWzI4zUt2wI4r0owj7O5g2+Y4zxlI8Og3iQLvublfskCf3pZTsX/ANCyfYGuhggW0tYLZDuWCJYg3qFAGf0rEvwLnxhodq2QkEc+oEY4ZlAjQfUeYxrfapwtNQi5d/0NG7v0IpKrSVZkqtJ3reRpErS96z7EA+PtEzzi2uyPb/VVfk6VnWrFPHnh9sZDxXcZPp8qN/7Kaml8aLrfw2eiVyvwn/5JZ4N/7Atl/wCiErqq5X4T/wDJLPBv/YFsv/RCV3nlnP8AxwGbTwoP+oyf/SK7rzyVVYgYAPQHHevRPjd/x7eEv+wyf/SK7rgXJDkdMHuKAGwJm3eM5O4VPZsrxrFIcOo6U+3wFLEZxS3doJV3wsY5V5VloAsBVVfmIBHX2qS3mX7yrnnbxxVK1XzEKyEmYcnnP4VIjtE33QcHpjtQBtPGGiD84HBqrcI6RfKSoznJqOLVJEyGtiynqRkUk2o2zLuCyKPT/wCsaAKMFwkNwGeQ8HPJ5+tYOuX5udQkm5wcKuewHpU2sXsJuGaCZS20ZQjGK5a6uzKwUE7e59aAHahc+ZIMchRjPrWZIdzE9hUszcGq8j4BJoAz7+TjaDwK5LX5ilncMP7pFdHeHqR2rkPE740+Uepx+tAHIqMKBThRilFAGnoOt6r4fvBd6FqV3p1yP47aUpn6gcEexr0WL4tJrcS2/wAR/C+leJo8bftiILW8UY6iRBz+leVCnigD1RfB3gHxW2fBXi99Gvn+7pniJNgJx0WZeP5msXxV8MvFHhaPfrOi3KWwAIvLb/SIGHruXOPxxXELt3AsquAehGRXZeEfiH4k8KlV0HW7u0hBybWQ+bAf+ANkD8MUAcp9mYqWiZZF9VNdB8Mo3HxL8IEqQBrVlnP/AF8JXe/8Jx4M8U8+O/ByWt4euq+HW8mT6tGeD+v0qLT9I8P6b8QvBE3hbxGNcs7rWLMlXgMU1ti5j+WQep+g6UAfVuvHHxO8Of8AYH1L/wBH2Nb+6uf8QHHxO8Of9gfUv/R1jW6DWU9zaC0JA1ANMzRmpuXYkzRmo8j1pc+9FxWH5ozTM+9GaLhYkzQGpmaM07isSbqyPFtlcar4evNNtQCb0C2lbft2QuQJWB65CbsY5zitPNLmi4WOc0fWNQ0HTY9P1nR9SuFtP3MV7aRidJ4wcIxVTvDbcZBXrmtH/hNtCHDXNyrDqrWc4IPofkrSB9KeJGx95vzqucjkMlvGVjKQumWeqai5zxb2bgA+hZwqj8TTF1TxLdEeRolpZIRnN9e5cf8AAI1b/wBCrZLk9WJ+tJmnzhyGMh8WO58y90KJf9i2mc/q4qnqvh3UNXQR6tqlheQqdyxy6WCEPqp8zcp9wc10uaXNLmY+RHGWvhrxNp7n7D4ntZrYfdtr6zebb7CTzN4HsS1TTT+MrLZnRNG1Rf4jaX727/gsikZ/4FXW5pc0tOw9V1OPn8babpwT/hIbXU9CLYG6/tiYgx7edHuT8yK6m0nhu7aO5tZop7eQbklicOjD1DDg15tqHxr0SymuTPofik6RBKYZtWXS2NmuDtJL5zjP+z3FdOvhTSpANS8NTy6NcTqJRPpzBYpgRkF4TmNweOcZ9xRZC5manie01i90W4t/DupQaZqLjCXM1t54T6LuAz7nIHoa+FfjB4J8Q6B4tvk1nVU8QagIBe3lxbmSRoI2YKplyPkySuBk4BHqK+tfG/xFv/h94euJPEdhDdXz5j06eyBEN5KfuoyE7o27kcjAOD2qz8Mvh/FpvhLUD4o8rU9b8RqZtYnbDCTeD+6BH8CgkDHGSSOMYpaEy1PIf2R7CKHwprd+HX7RcXaxsmfmCIvykj0Jdxn2NezeJSW0K7jHLz7IE/3ndQPw71J4W+GOl+H/AAvpmk2lzcxXOnmYQ6hAwSYrJIzlW6hh8w4II4yMVleJdBvJtb0rSdV1VbywYvdSxwwiB3RMACTacEEsF4A6sfSvGxeDl7b27fu7vudVOsuT2aWp13geIf8ACOafyCHjMgI6YZiw/nS+OdMfVfCeuabbnE13YzwR/wC8yED9auWcqxxqqKqqoACqMAAdAB2FOuLjBDDkjmtnWj7O/Un2bvY5rwHqcWp+EtEvouFms4sj+6yqFYfgVIrr0uMJgV5VoE8vhm71vS/sd3cWME5vLZotoSOOUlirMzBUGc47cMOtWpdS8ReKB9n0NP7D0onbNqsjCSdx3W3UfLnt5hJA7ZNYUZTp3a+Ho/IqVmkupt+JvGujaLeC1mu459UPKWUJ3yZ/28ZEa56s2MVlfDKNbPwvHZedHO9tczh5Im3K5dzIGB7gh8g1ueHfDtjoNp9n0mAwhsGSUsWlmb1d+rH9K5q5UeFPHNy7/utF1mJZyeiW9yp2s2Oytld2OhIY8ZIyqL2kZOKff7vL53Kj7rVz0O3kwBT5pcrWdHKV4PBHalkm4pxxPuWKdLUx9ffZqnh+5T/WpqUcO7/YlVkcfQ/L+IFdMegrlNWP2jVtAtVPMmoLMRjqkKNI367Pzrq29+tdeBk5Urvu/wBCJq0iKSq0nerMlVZO9dEjSBWk71j6hKbXWvDl3kKkeorFI3oJY3QfmxUVsSd6xPE9vLdaFfR2wzcqgmgGM/vYyHT8crj8azUuWSZrKPNBo9OrlfhP/wAks8G/9gWy/wDRCVvaRfw6ppdpf2zboLmJZkPswzWD8J/+SWeDf+wLZf8AohK9I8gwPjaM2/hIE4/4nJ/9IruuBnG1iMdK9B+NHMXhHr/yGT0Gf+XG7rhLlCCw9eooAbBKMHedrdAO1D3awvgtnuQKhhwSN2Q3UAe1RvGu+TIPPb1zQAPefZ7tbheYnOD7VuxyRMitGyfielcrMBmRFUsh7djj0qtGzkLyRkcrk44NAHYvfWsQJaXew5wvNUbnVAeEiB7fMAeKyYgSoHQfzqGZgM5zwOaAM3VLSKUvOihHPJ2/dP4Vhn73Paul/wCWhDE7cgHPpXOXLK1xM0Q+Qsdv0oAhk+Zh371VnPBOanc+gqpP93g0AZd0fkb1rjfFTD7IF9WFdddE+XnPeuM8VH91GP8AboA56nLTaetADhTxTRThQAopRRQKAHKSvKsQfauu+G12ZPiJ4RjZcE6zY8+v+kR1yGK6X4Zf8lM8If8AYZsv/ShKAPuTxEcfE3w5/wBgjUv/AEdY1t5rD8Sf8lM8Of8AYI1L/wBHWNbGawqPU6KS90kzS5qLNLmouaWJM0ZqPNLup3FYkzRmo91LuouFh+aXdUe6jNFwsSZpc1HuozRcViTNGaZmjNO4WJM+9GajzS5ouFiTNANR5pc0XFYkzS5rC0KaaXVvEqSSyOkN8iRKxyEXyIyQPQZJP41shuab0EtTyj43xX2oeEbzW9O8T2TeGLe1LXWklF8rUdrEsouUYOpYfKFXgkDPU16V4auor3w7pV1BbG0hntIpUtyMGFWQEJ+GcfhXHD4O/D4awNU/4Ri0N2H8zBeQxbv+uW7Z+G3Fd+vGMD8BTbQkn1PO7Hwhqes/FK88T+LUgNjpebbQrNWEiBSBuuGH985xgjjHspO3daHqGgyyX3gwqUZvMn0SeTbbz+phY/6iQ+3yE9QM7h1MriJd0xEa+rkKPzNMimimYrDLFI3XCSKx/IGmmxNIb4a1u08QaVHfWQlRSzRywTLslglU4eORf4WU8EfiMgg1S8X6Pc3v2PUNKWNtSsmbbHI+xZ4m4eItzjOAQcHDKPeubu5JvDfj/UdSsopZrO9tYbnUbWJCzfKTGZ1Ucl1ATIHLKOhKjPfaZf2mp2cd3p1zDdWsgyksThlP4inKEakXGS0Zndxd0cR/bMtplb/R9btmHBxaGdf++oywNI2uGZd0Ola7Ih+6y6c4z+eP1r0OmknNcLyyla3M7fL/ACNliZnkmkafJqPirVrvXbRUktjEkFnMVk8ncm5WYDKltv1ALNiu5hGSCTk+9ZXim3uNH1efW4YHuNMuIkS+WFS0sDJkLMFHLrtJDAcgAEZ5FWrC8hubaO4tpY57eQbkliYMjj1BHBrz8RD2NWzXu9PQ6KTUo6bm1CgNM1jQ7HWtOa01GISRE7lIOGRsY3Kw5BwT+BIOQagiucdDU4u8DrXbRr04oxnTkzhG8NeK/DwWLQ9Rs9Y09PlS21EmOSMdgJB2H+QKikfx3INg0XQ7Yn/lpJfM+33C45+hru5LnPeqc04PWuXESoN83KjSnGe1zltHFxoWsW9z4gRby4vCLMakk5It9x+WPyioCIzADcvfbnNdw3BrifG8iv4bu7YDfcXgFvaxKMtLMSCqqPXjOewBJxiu3mOXPOfU+/eunBVnVpvS1gnDklZEElVpO9WZKqyV0SNIFaTvVWQ4OR1HIqzL3qpKQM5xWEjpgWPhxcizudU0BuI7d/tdmP8Ap3lJO0f7sm8fTbV74T/8ks8G/wDYFsv/AEQlZOiWJn8T6ZexNIjWwlR2VflkjdD8jH03BGHuPetb4T/8ks8G/wDYFsv/AEQld9CfNBHl4mnyVGjE+M3+r8I4OD/bDc/9uN3Xn9y29SpzkdG9D9K7341ttg8JEdtZP/pDd15tNKd7/wC9j61sYDo5GVwjevf+dEr7InLN84Pb+VUhKAwBAIJwRRI24tkHrsweQfxoAapO9SQ3Qdf8KVFH2iRT0GG/OiJSCRyQDndkDP8A9eliBfVoRzh0wQKALQQKi554yKqyBWcjcwxjgjtWjOpKblz6moIrdWO4LnJ6E0AZesSeXpp2HDSnbx1x9a5grjPucV1viiJUsoipxh+B6+tcq464oAqsxGRVaQZ3c1O3OcVBcAgc0AY9wfkPsTXF+KT8sIP9+u1uuFP1rivFYOYP940AYIpwpKctAD1pwpFp1AAKUUAU4CgArpPhn/yUvwh/2GbL/wBKErnK6T4Z/wDJSvCH/Yasv/ShKAPt7xQcfEvw3/2CNS/9HWNawesbxacfEnw2f+oTqX/o6xrQD1y1XaR2UI3gWt/0oDVWD04NUcxryFgNS7qr76XfRcXKTgj1pc1X30oencOUnzS5qDfS76Li5SbNGai3+9G+ncXKSg0uai3+tQ39/aabB5+pXdvZw/37iURg/TPWi4mrblzdRurBh8QLenGjabqepg5xJFB5MRI7eZJtH5ZqwqeKbnb5OmaXYKRy13dNO6n/AHUAU/8AfVWoyZDnFGvurI8XX09h4bvZrGQpfuFhtNq7i0zsFQAHqSTS/wBleLv+grof/guf/wCO1Ul8KeIb3UrS9v8AxBY5tMtbwQ6d+7jkII83Bc5cAkDPA54yapQZDqLoZdxcsJ9XezkdTeeIra3g2EgymNYhMB7DZJk9MKa7diCxI6Z4rmLHwDe2L2DQeIpAbGGSG33Wcbbd5y789XPdvQn1rVTwvqEgK3vijVJEPaFIYD+apn8jTcGyVNI0jkLuPCf3jwPzrkbi+i1nXdRtZtbFpp2nutuYLe8SB55tu5y7Z3BVyqhQRk7ic8V0SeCdC3rJd2j38oGC99M85b6hiR+lNm8AeEJ3LzeF9Ekc9WayjJP44pqFhOpc5x9E8NICY7XSZCepknSUn672Oa53xBpOirAfLtNKQ/8ATIxofzUg/rXoi/D7wcv3fC2iD6WUf+FS/wDCD+Fdu3/hHNHx6fY4/wDCj2eu5tTxKg9YnE/BOS71K61K6nuGubTTQdMtbhnMhmXcJCC56+WTszk5xzyK7e/8J2M11Je6bJPpOovy1xYts3n/AG05R/8AgQNbdna29jaxW1nBFb28Q2pFEoVUHoAOBU1aGFSSnJyStc5Fta1bw7lfFEAu9PHTVbGI4Qf9Nohkp/vLuX12101rcwXltHc2k0c9vKu5JYmDKw9QRwRViuR1DQLrRZ5NS8IKiFmMlzpTNtguvUp2ilP94cE/eHcBB1JrmNQ8H6dNcSXWnNPpF9IdzT2DBA59XjOUf8Rn3rZ0bU7bWdLttQsixgnXcA4wynoVYdmBBBHqKttWcoqS5ZK6LT7HINoHiCI/uNesZkHa5075j+KOP5VG9j4qThY9Am9/Nnj/AEwa7E1ExrleDoP7P5mqqS7nIGz8UscGDQI1/vG4nf8ATaKX+wdcnz9q1+3tlP8ADYWI3D/gchb+VdcI3boppwtHb7xC/rSWCop/B+Y/avqznNL8O2WnXv23zLq8v9hQXV5L5jop6hBwqA99oGa02rTWzjH3izfjipkhjT7qKPeuhUrKy0RPtUjF8qST/Vxs30FKul3En3iiD3Oa3aKr2K6h7eXQyI9Di/5bSu/svyirUOmWcOCluhI7sNx/WrtFUqcVsiHVnLdiAADAAAHYVy3wn/5JZ4N/7Atl/wCiErqq5X4T/wDJLPBv/YFsv/RCVZmYPxr/ANR4S6/8hlun/Xjd15fIc3E47qa9R+NQJh8JAf8AQZP/AKRXdeX2KebdXzt9wvwPWgCKCORhvAwuc59PpU7WxOeTknPTj8Ktxpgj2H69qmRMlgfbNAGb9nKkPhdwIzz+pqXTod+pq5+6kbMfxq1dhVidsgAL19BUekhnjnuCPvHaPagCxchcYPT2qGMKGIUnkjqMUshO7jp9cU0Fw5yAcH06UAYvi2Us1vH0wC2Kx47CSW3WQMqq33RWlrCte6wIU7AA47etaVzbrHAkKcBVAoA4a5haGUhvwI6VXufnH0rpru2Em5WGC3oOh9a5uVWQlWHzKSCKAMS7GFP1ri/FY4iJ/vV296MBsVxnitf3EZ9HFAHN09abThQBItKKRaUUAOFOFIKUUALXSfDP/kpXhD/sNWX/AKUJXN4rpPhp/wAlK8If9hqy/wDShKAPtfxkcfEbw1/2CtS/9HWNZs3izTILhopnlQLKIixX72c4ZQDll46gY71f8cNt+Inhk/8AUK1L/wBHWVNit7SLcY7S2TPJ2xKM/wCcmuGvJKZ6WGi3T0K0XirSjLHBLewpdPj92hLDJ5A3YxkjnFOs/E+nX11bW9lOJJJ9pw6lNuc4U5/j4+51xzVwW8KxbRawJGc4/dKBz36dazRNoOliFHm0uCSFQiNJJGHAHTnrnqc9ayUkbOLJn8VaVEzCed4UywR3T5ZdrbTtxk9QeoGcEitGw1O01AziynWYQOEdk5UkjgqejDryPSsSPX9Aikk8ie33u29zDbO25um4lUOTyefepbXWdMjUrZQzgMdxWDT5gCfXAQVdn0RF4rdo6HfSb6xjq/HGma43+7psv9QKF1aRvu6J4hJ99PI/m1CjPsJzguptb/el31kJfXr/AOr8P643+9DGn83qSJfEV0dtp4fW1GcGTULxVA9wsYYn8SKpQm+hLq011NQPkgDknpVDU9bsdMlSC6nzeP8A6u0hUy3En+7GuW/PA9xU9v4T1O8Odc1t1iIwbbTENsh9mkJMhH0K10Oi6FpeiRMmlWMFtu++yL87n1Zjyx9yTWsaL+0YTxC+yczb6d4h1ogyH/hHtPPZSst7IPrykX4bj7itzSvCWiaZKJ4LCOS7xzdXGZpm9SXfJ/Wt2it1FR2OaUnLVhRRRVEhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHOaNY3OmeI9XgSFjpl4RfQyD7qTN8sqdc8kB/T5mrf8snqakopWHcj8pe+TTwoHQAUtFFhXCiiimAUUUUAFFFFABRRRQAVyvwn/5JZ4N/7Atl/wCiErqq5X4T/wDJLPBv/YFsv/RCUAT+OfCVt4vsLK2ur6+sTaXP2qKayMYcN5ckZB3o4IKyN29K5OH4PWkIIj8VeJVB6j/Q/wD5HoooAf8A8Kjt/wDobPEn5WX/AMjUv/CpYP8AobfEv5WX/wAjUUUANm+ENtMmyTxX4lK+mLIf+29LH8JLeNAieLPEgUdBiy/+RqKKAA/CS3Oc+LPEnPtZf/I1IfhFbHr4r8SflZf/ACNRRQBDF8GbCKV5Y/FHiQSOcs3+hkn/AMl6lk+EFrIMP4r8Sn8LL/5HoooAhPwW08g58UeJOf8Arz/+R6rTfAjR5pC8niTxIWPJO60H/tvRRQBXk/Z88Pyff8QeJD/20tf/AIxVK7/Zp8KXa7bjWvEjrnP+uth/KCiigCt/wy14L/6C3iT/AMCIP/jNH/DLfgv/AKC/iT/wIg/+M0UUAL/wy54M/wCgv4k/7/wf/GaP+GXfBv8A0F/En/f+3/8AjNFFAC/8Mu+Df+gv4k/7/wBv/wDGaP8Ahl7wd/0GPEn/AH/t/wD4zRRQAv8Awy/4O/6DHiT/AL/2/wD8Zq9oP7OPhPRdd03VbbVPEElxYXUV3Eks0BRnjcOobEQOMqM4IoooA9E8WeEY/EWo6ffDVtS0y6sopoEey8k70lMZYMJY3HWJMYx3rKb4fXBjZP8AhNfEyg/xIlirD6MLbIooqXCL1aLVSSVkzKb4O2ckjPc+KvEl0zHJN19jn/LfbnH4Vp2fw4Fkqi08TatCF6eXYaYuP/JSiimklsS23uaQ8LasOnjvxJ/3407/AORaX/hF9X/6HvxJ/wB+NO/+RaKKYg/4RfV/+h78Sf8AfjTv/kWj/hF9X/6HvxJ/3407/wCRaKKAD/hF9X/6HvxJ/wB+NO/+RaP+EX1f/oe/En/fjTv/AJFoooAP+EX1f/oe/En/AH407/5Fo/4RfV/+h78Sf9+NO/8AkWiigA/4RfV/+h78Sf8AfjTv/kWj/hF9X/6HvxJ/3407/wCRaKKAD/hF9X/6HvxJ/wB+NO/+RaP+EX1f/oe/En/fjTv/AJFoooAP+EX1f/oe/En/AH407/5Fo/4RfV/+h78Sf9+NO/8AkWiigA/4RfV/+h78Sf8AfjTv/kWj/hF9X/6HvxJ/3407/wCRaKKAD/hF9X/6HvxJ/wB+NO/+RaP+EX1f/oe/En/fjTv/AJFoooAP+EX1f/oe/En/AH407/5Fo/4RfV/+h78Sf9+NO/8AkWiigA/4RfV/+h78Sf8AfjTv/kWj/hF9X/6HvxJ/3407/wCRaKKAD/hF9X/6HvxJ/wB+NO/+RaP+EX1f/oe/En/fjTv/AJFoooAP+EX1f/oe/En/AH407/5Fo/4RfV/+h78Sf9+NO/8AkWiigA/4RfV/+h78Sf8AfjTv/kWj/hF9X/6HvxJ/3407/wCRaKKAD/hF9X/6HvxJ/wB+NO/+RaP+EX1f/oe/En/fjTv/AJFoooAP+EX1f/oe/En/AH407/5Fo/4RfV/+h78Sf9+NO/8AkWiigA/4RfV/+h78Sf8AfjTv/kWj/hF9X/6HvxJ/3407/wCRaKKAD/hF9X/6HvxJ/wB+NO/+RaP+EX1f/oe/En/fjTv/AJFoooAP+EX1f/oe/En/AH407/5Fra8PaVBoOgaZpFm0r22n2sVpE0pBdkjQKCxAAzgDOAKKKAP/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A Bennett fracture of the thumb is an oblique, intra-articular fracture of the thumb metacarpal base. The fracture is reduced by longitudinal traction, pronation of the thumb (rotate counter-clockwise), and pressure on the dorsal metacarpal base. This is an unstable fracture pattern that requires fixation after reduction of the fracture.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_1_26643=[""].join("\n");
var outline_f26_1_26643=null;
var title_f26_1_26644="BAC lung CT histo";
var content_f26_1_26644=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F81088&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F81088&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Adenocarcinoma in situ",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 358px; height: 531px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) CT from a 75-year-old man showing a 2.5 cm, ground-glass nodule in the left upper lobe that was an adenocarcinoma in situ (formerly&nbsp;bronchioloalveolar carcinoma) at resection. B) Histology. Adenocarcinoma in situ (mucinous type) growing on a normal alveolar wall.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Henry D. Tazelaar MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_1_26644=[""].join("\n");
var outline_f26_1_26644=null;
var title_f26_1_26645="M mode LA aorta";
var content_f26_1_26645=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F51366&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F51366&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    M mode echocardiogram",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 248px; height: 306px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    M mode echocardiogram obtained from the parasternal long axis view at the level of the aortic valve (AoV) and left atrium (LA). The AoV leaflets are seen to open and close within the aortic root (Ao).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_1_26645=[""].join("\n");
var outline_f26_1_26645=null;
var title_f26_1_26646="Cisatracurium: Drug information";
var content_f26_1_26646=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cisatracurium: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?33/60/34755?source=see_link\">",
"    see \"Cisatracurium: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/29/44501?source=see_link\">",
"    see \"Cisatracurium: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F152161\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Nimbex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F152162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Nimbex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F152194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Neuromuscular Blocker Agent, Nondepolarizing",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F152166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Neuromuscular blockade: I.V. (not to be used I.M.):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Operating room administration:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Intubating dose:",
"     </i>",
"     0.15-0.2 mg/kg as components of propofol/nitrous oxide/oxygen induction-intubation technique. (",
"     <b>",
"      Note:",
"     </b>",
"     May produce generally good or excellent conditions for tracheal intubation in 1.5-2 minutes with clinically effective duration of action during propofol anesthesia of 55-61 minutes.) Initial dose after succinylcholine for intubation: 0.1 mg/kg; maintenance dose: 0.03 mg/kg 40-60 minutes after initial dose, then at ~20-minute intervals based on clinical criteria.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Continuous infusion:",
"     </i>",
"     After an initial bolus, a diluted solution can be given by continuous infusion for maintenance of neuromuscular blockade during extended surgery; adjust the rate of administration according to the patient's response as determined by peripheral nerve stimulation. An initial infusion rate of 3 mcg/kg/minute may be required to rapidly counteract the spontaneous recovery of neuromuscular function; thereafter, a rate of 1-2 mcg/kg/minute should be adequate to maintain continuous neuromuscular block in the 89% to 99% range in most pediatric and adult patients. Consider reduction of the infusion rate by 30% to 40% when administering during stable isoflurane, enflurane, sevoflurane, or desflurane anesthesia. Spontaneous recovery from neuromuscular blockade following discontinuation of infusion of cisatracurium may be expected to proceed at a rate comparable to that following single bolus administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Intensive care unit administration:",
"     </b>",
"     Follow the principles for infusion in the operating room. At initial signs of recovery from bolus dose, begin the infusion at a dose of 3 mcg/kg/minute and adjust rates accordingly; dosage ranges of 0.5-10 mcg/kg/minute have been reported. If patient is allowed to recover from neuromuscular blockade, readministration of a bolus dose may be necessary to quickly re-establish neuromuscular block prior to reinstituting the infusion.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F152182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/29/44501?source=see_link\">",
"      see \"Cisatracurium: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Neuromuscular blockade: I.V. (not to be used I.M.):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Operating room administration:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants 1-23 months:",
"     <i>",
"      Intubating dose:",
"     </i>",
"     0.15 mg/kg over 5-10 seconds",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 2-12 years:",
"     <i>",
"      Intubating dose:",
"     </i>",
"     0.1-0.15 mg/kg over 5-15 seconds (",
"     <b>",
"      Note:",
"     </b>",
"     When given during stable opioid/nitrous oxide/oxygen anesthesia, 0.1 mg/kg produces maximum neuromuscular block in an average of 2.8 minutes and clinically effective block for 28 minutes.)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;2 years:",
"     <i>",
"      Continuous infusion:",
"     </i>",
"     Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Intensive care unit administration:",
"     </b>",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F152167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F152168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Because slower times to onset of complete neuromuscular block were observed in renal dysfunction patients, extending the interval between the administration of cisatracurium and intubation attempt may be required to achieve adequate intubation conditions.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15682669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F152143\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 2 mg/mL (5 mL, 10 mL); 10 mg/mL (20 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nimbex&reg;: 2 mg/mL (5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nimbex&reg;: 2 mg/mL (10 mL) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nimbex&reg;: 10 mg/mL (20 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F152129\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F152146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer I.V. only; the use of a peripheral nerve stimulator will permit the most advantageous use of cisatracurium, minimize the possibility of overdosage or underdosage and assist in the evaluation of recovery",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Give undiluted as a bolus injection; not for I.M. injection, too much tissue irritation; continuous administration requires the use of an infusion pump",
"    </p>",
"   </div>",
"   <div class=\"block uica drugH1Div\" id=\"F14471321\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     100 mg in 250 mL (total volume) (concentration: 400",
"     <b>",
"      mcg",
"     </b>",
"     /mL) of  D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F152201\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in D",
"     <sub>",
"      5",
"     </sub>",
"     LR.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Alfentanil, amikacin, aztreonam, bumetanide, buprenorphine, butorphanol, calcium gluconate, chlorpromazine, cimetidine, ciprofloxacin, clindamycin, dexamethasone sodium phosphate, dexmedetomidine, digoxin, diphenhydramine, dobutamine, dopamine, doxycycline, droperidol, drotrecogin alfa, enalaprilat, epinephrine, esmolol, famotidine, fenoldopam, fentanyl, fluconazole, gentamicin, haloperidol, hetastarch in lactate electrolyte injection (Hextend&reg;), hydrocortisone sodium succinate, hydromorphone, hydroxyzine, imipenem/cilastatin, inamrinone, isoproterenol, ketorolac, lidocaine, linezolid, lorazepam, magnesium sulfate, mannitol, meperidine, metoclopramide, metronidazole, midazolam, minocycline, morphine, nalbuphine, nitroglycerin, norepinephrine, ondansetron, palonosetron, phenylephrine, potassium chloride, procainamide, prochlorperazine edisylate, promethazine, ranitidine, remifentanil, sufentanil, theophylline, tobramycin, vancomycin, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B cholesteryl sulfate complex, micafungin.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Acyclovir, aminophylline, amphotericin B, ampicillin, ampicillin/sulbactam, cefazolin, cefotaxime, cefotetan, cefoxitin, ceftazidime, ceftriaxone, cefuroxime, diazepam, furosemide, ganciclovir, heparin, methylprednisolone sodium succinate, nitroprusside, piperacillin, piperacillin/tazobactam, propofol, sodium bicarbonate, sulfamethoxazole/trimethoprim,  thiopental, ticarcillin/clavulanate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Ceftriaxone.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F152144\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunct to general anesthesia to facilitate endotracheal intubation and to relax skeletal muscles during surgery; to facilitate mechanical ventilation in ICU patients; does not relieve pain or produce sedation",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F152203\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Nimbex&reg; may be confused with NovoLOG&reg;, Revex&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       United States Pharmacopeia (USP) 2006: The Interdisciplinary Safe Medication Use Expert Committee of the USP has recommended the following:",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"       - Hospitals, clinics, and other practice sites should institute special safeguards in the storage, labeling, and use of these agents and should include these safeguards in staff orientation and competency training.",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"       - Healthcare professionals should be on high alert (especially vigilant) whenever a neuromuscular-blocking agent (NMBA) is stocked, ordered, prepared, or administered.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F152193\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     &lt;1%: Effects are minimal and transient, bradycardia and hypotension, flushing, pruritus, rash, bronchospasm, acute quadriplegic myopathy syndrome (prolonged use), myositis ossificans (prolonged use)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F152149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to cisatracurium besylate or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F152133\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concern related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bradycardia: May be more common with cisatracurium than with other neuromuscular-blocking agents since it has no clinically-significant effects on heart rate to counteract the bradycardia produced by anesthetics.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuromuscular cross-sensitivity: Cross-sensitivity with other neuromuscular-blocking agents may occur; use extreme caution in patients with previous anaphylactic reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Burn injury: Resistance may occur in burn patients (&gt;30% of body) for period of 5-70 days postinjury.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Conditions which may antagonize neuromuscular blockade: Alkalosis, hypercalcemia, demyelinating lesions, peripheral neuropathies, denervation, infection, muscle trauma, and diabetes mellitus may result in antagonism of neuromuscular blockade.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Conditions which may potentiate neuromuscular blockade: Electrolyte abnormalities, severe hyponatremia, severe hypocalcemia, severe hypokalemia, hypermagnesemia, neuromuscular diseases, acidosis, acute intermittent porphyria, Eaton-Lambert syndrome, myasthenia gravis, renal failure, and hepatic failure may result in potentiation of neuromuscular blockade.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly, effects and duration are more variable.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immobilized patients: Resistance may occur in patients who are immobilized.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Benzyl alcohol: Some dosage forms may contain benzyl alcohol which has been associated with &ldquo;gasping syndrome&rdquo; in neonates.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Maintenance of an adequate airway and respiratory support is critical.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced personnel: Should be administered by adequately trained individuals familiar with its use.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299048\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F152137\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors: May diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: May enhance the respiratory depressant effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capreomycin: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Neuromuscular-Blocking Agents may enhance the arrhythmogenic effect of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colistimethate: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Neuromuscular-Blocking Agents (Nondepolarizing) may enhance the adverse neuromuscular effect of Corticosteroids (Systemic). Increased muscle weakness, possibly progressing to polyneuropathies and myopathies, may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Inhalational Anesthetics: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May enhance the adverse/toxic effect of Neuromuscular-Blocking Agents (Nondepolarizing). Specifically, episodes of apnea have been reported in patients using this combination.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May enhance the adverse/toxic effect of Neuromuscular-Blocking Agents (Nondepolarizing). Specifically, episodes of apnea have been reported in patients using this combination.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lincosamide Antibiotics: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Loop Diuretics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Salts: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: Neuromuscular-Blocking Agents may enhance the neuromuscular-blocking effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Polymyxin B: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Procainamide: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: Neuromuscular-Blocking Agents may enhance the neuromuscular-blocking effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Spironolactone: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vancomycin: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F152139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13494843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F152171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323070\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Cisatracurium Besylate Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg/mL (5 mL): $16.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/mL (20 mL): $312.56",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Nimbex Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg/mL (5 mL): $18.81",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/mL (20 mL): $356.40",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F152141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vital signs (heart rate, blood pressure, respiratory rate)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F152152\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Nimbex (AE, AR, AT, AU, BB, BE, BH, BM, BS, BZ, CH, CL, CN, CR, CY, CZ, DE, DK, DO, EC, EG, ES, FI, FR, GB, GR, GT, GY, HK, HN, IE, IL, IQ, IR, IT, JM, JO, KW, LB, LU, LY, MX, MY, NI, NL, NO, OM, PA, PE, PL, PR, PT, QA, RU, SA, SE, SR, SV, SY, TH, TR, TT, TW, YE);",
"     </li>",
"     <li>",
"      Nimbium (BR, CO)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F152132\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blocks neural transmission at the myoneural junction by binding with cholinergic receptor sites",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F152148\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: I.V.: 2-3 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect: 3-5 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Recovery begins in 20-35 minutes when anesthesia is balanced; recovery is attained in 90% of patients in 25-93 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Undergoes rapid nonenzymatic degradation in the bloodstream (Hofmann elimination) to laudanosine and inactive metabolites; laudanosine may cause CNS stimulation (association not established in humans) and has less accumulation with prolonged use than atracurium due to lower requirements for clinical effect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 22-29 minutes",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Belmont MR, Lien CA, Quessy S, et al, &ldquo;The Clinical Neuromuscular Pharmacology of 51W89 in Patients Receiving Nitrous Oxide/Opioid/Barbiturate Anesthesia,&rdquo;",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 1995, 82(5):1139-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/1/26646/abstract-text/7741288/pubmed\" id=\"7741288\" target=\"_blank\">",
"        7741288",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Breslin DS, Jiao K, Habib AS, et al, &ldquo;Pharmacodynamic Interactions Between Cisatracurium and Rocuronium,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2004, 98(1):107-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/1/26646/abstract-text/14693597/pubmed\" id=\"14693597\" target=\"_blank\">",
"        14693597",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dellinger RP, Levy MM, Carlet JM, et al, &ldquo;Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2008,&rdquo;",
"      <i>",
"       Intensive Care Med",
"      </i>",
"      , 2008, 34(1):17-60. Available at",
"      <a href=\"file://www.ncbi.nlm.nih.gov/pmc/articles/PMC2249616/pdf/134_2007_Article_934.pdf\" target=\"_blank\">",
"       file://www.ncbi.nlm.nih.gov/pmc/articles/PMC2249616/pdf/134_2007_Article_934.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/1/26646/abstract-text/18058085/pubmed\" id=\"18058085\" target=\"_blank\">",
"        18058085",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dellinger RP, Levy MM, Rhodes A, et al, &ldquo;Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2013, 41(2):580-637.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/1/26646/abstract-text/23353941/pubmed\" id=\"23353941\" target=\"_blank\">",
"        23353941",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Konstadt SN, Reich DL, Stanley TE 3d, et al, &ldquo;A Two Center Comparison of the Cardiovascular Effects of Cisatracurium (Nimbex&reg;) and Vecuronium in Patients With Coronary Artery Disease,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 1995, 81(5):1010-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/1/26646/abstract-text/7486039/pubmed\" id=\"7486039\" target=\"_blank\">",
"        7486039",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lien CA, Belmont MR, Abalos A, et al, &ldquo;The Cardiovascular Effects and Histamine-Releasing Properties of 51W89 in Patients Receiving Nitrous Oxide/Opioid/Barbiturate Anesthesia,&rdquo;",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 1995, 82(5):1131-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/1/26646/abstract-text/7537945/pubmed\" id=\"7537945\" target=\"_blank\">",
"        7537945",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Murray MJ, Cowen J, DeBlock H, et al, &ldquo;Clinical Practice Guidelines for Sustained Neuromuscular Blockade in the Adult Critically Ill Patient. Task Force of the American College of Critical Care Medicine (ACCM) of the Society of Critical Care Medicine (SCCM), American Society of Health-System Pharmacists, American College of Chest Physicians,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2002, 30(1):142-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/1/26646/abstract-text/11902255/pubmed\" id=\"11902255\" target=\"_blank\">",
"        11902255",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prielipp RC, Coursin DB, Scuderi PE, et al, &ldquo;Comparison of the Infusion Requirements and Recovery Profiles of Vecuronium and Cisatracurium 51W89 in Intensive Care Unit Patients,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 1995, 81(1):3-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/1/26646/abstract-text/7598277/pubmed\" id=\"7598277\" target=\"_blank\">",
"        7598277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sorooshian SS, Stafford MA, Eastwood NB, et al, &ldquo;Pharmacokinetics and Pharmacodynamics of Cisatracurium in Young and Elderly Adult Patients,&rdquo;",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 1996, 84(5):1083-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/1/26646/abstract-text/8624002/pubmed\" id=\"8624002\" target=\"_blank\">",
"        8624002",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Xu QA, Zhang YP, Trissel LA, et al, &ldquo;Stability of Cisatracurium Besylate in Vials, Syringes, and Infusion Admixtures,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 1998, 55(10) :1037-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/1/26646/abstract-text/9606456 /pubmed\" id=\"9606456 \" target=\"_blank\">",
"        9606456",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9270 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-13CD9D8202-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_1_26646=[""].join("\n");
var outline_f26_1_26646=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152161\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152162\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152194\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152166\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152182\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152167\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152168\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682669\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152143\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152129\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152146\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14471321\">",
"      Usual Infusion Concentrations: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152201\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152144\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152203\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152193\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152149\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152133\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299048\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152137\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152139\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13494843\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152171\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323070\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152141\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152152\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152132\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152148\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9270\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9270|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?33/60/34755?source=related_link\">",
"      Cisatracurium: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/29/44501?source=related_link\">",
"      Cisatracurium: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_1_26647="Anti-tumor necrosis factor therapy in ulcerative colitis";
var content_f26_1_26647=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Anti-tumor necrosis factor therapy in ulcerative colitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/1/26647/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/1/26647/contributors\">",
"     Yousif I A-Rahim, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/1/26647/contributors\">",
"     Richard J Farrell, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/1/26647/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/1/26647/contributors\">",
"     Paul Rutgeerts, MD, PhD, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/1/26647/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/1/26647/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/1/26647/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tumor necrosis factor-alpha (TNF-a) has a central role in the pathogenesis of mucosal inflammation in Crohn's disease. Therapy with the chimeric monoclonal antibody to TNF (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    ) has profoundly changed the management of refractory luminal and fistulizing Crohn's disease. Over two-thirds of patients with Crohn's disease treated with infliximab show response to the drug whereas one-third achieve remission, and maintenance therapy has been approved on account of its glucocorticoid-sparing efficacy in refractory luminal and fistulizing Crohn's disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/4/44105?source=see_link\">",
"     \"Infliximab in Crohn's disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy in Crohn's disease provided the rationale for clinical trials of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    (and other anti-TNF agents) in patients with ulcerative colitis, a disorder in which TNF may also have an important role. TNF-a is expressed at high levels in the colonic mucosa of patients with ulcerative colitis (UC) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26647/abstract/1\">",
"     1",
"    </a>",
"    ]. There is also an increased production of TNF-a by colonic lamina propria mononuclear cells and high concentrations of TNF-a in stools, rectal dialysates, and urine of patients with UC [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26647/abstract/2-5\">",
"     2-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic review will focus on experience with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    (and other anti-TNF agents) in the management of ulcerative colitis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26647/abstract/6\">",
"     6",
"    </a>",
"    ]. An approach to the management of ulcerative colitis is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3319?source=see_link\">",
"     \"Management of severe ulcerative colitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL TRIALS OF INFLIXIMAB",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several open-label clinical trials evaluated the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    in ulcerative colitis (UC) and provided the rational for subsequent controlled trials [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26647/abstract/7-13\">",
"     7-13",
"    </a>",
"    ]. At least five placebo-controlled trials of infliximab in active UC have been reported as abstracts or in final form [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26647/abstract/14-17\">",
"     14-17",
"    </a>",
"    ]. A meta-analysis examined the role of infliximab in UC [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26647/abstract/18\">",
"     18",
"    </a>",
"    ]. Failure to achieve remission was less likely in patients treated with infliximab compared with placebo (43 versus 70 percent; RR 0.72). The meta-analysis estimated that in order to achieve one remission, four patients would need to be treated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     ACT 1 and ACT 2 trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two largest trials (ACT 1 and ACT 2, each with 364 patients) focused on patients with active ulcerative colitis treated with glucocorticoids",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <span class=\"nowrap\">",
"     6-mercaptopurine/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"      azathioprine",
"     </a>",
"    </span>",
"    (ACT 1) or with ulcerative colitis refractory to at least one standard therapy including 5-ASA, glucocorticoids, or immunosuppressants (ACT 2) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26647/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    at a dose of 5 or 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    or placebo at week 0, 2, and 6 and every eight weeks through week 22 (in ACT 2) or week 46 (in ACT 1). Patients were followed through week 30 in ACT 2 and week 54 in ACT 1. The following were the major findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In ACT 1, the rate of clinical response (defined as a decrease in the Mayo score (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?8/46/8929?source=see_link\">",
"       calculator 1",
"      </a>",
"      ) of at least 3 points and at least 30 percent) at week 8 was significantly higher in both",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      groups compared with placebo (69 and 61 versus 37 percent in the 5",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      and placebo groups, respectively).",
"     </li>",
"     <li>",
"      The clinical response rates were also greater with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      therapy in ACT 2 at week 8 (64 and 69 versus 29 percent, in the 5",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      and placebo groups, respectively).",
"     </li>",
"     <li>",
"      In both studies, patients who received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      were more likely to have a clinical response at week 30.",
"     </li>",
"     <li>",
"      In ACT 1, a significantly higher proportion of patients who received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      had a clinical response at week 54 compared with placebo (45 and 44 versus 20 percent in the 5",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      and placebo groups, respectively).",
"     </li>",
"     <li>",
"      The rate of clinical remission (defined as a total Mayo score of 2 points or lower with no individual subscore exceeding 1 point) was significantly higher in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      groups at all time points examined. In ACT I, clinical remission was observed at week 54 in approximately 34 percent of the two infliximab groups compared with 17 percent in placebo. In ACT II, clinical remission at week 30 was observed in 26 and 36 percent of the infliximab groups compared with 11 percent in placebo.",
"     </li>",
"     <li>",
"      Endoscopic healing, defined as an endoscopic Mayo subscore of 0 or 1 at weeks 8 and 30 and at week 54 in ACT 1 (55 and 57 versus 22 percent in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      and placebo groups), was present significantly more often in the infliximab groups compared with placebo.",
"     </li>",
"     <li>",
"      The proportion of serious adverse events was similar to placebo in the two",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      groups in both studies (ranging from 9 to 26 percent). In ACT 1, a similar proportion of patients receiving infliximab or placebo discontinued treatment because of an adverse event while in ACT 2, more patients in the placebo group than the two infliximab groups discontinued treatment.",
"     </li>",
"     <li>",
"      Patients with moderately to severely active colitis treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      in ACT 1 and ACT 2 were significantly less likely to undergo colectomy through 54 weeks than those receiving placebo (10 versus 17 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/1/26647/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Other controlled trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;At least three earlier controlled trials showed variable results, although the largest (n = 42) was substantially smaller than the two ACT trials described above [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26647/abstract/9,14-16\">",
"     9,14-16",
"    </a>",
"    ]. A fourth trial included 45 hospitalized patients with moderate to severe ulcerative colitis unresponsive to conventional treatment including high-dose glucocorticoids who were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    (4 to 5",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    or placebo four to seven days (depending upon the severity of colitis) after the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/5/44120?source=see_link\">",
"     betamethasone",
"    </a>",
"    4 mg IV twice daily at day 0 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26647/abstract/20\">",
"     20",
"    </a>",
"    ]. A colectomy was required significantly less often in the infliximab group within three months after randomization (30 versus 66 percent). Three patients in the placebo group required surgery for septic complications. There were no serious adverse events related to infliximab. During three years of follow-up, an additional seven patients underwent colectomy, five in the infliximab group and two in the placebo group [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26647/abstract/21\">",
"     21",
"    </a>",
"    ]. Overall, 12 of 24 patients (50 percent) in the infliximab group and 16 of 21 patients (76 percent) in the placebo group underwent colectomy. None of the eight patients who were in endoscopic remission at three months later required colectomy, whereas seven of 14 patients who were not in remission at three months required colectomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Cyclosporine versus infliximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;No studies directly compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    infusions for glucocorticoid-resistant UC. It is worth noting that most intravenous cyclosporine trials report 60 to 85 percent response rates in glucocorticoid-resistant UC [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26647/abstract/22-24\">",
"     22-24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A potential concern in using the drugs in tandem is the risk of adverse events from immunosuppression. One study found significantly increased surgical morbidity following colectomy in patients with refractory ulcerative colitis treated with cyclosporin after failure of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    compared with infliximab alone [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26647/abstract/25\">",
"     25",
"    </a>",
"    ]. However, there were only five patients in the combination group.",
"   </p>",
"   <p>",
"    Another study described 19 patients with glucocorticoid-refractory ulcerative colitis who received either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    after failed",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    or cyclosporine after failed infliximab [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26647/abstract/26\">",
"     26",
"    </a>",
"    ]. Overall, 30 to 40 percent of patients achieved remission. However, remission was generally of only limited duration and there were several serious adverse events including a death from sepsis. The authors concluded that the risk of serious events may outweigh the benefits of salvage therapy. Results from a study from Germany evaluating the efficacy of infliximab-salvage therapy in 24 patients with refractory UC or indeterminate colitis failing to respond to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    (a calcineurin inhibitor related to cyclosporine) highlight this poor risk-benefit ratio on anti-TNF salvage therapy. The study reported a 25 percent remission rate compared with a 33 percent significant adverse event rate including two infectious complications (herpes zoster and herpes pneumonia) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26647/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ADALIMUMAB AND ULCERATIVE COLITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;An open-label study of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    in 20 patients with ulcerative colitis (UC) included 13 patients with prior loss of response or intolerance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26647/abstract/28\">",
"     28",
"    </a>",
"    ]. Seven patients had dose escalation of adalimumab between weeks 8 and 16, from 40 mg every other week to 40 mg weekly, due to incomplete response. At weeks 8 and 24, the rates of clinical response were 25 and 50 percent, respectively, and the rates of clinical remission were 5 and 20 percent, respectively. The rate of mucosal healing was 30 percent at week 8. The rates of clinical response and remission and mucosal healing were similar in infliximab-na&iuml;ve and previously exposed patients. Adalimumab was well tolerated and none of the patients experienced hypersensitivity reactions during treatment with adalimumab. The authors concluded that adalimumab appeared to be of clinical benefit for patients with UC, including those who have previously lost their response to or cannot tolerate infliximab.",
"   </p>",
"   <p>",
"    In another open-label study including 13 patients,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    was well tolerated and effective in maintaining clinical remission in a subgroup of UC patients who had lost response or intolerance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26647/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a multicenter, randomized, double blind, placebo-controlled study (ULTRA 1), anti-tumor necrosis factor (anti-TNF) na&iuml;ve patients with moderately to severely active ulcerative colitis failing glucocorticoids",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    immunosuppression were randomized to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    <span class=\"nowrap\">",
"     160/80",
"    </span>",
"    mg (160 mg at week 0, 80 mg at week 2, 40 mg at weeks 4 and 6), adalimumab",
"    <span class=\"nowrap\">",
"     80/40",
"    </span>",
"    mg (80 mg at week 0, 40 mg at weeks 2, 4, and 6) or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26647/abstract/30\">",
"     30",
"    </a>",
"    ]. At week 8, more patients in the higher dose adalimumab group were in remission compared with patients the placebo groups (19 versus 9 percent), while patients in the lower dose adalimumab group had similar remission rates compared to placebo (10 versus 9 percent). However, higher than expected response rates were seen in placebo patients for several secondary end points, including clinical response and mucosal healing.",
"   </p>",
"   <p>",
"    The Ulcerative Colitis Long Term Remission and maintenance with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     Adalimumab",
"    </a>",
"    2 (ULTRA 2) trial evaluated the efficacy of adalimumab in induction and maintenance of clinical remission in 494 patients with moderate to severe ulcerative colitis who did not have an adequate response to conventional therapy with steroids or immunosuppressants or anti-TNF [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26647/abstract/31\">",
"     31",
"    </a>",
"    ]. Patients were randomly assigned to adalimumab (160 mg at week 0, 80 mg at week 2, and then 40 mg every other week) or placebo. In this study, adalimumab was safe and more effective than placebo in inducing remission (17 versus 9 percent at week 8) and maintaining clinical remission (17 and 9 percent at week 52). The efficacy of adalimumab was lower in patients who had already been treated with other anti-TNF agents, especially",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    , than in patients who were na&iuml;ve to anti-TNF.",
"   </p>",
"   <p>",
"    It was based on these two randomized controlled trials that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    was approved by the US Food and Drug Administration (FDA) for use in the treatment of patients with moderate to severe ulcerative colitis refractory to steroids and",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"      azathioprine",
"     </a>",
"     /6-mercaptopurine",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26647/abstract/32\">",
"     32",
"    </a>",
"    ]. The recommended initial dose of adalimumab is 160 milligrams followed by a second dose two weeks later of 80 mg, and a maintenance dose of 40 mg every other week, thereafter. The US FDA also recommends that adalimumab be continued only in patients who have shown evidence of clinical remission by eight weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3948324\">",
"    <span class=\"h1\">",
"     GOLIMUMAB AND ULCERATIVE COLITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another monoclonal antibody against TNF,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35206?source=see_link\">",
"     golimumab",
"    </a>",
"    , has also been shown to be effective in refractory ulcerative colitis in phase",
"    <span class=\"nowrap\">",
"     2/3",
"    </span>",
"    studies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26647/abstract/33\">",
"     33",
"    </a>",
"    ]. Further studies are needed before golimumab can be used in patients with refractory ulcerative colitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     REFRACTORY POUCHITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proctocolectomy with ileal pouch-anal anastomosis (IPAA) is the favored alternative to proctocolectomy with permanent ileostomy for the surgical treatment of ulcerative colitis (UC) and familial adenomatous polyposis (FAP). It preserves intestinal continuity and sphincter function and removes the entire colorectal mucosa. This procedure consists of total abdominal colectomy, stripping of the rectal mucosa with preservation of the anal sphincter, and the construction of an ileal pouch that is anastomosed to the anus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/63/32759?source=see_link\">",
"     \"Pouchitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most frequently observed long-term complication of IPAA is acute",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chronic inflammation of the ileal reservoir, called pouchitis. Refractory pouchitis develops in a very small percentage of patients with chronic pouchitis and approximately 3 to 5 percent of patients may lose their pouch.",
"   </p>",
"   <p>",
"    There is limited experience with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    in chronic pouchitis, although a benefit has been suggested in case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26647/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. Controlled studies with longer follow-up and careful exclusion of Crohn's disease are needed before this treatment can be recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PEDIATRIC EXPERIENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of short- or long-term therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    in children with ulcerative colitis (UC) remains undefined. Short-term improvement was seen in 14 of 17 children with moderate to severe UC in a case series [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26647/abstract/37\">",
"     37",
"    </a>",
"    ]. Sustained improvement was observed in 10 of 16 patients who were followed-up for more than nine months. In another report, the need for subsequent surgery did not appear to be lower in those with an initial response to treatment compared with nonresponders [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26647/abstract/38\">",
"     38",
"    </a>",
"    ]. In a third series of 12 children, treatment was associated with a significant decrease in glucocorticoid requirements [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26647/abstract/39\">",
"     39",
"    </a>",
"    ]. Eight patients were considered to have a long-term response during a median follow-up of 10 months. Another report found that infliximab was more effective in acutely ill children with UC compared with those who were chronically steroid dependent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26647/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SAFETY",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, adverse events including fatalities have been described with use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    in ulcerative colitis (UC). The total number of patients with UC who have been treated is relatively small compared to the experience with infliximab for Crohn's disease and rheumatoid arthritis. Thus, precise estimates of the types of adverse events and their frequency are not available. However, adverse events seen with use of infliximab for Crohn's disease and rheumatoid arthritis are also likely to occur with treatment of UC. Many patients eligible for infliximab are on high dose glucocorticoids, making infectious complications a particular concern. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40825?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/4/44105?source=see_link\">",
"     \"Infliximab in Crohn's disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24169?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors and mycobacterial infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A detailed discussion of the adverse events seen following treatment with anti-TNF-alpha agents is presented separately, along with recommendations for screening patients prior to starting these medications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40825?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32538?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: Risk of bacterial, viral, and fungal infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24169?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors and mycobacterial infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33624?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: Risk of malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?10/39/10869?source=see_link\">",
"       \"Patient information: Ulcerative colitis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/11/17586?source=see_link\">",
"       \"Patient information: Sulfasalazine and the 5-aminosalicylates (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of anti-tumor necrosis factor (anti-TNF) therapy in active ulcerative colitis (UC), steroid-dependent UC, refractory pouchitis, and in maintenance of disease remission is evolving. Unlike Crohn's disease, ulcerative colitis can ultimately be cured by colectomy. Whether",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    can prevent this outcome, particularly in those with severe and refractory disease, is uncertain. Such patients may be exposed to the risk and expense of infliximab treatment while not preventing (or only delaying) subsequent colectomy.",
"   </p>",
"   <p>",
"    The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    is not as pronounced if one considers clinical remission as a reasonable endpoint for treatment of ulcerative colitis and the uncertain durability of the response produced by infliximab. In the ACT 1 trial, for example, clinical remission was achieved significantly more often by eight weeks in the two infliximab groups compared with placebo (39 and 32 versus 15 percent, respectively) and the differences persisted at week 30. Put another way, this means that infliximab was 24 percent better at achieving clinical remission than placebo (or approximately four patients would need to be treated to achieve one response). A similar magnitude of benefit was observed in ACT 2.",
"   </p>",
"   <p>",
"    Response rates in controlled trials with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    in glucocorticoid-refractory UC patients are inferior to those reported with intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    therapy, although the two drugs have not been compared directly, and there have been no controlled trials with cyclosporine that were comparable in size to ACT 1 and ACT 2. There are also safety concerns about giving cyclosporine or infliximab in patients with refractory disease to one or the other of these drugs. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Cyclosporine versus infliximab'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Until long-term data are available, we suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    be considered in patients with acute steroid-refractory disease who are reluctant to undergo colectomy and in whom",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    is contraindicated (",
"    <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"     Grade 2B",
"    </a>",
"    ).",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26647/abstract/1\">",
"      Masuda H, Iwai S, Tanaka T, Hayakawa S. Expression of IL-8, TNF-alpha and IFN-gamma m-RNA in ulcerative colitis, particularly in patients with inactive phase. J Clin Lab Immunol 1995; 46:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26647/abstract/2\">",
"      Reinecker HC, Steffen M, Witthoeft T, et al. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 1993; 94:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26647/abstract/3\">",
"      Reimund JM, Wittersheim C, Dumont S, et al. Mucosal inflammatory cytokine production by intestinal biopsies in patients with ulcerative colitis and Crohn's disease. J Clin Immunol 1996; 16:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26647/abstract/4\">",
"      Nielsen OH, Gionchetti P, Ainsworth M, et al. Rectal dialysate and fecal concentrations of neutrophil gelatinase-associated lipocalin, interleukin-8, and tumor necrosis factor-alpha in ulcerative colitis. Am J Gastroenterol 1999; 94:2923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26647/abstract/5\">",
"      Saiki T, Mitsuyama K, Toyonaga A, et al. Detection of pro- and anti-inflammatory cytokines in stools of patients with inflammatory bowel disease. Scand J Gastroenterol 1998; 33:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26647/abstract/6\">",
"      Danese S, Colombel JF, Peyrin-Biroulet L, et al. Review article: the role of anti-TNF in the management of ulcerative colitis - past, present and future. Aliment Pharmacol Ther 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26647/abstract/7\">",
"      Chey WY, Hussain A, Ryan C. Infliximab is an effective therapeutic agent for ulcerative colitis (abstract). Am J Gastroenterol 2000; 95:A2530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26647/abstract/8\">",
"      Chey WY. Infliximab for patients with refractory ulcerative colitis. Inflamm Bowel Dis 2001; 7 Suppl 1:S30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26647/abstract/9\">",
"      Rutgeerts P. Infliximab for ulcerative colitis: the need for adequately powered placebo-controlled trials. Am J Gastroenterol 2002; 97:2488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26647/abstract/10\">",
"      Su C, Salzberg BA, Lewis JD, et al. Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Am J Gastroenterol 2002; 97:2577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26647/abstract/11\">",
"      Kaser A, Mairinger T, Vogel W, Tilg H. Infliximab in severe steroid-refractory ulcerative colitis: a pilot study. Wien Klin Wochenschr 2001; 113:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26647/abstract/12\">",
"      Actis GC, Bruno M, Pinna-Pintor M, et al. Infliximab for treatment of steroid-refractory ulcerative colitis. Dig Liver Dis 2002; 34:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26647/abstract/13\">",
"      Gornet JM, Couve S, Hassani Z, et al. Infliximab for refractory ulcerative colitis or indeterminate colitis: an open-label multicentre study. Aliment Pharmacol Ther 2003; 18:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26647/abstract/14\">",
"      Probert CS, Hearing SD, Schreiber S, et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 2003; 52:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26647/abstract/15\">",
"      Sands BE, Tremaine WJ, Sandborn WJ, et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis 2001; 7:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26647/abstract/16\">",
"      Ochsenkuhn T, Sackmann M, Goeke B. Infliximab for acute severe ulcerative colitis: A randomized pilot study in non-steroid refractory patients (abstract). Gastroenterology 2003; 124:A62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26647/abstract/17\">",
"      Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353:2462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26647/abstract/18\">",
"      Ford AC, Sandborn WJ, Khan KJ, et al. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011; 106:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26647/abstract/19\">",
"      Sandborn WJ, Rutgeerts P, Feagan BG, et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 2009; 137:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26647/abstract/20\">",
"      J&auml;rnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005; 128:1805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26647/abstract/21\">",
"      Gustavsson A, J&auml;rnerot G, Hertervig E, et al. Clinical trial: colectomy after rescue therapy in ulcerative colitis - 3-year follow-up of the Swedish-Danish controlled infliximab study. Aliment Pharmacol Ther 2010; 32:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26647/abstract/22\">",
"      Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330:1841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26647/abstract/23\">",
"      Stack WA, Long RG, Hawkey CJ. Short- and long-term outcome of patients treated with cyclosporin for severe acute ulcerative colitis. Aliment Pharmacol Ther 1998; 12:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26647/abstract/24\">",
"      Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am J Gastroenterol 1999; 94:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26647/abstract/25\">",
"      Schluender SJ, Ippoliti A, Dubinsky M, et al. Does infliximab influence surgical morbidity of ileal pouch-anal anastomosis in patients with ulcerative colitis? Dis Colon Rectum 2007; 50:1747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26647/abstract/26\">",
"      Maser EA, Deconda D, Lichtiger S, et al. Cyclosporine and infliximab as rescue therapy for each other in patients with steroid-refractory ulcerative colitis. Clin Gastroenterol Hepatol 2008; 6:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26647/abstract/27\">",
"      Herrlinger KR, Barthel DN, Schmidt KJ, et al. Infliximab as rescue medication for patients with severe ulcerative/indeterminate colitis refractory to tacrolimus. Aliment Pharmacol Ther 2010; 31:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26647/abstract/28\">",
"      Afif W, Leighton JA, Hanauer SB, et al. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis 2009; 15:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26647/abstract/29\">",
"      Oussalah A, Laclotte C, Chevaux JB, et al. Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience. Aliment Pharmacol Ther 2008; 28:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26647/abstract/30\">",
"      Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011; 60:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26647/abstract/31\">",
"      Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012; 142:257.",
"     </a>",
"    </li>",
"    <li>",
"     FDA approves Humira to treat ulcerative colitis (FDA news release September 28, 2012). Available at: file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm321650.htm.",
"    </li>",
"    <li>",
"     Sandborn W, Feagan B, Marano C, et al. A phase 2/3 multicenter, randomized, placebo-controlled, double-blind study to evaluate the safety and efficacy of golimumab induction therapy, administered subcutaneously, in patients with moderately to severely active ulcerative colitis: Results from the PURSUIT SC study. DDW abstract 2012.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26647/abstract/34\">",
"      Arnott ID, McDonald D, Williams A, Ghosh S. Clinical use of Infliximab in Crohn's disease: the Edinburgh experience. Aliment Pharmacol Ther 2001; 15:1639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26647/abstract/35\">",
"      Viscido A, Habib FI, Kohn A, et al. Infliximab in refractory pouchitis complicated by fistulae following ileo-anal pouch for ulcerative colitis. Aliment Pharmacol Ther 2003; 17:1263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26647/abstract/36\">",
"      Barreiro-de Acosta M, Garc&iacute;a-Bosch O, Souto R, et al. Efficacy of infliximab rescue therapy in patients with chronic refractory pouchitis: a multicenter study. Inflamm Bowel Dis 2012; 18:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26647/abstract/37\">",
"      Mamula P, Markowitz JE, Cohen LJ, et al. Infliximab in pediatric ulcerative colitis: two-year follow-up. J Pediatr Gastroenterol Nutr 2004; 38:298.",
"     </a>",
"    </li>",
"    <li>",
"     McGinnis JK, Murray KF. Infliximab for ulcerative colitis in children. 2nd World Congress of Pediatric Gastroenterology, Hepatology, and Nutrition. 2004, abstract P0593.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26647/abstract/39\">",
"      Eidelwein AP, Cuffari C, Abadom V, Oliva-Hemker M. Infliximab efficacy in pediatric ulcerative colitis. Inflamm Bowel Dis 2005; 11:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26647/abstract/40\">",
"      Fanjiang G, Russell GH, Katz AJ. Short- and long-term response to and weaning from infliximab therapy in pediatric ulcerative colitis. J Pediatr Gastroenterol Nutr 2007; 44:312.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4054 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-71122602D8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_1_26647=[""].join("\n");
var outline_f26_1_26647=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL TRIALS OF INFLIXIMAB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ACT 1 and ACT 2 trials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Other controlled trials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Cyclosporine versus infliximab",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ADALIMUMAB AND ULCERATIVE COLITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3948324\">",
"      GOLIMUMAB AND ULCERATIVE COLITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      REFRACTORY POUCHITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PEDIATRIC EXPERIENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SAFETY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?8/46/8929?source=related_link\" title=\"calculator 1\">",
"      Calculator: Mayo score for assessing ulcerative colitis activity",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/4/44105?source=related_link\">",
"      Infliximab in Crohn's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3319?source=related_link\">",
"      Management of severe ulcerative colitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/11/17586?source=related_link\">",
"      Patient information: Sulfasalazine and the 5-aminosalicylates (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/39/10869?source=related_link\">",
"      Patient information: Ulcerative colitis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/63/32759?source=related_link\">",
"      Pouchitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24169?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors and mycobacterial infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40825?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: An overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32538?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: Risk of bacterial, viral, and fungal infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33624?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: Risk of malignancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_1_26648="ECG showing changes in VF over time";
var content_f26_1_26648=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F67777&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F67777&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 545px\">",
"   <div class=\"ttl\">",
"    Continuous electrocardigraphic (ECG) strip during an episode of ventricular fibrillation (VF) that progresses to fine VF and then asystole",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 525px; height: 304px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    At the onset of ventricular fibrillation (VF), the QRS complexes are regular, widened, and of tall amplitude, suggesting a more organized ventricular tachyarrhythmia. Over a brief period of time, the rhythm becomes more disorganized with high amplitude fibrillatory waves; this is coarse VF. After a longer period of time, the fibrillatory waves become fine, culminating in asystole.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_1_26648=[""].join("\n");
var outline_f26_1_26648=null;
var title_f26_1_26649="Complications of Staphylococcus aureus bacteremia";
var content_f26_1_26649=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Complications of Staphylococcus aureus bacteremia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/1/26649/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/1/26649/contributors\">",
"     Vance G Fowler, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/1/26649/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/1/26649/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/1/26649/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/1/26649/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/1/26649/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/1/26649/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Staphylococcus aureus is a leading cause of both community-acquired and hospital-acquired bacteremia. Patients with S. aureus bacteremia (SAB) can develop a broad array complications which may be difficult to recognize and which can lead to disability or death. Complications of SAB are common; frequencies range from 11 to 53 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Complications of SAB can occur in almost any body site. However, certain complications are especially important because of their notoriously poor outcome and because early diagnosis can be difficult.",
"   </p>",
"   <p>",
"    The complications of SAB will be reviewed here. The epidemiology, risk factors, and treatment of S. aureus bacteremia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/1/10263?source=see_link\">",
"     \"Epidemiology of Staphylococcus aureus bacteremia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24249?source=see_link\">",
"     \"Treatment of Staphylococcus aureus bacteremia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk for the developing complications of SAB varies depending on the route of acquisition, site of infection, presence or absence of foreign material, pathogen characteristics, and host predisposition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Community acquisition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with community-acquired SAB have an increased risk for metastatic complications [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/3-8\">",
"     3-8",
"    </a>",
"    ]. Among 281 patients of S. aureus bacteremia, metastatic complications were significantly more common among patients with community-acquired rather than hospital-acquired bacteremia (43 versus 21 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The explanation for this finding is not fully understood but may be related to prolonged duration of bacteremia. A prospective observational study of 245 consecutive SAB patients (125 MRSA and 120 methicillin-susceptible S. aureus [MSSA]) found that the complication rate increased steadily with duration of bacteremia (6.6, 24, and 38 percent in bacteremia for 1 to 2, 3, and &ge;4 days, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Prosthetic device",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of an indwelling prosthetic device is frequently both the source for staphylococcal bacteremia as well as an important risk factor for a complicated course [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/10\">",
"     10",
"    </a>",
"    ]. Prosthetic devices can become contaminated with staphylococci at the time of insertion, as a result of contiguous spread of infection, or via hematogenous seeding at the time of bacteremia. Once S. aureus infection develops in the setting of a prosthetic device, removal of the prosthesis is usually necessary for cure [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/2,11-13\">",
"     2,11-13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37464?source=see_link\">",
"     \"Epidemiology, pathogenesis, and microbiology of intravascular catheter infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Underlying medical conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of complications from SAB is increased in immunosuppressed patients. Among patients with HIV, both the underlying immunocompromised state and treatments patients are receiving may contribute to risk of complications. In one study, the incidence of SAB among a large population of HIV-infected patients was 5.4 episodes per 1000 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/14\">",
"     14",
"    </a>",
"    ]. Over one-third of these patients developed metastatic sequelae. Several unusual complications have been reported including purulent pericarditis with tamponade [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/15\">",
"     15",
"    </a>",
"    ] and hepatic abscesses [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with malignancy who develop SAB also have high rates of complications, ranging from 30 to 40 percent in some reports [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. Certain forms of chemotherapy may increase the risk of complications [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     No identifiable focus of bacteremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The absence of a clinically identifiable source for SAB is an important predictor of subsequent complications [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. In a series of 281 patients with S. aureus bacteremia, the incidence of a metastatic complication was lower with an identifiable source of bacteremia than among patients without a clear source (21 versus 51 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PREDICTING COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factors that may predict subsequent complications in individual patients with SAB include the following clinical and laboratory findings [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Positive follow-up blood cultures 48 to 96 hours after admission (odds ratio [OR] 5.58, 95% CI 3.93-7.95)",
"     </li>",
"     <li>",
"      Persistent fever at 72 hours after admission (OR 2.23, 95% CI 1.55-3.12)",
"     </li>",
"     <li>",
"      Skin findings suggestive of acute systemic infection (OR 2.04, 95% CI 1.3-3.18)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These independent findings along with the host factor of community acquisition of SAB were used to derive a risk score for SAB complications. Patients with none of the findings had a 16 percent complication rate while those with all four factors had a 90 percent complication rate. The scoring system was internally validated, but has not been externally validated.",
"   </p>",
"   <p>",
"    Other studies have also found that persistent positive blood cultures and fever predict complications [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/7,17,21,22\">",
"     7,17,21,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Time to positive blood cultures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Growth of S. aureus within 14 hours after the initiation of blood culture incubation may also identify patients with a high likelihood of complications of SAB. A prospective observational study of 312 SABs in adult patients examined whether the time to positivity of blood cultures correlated with outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/23\">",
"     23",
"    </a>",
"    ]. Logistic regression analyses revealed that a time to positivity of &le;14 hours was an independent predictor of an endovascular source of infection, extended bacteremia, metastatic infection, and attributable mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     APACHE II score",
"    </span>",
"    &nbsp;&mdash;&nbsp;The APACHE II score has been studied as a predictor of SAB complications. One study evaluated the utility of APACHE II scores in predicting the risk of metastatic foci or death among 99 prospectively identified patients with SAB. A change in APACHE score of &ge;7 had a positive predictive value of 53 and 83 percent respectively for fatal and complicated outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/24\">",
"     24",
"    </a>",
"    ]. A second series of 89 episodes also found an association between the APACHE score and subsequent mortality due to SAB [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC DIFFICULTIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of investigations have now demonstrated that reliance solely upon physical examination findings and predictions of the clinician, results in underdiagnosis of complicated S. aureus infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Endocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reliance upon uncommon clinical findings such as peripheral stigmata of infectious endocarditis (IE) has historically also led to an underdiagnosis of S. aureus IE. The following studies illustrate the difficulty in making a clinical diagnosis of S. aureus IE [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnosis of S. aureus IE was not clinically suspected and was only obtained at autopsy in 55 percent of 119 Danish patients with S. aureus IE identified from 1976 to 1981 [",
"      <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/26\">",
"       26",
"      </a>",
"      ], in 32 percent of 260 Danish patients with S. aureus IE identified from 1982 to 1991 [",
"      <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/27\">",
"       27",
"      </a>",
"      ], and in 17 percent of 180 consecutive Brazilian IE patients [",
"      <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The Duke criteria employing a combination of clinical, microbiologic, and echocardiographic findings are superior to previous diagnostic schema. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31094?source=see_link\">",
"     \"Infective endocarditis: Historical and Duke criteria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Echocardiography is superior to clinical findings and transesophageal echocardiography (TEE) is more sensitive than transthoracic echocardiography (TTE) in establishing the diagnosis of IE in patients with SAB as illustrated by the following studies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/29-32\">",
"     29-32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Available clinical and laboratory data were inadequate to establish a diagnosis of IE among the majority of febrile IDUs who were ultimately diagnosed with IE using methods such as echocardiography [",
"      <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a series of 103 consecutive patients with SAB, diagnostic cardiac findings of IE were identified in 25 percent by TEE compared to only 7 percent by transthoracic echocardiography (TTE) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/30\">",
"       30",
"      </a>",
"      ]. This high rate of echocardiographic evidence of IE in patients with SAB has been validated in studies from two separate institutions [",
"      <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/31,32\">",
"       31,32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The similar results in these studies emphasize the incremental diagnostic benefit of TEE as compared to either clinical evaluation or TTE in patients with SAB. However, these studies should not be interpreted as estimating the prevalence of IE in these patients, since patients underwent TEE based on a higher clinical suspicion of IE rather than being randomly selected, thereby resulting in higher rates of prevalence of IE.",
"   </p>",
"   <p>",
"    We recommend that all patients with SAB undergo some form of echocardiography in the absence of extenuating clinical circumstances. Transthoracic echocardiography is helpful in many cases of patients with SAB, but is less sensitive than TEE. The precise clinical indications for TEE in patients with SAB remain controversial. Because several studies have found TEE to be significantly more sensitive than TTE in patients with SAB, its use should be considered in each patient with SAB, particularly if short course therapy is being contemplated or if particular risks for IE exist (eg, persistent fever",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bacteremia, community acquisition, cardiac prosthetic material or predisposing valvular abnormality, no",
"    <span class=\"nowrap\">",
"     evident/removable",
"    </span>",
"    source, or the presence of peripheral stigmata for IE) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/30-32\">",
"     30-32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While TEE should be performed earlier in patients with SAB than in those with bacteremia due to other organisms, TTE should still be performed first since it is an easier procedure. Finding a vegetation on TTE usually would obviate the need for the more invasive TEE [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Other metastatic infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of metastatic S. aureus infection in other sites is similarly difficult to establish. In several case series, only 39 percent of 133 patients with bacteremic S. aureus vertebral osteomyelitis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/35\">",
"     35",
"    </a>",
"    ] and 57 percent of 35 patients with epidural abscess [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/36\">",
"     36",
"    </a>",
"    ] had a diagnosis on admission related to the spine. Failure to identify such complications of SAB may lead to catastrophic complications (eg, death, paralysis) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/37\">",
"     37",
"    </a>",
"    ] or relapsing bacteremia due to inadequately treated infections [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Almost any body site can become secondarily infected during the course of SAB.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Infective endocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infective endocarditis (IE) is a common and often devastating complication of SAB, with incidence ranging from 10 to 15 percent in prospective, observational studies in adults and children [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/7,19,39,40\">",
"     7,19,39,40",
"    </a>",
"    ]. Risk factors for IE in the setting of S. aureus bacteremia include [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/19,41-43\">",
"     19,41-43",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prosthetic heart valve (incidence up to 50 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/41,42\">",
"       41,42",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Predisposing cardiac abnormalities",
"     </li>",
"     <li>",
"      Injection drug use",
"     </li>",
"     <li>",
"      Intravascular catheter infection",
"     </li>",
"     <li>",
"      Bacteremia of unclear origin",
"     </li>",
"     <li>",
"      Persistent bacteremia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When IE complicates SAB, the course of the IE, in turn, is often complicated. In a prospective evaluation of 194 consecutive patients with IE, S. aureus IE compared with IE caused by other pathogens, was more often associated with severe sepsis (39 versus 6 percent), major neurological events (18 versus 8 percent), multi-organ failure (29 versus 10 percent), and higher mortality (34 versus 10 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18249?source=see_link\">",
"     \"Complications and outcome of infective endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The increased cardiac and neurologic complications have been noted previously, findings included:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiac complications occurred in 67 percent of 33 patients with S. aureus prosthetic valve IE [",
"      <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/45\">",
"       45",
"      </a>",
"      ]. Complications include perivalvular or myocardial abscess, valvular destruction, and conduction abnormalities [",
"      <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The incidence of embolic stroke among patients with S. aureus native valve endocarditis ranged from 5 to 51 percent in various studies [",
"      <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/47-51\">",
"       47-51",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Prosthetic device infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with permanent pacemakers or implantable cardioverter-defibrillators who develop SAB are at increased risk for IE",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    infection involving the cardiac device. Among 33 prospectively identified patients with a permanent pacemaker or implantable cardioverter-defibrillator who developed SAB, the overall rate of confirmed device infection was 45 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/52\">",
"     52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44345?source=see_link\">",
"     \"Infections involving cardiac implantable electronic devices\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other prosthetic devices are at high risk for infection among patients with SAB. In a series of 80 prospectively identified patients with SAB and orthopedic devices, the rate of hematogenous seeding of an arthroplasty was 34 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/53\">",
"     53",
"    </a>",
"    ]. In addition to device infection around the time of SAB, the presence of prosthetic material is an important risk factor for subsequent relapsing infection. Among 309 prospectively identified cases of SAB, the presence of an indwelling foreign body was the single greatest predictor (OR, 18.2; 95% CI, 7.6-43.6) of subsequent relapse (as confirmed by pulsed-field gel electrophoresis) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infected foreign bodies should almost always be removed. Although successful retention of infected orthopedic prostheses has been reported in a limited number of highly selected patients with S. aureus infections [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/54\">",
"     54",
"    </a>",
"    ], this practice should generally be discouraged because of its high associated failure rate observed in patients with prosthetic joints [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/55\">",
"     55",
"    </a>",
"    ], prosthetic cardiac valves [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/45,56\">",
"     45,56",
"    </a>",
"    ], tunneled intravascular catheters [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/11\">",
"     11",
"    </a>",
"    ], and permanent pacemakers [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/57\">",
"     57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/19/6457?source=see_link\">",
"     \"Treatment of prosthetic joint infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Waterhouse-Friderichsen syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Waterhouse-Friderichsen syndrome, characterized by petechial rash, coagulopathy, cardiovascular collapse, and adrenal hemorrhage, is usually associated with fulminant meningococcemia, but has also been reported with sepsis from Streptococcus pneumoniae, Neisseria gonorrhoeae, Escherichia coli, and Haemophilus influenzae. Reports of a syndrome of fatal, severe sepsis in children caused by S. aureus, both MSSA and community-associated MRSA, suggest that S. aureus should be added to the list of etiologic agents [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/58-61\">",
"     58-61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The frequency with which Waterhouse-Friderichsen syndrome occurs among patients infected with community-associated MRSA is presumably low. Despite the low frequency, when patients present with findings typical of this devastating and fulminant illness, antibiotic coverage for MRSA should be empirically provided until the culture are available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Henoch-Schonlein purpura",
"    </span>",
"    &nbsp;&mdash;&nbsp;A case report and review of the literature identified 14 cases of Henoch-Schonlein purpura associated with S. aureus infection [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/62\">",
"     62",
"    </a>",
"    ]. The authors propose the pathogenetic mechanism that S. aureus superantigen action on T cells was responsible for the autoimmune phenomenon. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40729?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Metastatic seeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metastatic infection other than IE and prosthetic device infection can occur in patients with SAB; as many as 31 percent of such patients ultimately develop one or more metastatic infections due to this organism [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/4\">",
"     4",
"    </a>",
"    ]. These metastatic sites of infection are evident within the first 48 to 72 hours of hospitalization in many patients. However, in an important subset of bacteremic patients, metastatic seeding may not be discovered for several weeks. The development of localized symptoms such as back or joint pain should raise the suspicion of an occult site of infection in every patient with a recent history of SAB.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Vertebral osteomyelitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In adults, hematogenous S. aureus osteomyelitis is most commonly found in the vertebral column [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/63\">",
"     63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/28/22985?source=see_link\">",
"     \"Vertebral osteomyelitis and discitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a retrospective analysis of 309 cases of hematogenous S. aureus osteomyelitis in Danish patients from 1980 to 1990, the highest risk of vertebral osteomyelitis (six percent) occurred among older patients (&gt;50 years) with community-acquired bacteremia and no evident inciting source [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/63\">",
"     63",
"    </a>",
"    ]. The rate of vertebral osteomyelitis increased significantly from the first half (1980 to 1985) to the second half (1986 to 1990) of the study period [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/63,64\">",
"     63,64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Septic arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Septic arthritis is an occasional complication of SAB. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11049?source=see_link\">",
"     \"Septic arthritis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because the joint space synovium is a highly vascular tissue without a basement membrane, the joint is particularly susceptible to hematogenous infection. In two case series of patients with SAB, septic arthritis developed in approximately 10 percent of 281 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/5\">",
"     5",
"    </a>",
"    ] and 3 percent of 91 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/18\">",
"     18",
"    </a>",
"    ]. The incidence of this complication also may be increasing; in the Danish study cited above, the incidence of septic arthritis increased significantly in the period 1984 to 1988 compared to 1959 to 1968 (3 versus 0.6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Septic joint complications usually involve a single joint (most commonly the knee) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/65\">",
"     65",
"    </a>",
"    ], but a variety of other joints can be affected such as the diarthric joints (eg, sacroiliac, sternoclavicular), especially in IDUs. The risk of septic arthritis among patients with SAB increases in those who are immunosuppressed",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    have rheumatoid arthritis. In the latter group, over 80 percent of joint infections are caused by S. aureus; more than 30 percent of such cases have polyarticular involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Splenic abscess",
"    </span>",
"    &nbsp;&mdash;&nbsp;Splenic abscess is an infrequent complication of staphylococcal sepsis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    IE [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/67-71\">",
"     67-71",
"    </a>",
"    ]. The typical clinical manifestations are fever that may be recurrent or persistent despite antimicrobial therapy and left upper quadrant pain with or without splenomegaly [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/67,69\">",
"     67,69",
"    </a>",
"    ]. However, some patients lack these classic features [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/70,71\">",
"     70,71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis is usually confirmed by computed tomography or ultrasonography [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/67,68\">",
"     67,68",
"    </a>",
"    ], although the lesion may be incorrectly called an infarct [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/67\">",
"     67",
"    </a>",
"    ] which also can be a complication of IE [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/68,70\">",
"     68,70",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/34/34346?source=see_link&amp;anchor=H7#H7\">",
"     \"Approach to the adult patient with splenomegaly and other splenic disorders\", section on 'Splenic abscess'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Splenic abscess is usually managed by a combination of antibiotic therapy and splenectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/67-70\">",
"     67-70",
"    </a>",
"    ]. CT-guided percutaneous aspiration is occasionally successful, but this approach has not replaced splenectomy as the standard of care [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Thrombophlebitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Septic thrombophlebitis due to S. aureus is usually due to an infected intravascular catheter. Patients with this complication also often have prolonged intervals of fever",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bacteremia. Clinical evidence of venous congestion (eg, venous distension or asymmetric swelling of the extremities) is a helpful clue, if present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/0/2055?source=see_link\">",
"     \"Suppurative (septic) thrombophlebitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Central nervous system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although S. aureus meningitis most commonly occurs in the postoperative neurosurgical patient, it may occur as a complication of SAB [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. In two recent series of patients with S. aureus meningitis, between 27 and 34 percent of patients developed meningitis as a consequence of SAB [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. Patients with SAB-related meningitis usually have overwhelming, disseminated disease (eg, endocarditis, osteomyelitis) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Pulmonary infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain subgroups of patients are especially prone to pulmonary complications of SAB, such as injection drug users who develop emboli to the lungs from tricuspid valve endocarditis. Such patients typically complain of pleuritic chest pain; multiple nodular infiltrates that may cavitate are usually evident on chest radiography. The mortality rate among these patients is typically below 10 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/34/38439?source=see_link\">",
"     \"Overview of pulmonary disease in injection drug users\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/17/40215?source=see_link\">",
"     \"Infective endocarditis in injection drug users\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pulmonary complications, including necrotizing pneumonia, can also be seen as part of a severe sepsis syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/58,61\">",
"     58,61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36858?source=see_link\">",
"     \"Treatment of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Soft tissue infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Necrotizing fasciitis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    myositis is a life-threatening infection requiring urgent surgical and medical therapy. Community-associated MRSA has been described in a series of 14 cases; blood cultures were positive in four of ten patients in whom they were obtained [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/74\">",
"     74",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/22/362?source=see_link\">",
"     \"Necrotizing soft tissue infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32950?source=see_link\">",
"     \"Pyomyositis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Bacteriuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the setting of S. aureus bacteriuria associated with the presence of a urinary catheter, investigation for a metastatic source of infection is not warranted. Catheter and antibiotic management is as discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/24/44422?source=see_link\">",
"     \"Urinary tract infection associated with urethral catheters\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, S. aureus bacteriuria in a febrile patient without a urinary catheter may be a marker of unrecognized S. aureus bacteremia. In this setting, blood cultures should be obtained together with careful clinical evaluation for signs and symptoms of a metastatic or occult staphylococcal infection, particularly if there are other clinical clues of infection such as leukocytosis or localizing symptoms such as back pain.",
"   </p>",
"   <p>",
"    In some circumstances S. aureus bacteriuria may be a reflection of bacteremia rather than a site of overt infection. Support for this hypothesis came from a study of 59 patients with SAB in whom a urine culture was obtained within 48 hours of a positive blood culture [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/75\">",
"     75",
"    </a>",
"    ]. S. aureus &gt;10(5) colony-forming",
"    <span class=\"nowrap\">",
"     units/mL",
"    </span>",
"    was present in the urine in 16 (27 percent). Such observations led to the suggestion that S. aureus bacteriuria should trigger the physician to obtain blood cultures and, if SAB is also present or likely, a careful evaluation for a source of infection",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    other sites of metastatic infection should be undertaken.",
"   </p>",
"   <p>",
"    However, the association between S. aureus bacteriuria and SAB is not clearly established as illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the above study, 6 of the 16 cases of S. aureus bacteriuria were felt to represent primary urinary tract infection and bacteremic causality was not claimed in the remaining cases [",
"      <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/75\">",
"       75",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a series of 39 patients with S. aureus bacteriuria without demonstrated bacteremia seen over a one year period, a distant site of S. aureus infection was found in only one patient [",
"      <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/76\">",
"       76",
"      </a>",
"      ]. Transient bacteremia could not be excluded.",
"     </li>",
"     <li>",
"      The frequency with which SAB produces bacteriuria was directly addressed in a retrospective cohort study with SAB [",
"      <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/77\">",
"       77",
"      </a>",
"      ]. In an attempt to identify cases of S. aureus bacteriuria that could unambiguously be attributed to SAB, patients with urinary catheters were excluded, since they predispose of S. aureus urinary colonization and accounted for most of the cases of S. aureus bacteriuria, as were patients with symptoms of a urinary tract infection. Only 2 of the 79 patients who fulfilled the entry criteria (2.5 percent) had S. aureus bacteriuria (&ge;10(4) colony-forming",
"      <span class=\"nowrap\">",
"       units/mL)",
"      </span>",
"      in a urine culture obtained on the same day that SAB was detected.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two other reports examined the association between S. aureus bacteriuria and the risk of subsequent S. aureus bacteremia:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 102 hospitalized men with S. aureus bacteriuria (mostly MRSA), eight subsequently developed S. aureus bacteremia at up to 12 months [",
"      <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/78\">",
"       78",
"      </a>",
"      ]. The organism isolated from the blood matched the original urinary isolate in five of the eight patients. However, at the initial evaluation, most of the 102 patients (82 percent) had undergone recent urinary catheterization, 33 percent had a symptomatic urinary tract infection, and 13 percent were bacteremic at presentation.",
"     </li>",
"     <li>",
"      Investigators from the Duke Infection Control Outreach Network retrospectively examined the records of 1015 patients who had positive urine cultures for MRSA (overall rate",
"      <span class=\"nowrap\">",
"       0.4/1000",
"      </span>",
"      patient days) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/79\">",
"       79",
"      </a>",
"      ]. Five percent had concurrent MRSA bacteremia and bacteriuria, 1.8 percent had MRSA bacteremia 1 to 265 days prior to detection of MRSA bacteriuria, and 1.7 percent had bacteremia 1 to 33 days following the detection of MRSA bacteriuria. The rate of urinary catheterization was not reported.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;SAB remains a highly lethal disease. In the preantibiotic era, mortality rates exceeded 80 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/80\">",
"     80",
"    </a>",
"    ]. Even now, mortality rates of 20 to 40 percent have been reported in most case series of patients with SAB; these rates have not changed over the past several decades despite seemingly important diagnostic and therapeutic advances [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/81,82\">",
"     81,82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite often being regarded as a benign condition, mortality rates associated with catheter-associated SAB may exceed 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/5,81,83\">",
"     5,81,83",
"    </a>",
"    ]. In addition, these infections are notoriously likely to relapse unless appropriate therapy is administered. A meta-analysis of published studies estimated that approximately 1 in 16 patients with SAB relapse and develop late complications (endocarditis and epidural abscess) following an apparent clinical response to therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The higher mortality rates occur in patients with comorbidities and in those patients who develop complications of SAB [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/19,84\">",
"     19,84",
"    </a>",
"    ]. The role of comorbidity in mortality due to SAB is illustrated by a prospective cohort study of 166 adult patients diagnosed with SAB [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/84\">",
"     84",
"    </a>",
"    ]. Using the Charlson weighted index of comorbidity, a score of &gt;3 was independently predictive of mortality (odds ratio [OR] 3, 95% CI, 1.3-5.5); overall mortality was 24 versus 60 percent in those with a Charlson score &lt;3 compared to those with a higher score. An additional finding in this study was that age (independent of comorbidity) was associated with death; observed mortality rates were 57, 50, 30, 19, and 11 percent with age &ge;90, 80 to 89, 70 to 79, 60 to 69, and 18 to 59 years, respectively.",
"   </p>",
"   <p>",
"    A retrospective study of patients with SAB also identified comorbidity as a predictor of mortality. In this study the following independent predictors of hospital mortality were identified by multivariate analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26649/abstract/85\">",
"     85",
"    </a>",
"    ] :",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Charlson score (comorbidity index) &ge;3 (Odds ratio [OR], 14.4; 95% CI, 2.2-92.5)",
"     </li>",
"     <li>",
"      MRSA (OR, 9.3; 95% CI, 1.5-59.2)",
"     </li>",
"     <li>",
"      Time to positivity of blood cultures &le;12 hours (OR, 6.9; 95% CI, 1.1-44.7)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Staphylococcus aureus is a leading cause of both community-acquired and hospital-acquired bacteremia. Patients with S. aureus bacteremia (SAB) can develop diverse complications which may be difficult to recognize and which can lead to disability or death. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complications of SAB are common with frequencies ranging from 11 to 53 percent. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most significant host risk factors for the development of complications of SAB include community acquisition of SAB, patients with no identifiable focus of infection, presence of a prosthetic device, and patient comorbidities. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinically relevant factors that may predict subsequent complications of SAB include positive follow-up blood cultures 48 to 96 hours after admission, persistent fever at 72 hours after admission, skin findings suggestive of acute systemic infection, a time to blood culture positivity of &le;14 hours, and a change in APACHE score &ge;7 at the time of bacteremia compared to the day before bacteremia. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Predicting complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Reliance solely upon physical examination findings and predictions of the clinician, results in underdiagnosis of complicated S. aureus infections. Due to the difficulty in making the diagnosis of endocarditis clinically in patients with S. aureus bacteremia, we recommend that all patients with SAB undergo some form of echocardiography in the absence of extenuating clinical circumstances. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnostic difficulties'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Any body site can become secondarily infected during the course of SAB. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Endocarditis is a common and often devastating complication of SAB, with incidence ranging from 10 to 13 percent in prospective, observational studies in adults and children. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Infective endocarditis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Metastatic sites of infection are evident within the first 48 to 72 hours of hospitalization in many patients. However, in an important subset of bacteremic patients, metastatic seeding may not be discovered for several weeks. The development of localized symptoms such as back or joint pain should raise the suspicion of an occult site of infection in every patient with a recent history of SAB. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Metastatic seeding'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      SAB remains a highly lethal disease with mortality rates of 20 to 40 percent. Higher mortality rates are seen in patients with comorbidities and increases with increasing age. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/1\">",
"      Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998; 339:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/2\">",
"      Fowler VG Jr, Justice A, Moore C, et al. Risk factors for hematogenous complications of intravascular catheter-associated Staphylococcus aureus bacteremia. Clin Infect Dis 2005; 40:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/3\">",
"      Finkelstein R, Sobel JD, Nagler A, Merzbach D. Staphylococcus aureus bacteremia and endocarditis: comparison of nosocomial and community-acquired infection. J Med 1984; 15:193.",
"     </a>",
"    </li>",
"    <li>",
"     Ing MB, Baddour LM, Bayer AS. Bacteremia and infective endocarditis: Pathogenesis, diagnosis, and complications. In: The Staphylococci in Human Disease, Crossley KB, Archer GL (Eds), Churchill Livingstone, New York 1997. p.331.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/5\">",
"      Lautenschlager S, Herzog C, Zimmerli W. Course and outcome of bacteremia due to Staphylococcus aureus: evaluation of different clinical case definitions. Clin Infect Dis 1993; 16:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/6\">",
"      Nolan CM, Beaty HN. Staphylococcus aureus bacteremia. Current clinical patterns. Am J Med 1976; 60:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/7\">",
"      Fowler VG Jr, Olsen MK, Corey GR, et al. Clinical identifiers of complicated Staphylococcus aureus bacteremia. Arch Intern Med 2003; 163:2066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/8\">",
"      Willcox PA, Rayner BL, Whitelaw DA. Community-acquired Staphylococcus aureus bacteraemia in patients who do not abuse intravenous drugs. QJM 1998; 91:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/9\">",
"      Khatib R, Johnson LB, Fakih MG, et al. Persistence in Staphylococcus aureus bacteremia: incidence, characteristics of patients and outcome. Scand J Infect Dis 2006; 38:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/10\">",
"      Chu VH, Crosslin DR, Friedman JY, et al. Staphylococcus aureus bacteremia in patients with prosthetic devices: costs and outcomes. Am J Med 2005; 118:1416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/11\">",
"      Dugdale DC, Ramsey PG. Staphylococcus aureus bacteremia in patients with Hickman catheters. Am J Med 1990; 89:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/12\">",
"      Hartstein AI, Mulligan ME, Morthland VH, Kwok RY. Recurrent Staphylococcus aureus bacteremia. J Clin Microbiol 1992; 30:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/13\">",
"      Fowler VG Jr, Kong LK, Corey GR, et al. Recurrent Staphylococcus aureus bacteremia: pulsed-field gel electrophoresis findings in 29 patients. J Infect Dis 1999; 179:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/14\">",
"      Jacobson MA, Gellermann H, Chambers H. Staphylococcus aureus bacteremia and recurrent staphylococcal infection in patients with acquired immunodeficiency syndrome and AIDS-related complex. Am J Med 1988; 85:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/15\">",
"      Decker CF, Tuazon CU. Staphylococcus aureus pericarditis in HIV-infected patients. Chest 1994; 105:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/16\">",
"      Gunnarsson G, Friedman LS, Wanke C. Liver abscesses due to Staphylococcus aureus in a patient with AIDS who underwent small bowel biopsy: case report and review. Clin Infect Dis 1994; 18:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/17\">",
"      Raad II, Sabbagh MF. Optimal duration of therapy for catheter-related Staphylococcus aureus bacteremia: a study of 55 cases and review. Clin Infect Dis 1992; 14:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/18\">",
"      Ghanem GA, Boktour M, Warneke C, et al. Catheter-related Staphylococcus aureus bacteremia in cancer patients: high rate of complications with therapeutic implications. Medicine (Baltimore) 2007; 86:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/19\">",
"      Gopal AK, Fowler VG Jr, Shah M, et al. Prospective analysis of Staphylococcus aureus bacteremia in nonneutropenic adults with malignancy. J Clin Oncol 2000; 18:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/20\">",
"      Snydman DR, Sullivan B, Gill M, et al. Nosocomial sepsis associated with interleukin-2. Ann Intern Med 1990; 112:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/21\">",
"      Eng RH, Bishburg E, Smith SM, Scadutto P. Staphylococcus aureus bacteremia during therapy. J Infect Dis 1987; 155:1331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/22\">",
"      Lesens O, Hansmann Y, Brannigan E, et al. Positive surveillance blood culture is a predictive factor for secondary metastatic infection in patients with Staphylococcus aureus bacteraemia. J Infect 2004; 48:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/23\">",
"      Khatib R, Riederer K, Saeed S, et al. Time to positivity in Staphylococcus aureus bacteremia: possible correlation with the source and outcome of infection. Clin Infect Dis 2005; 41:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/24\">",
"      Yzerman EP, Boelens HA, Tjhie JH, et al. Delta APACHE II for predicting course and outcome of nosocomial Staphylococcus aureus bacteremia and its relation to host defense. J Infect Dis 1996; 173:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/25\">",
"      Mylotte JM, Aeschlimann JR, Rotella DL. Staphylococcus aureus bacteremia: factors predicting hospital mortality. Infect Control Hosp Epidemiol 1996; 17:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/26\">",
"      Espersen F, Frimodt-M&oslash;ller N. Staphylococcus aureus endocarditis. A review of 119 cases. Arch Intern Med 1986; 146:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/27\">",
"      R&oslash;der BL, Wandall DA, Frimodt-M&oslash;ller N, et al. Clinical features of Staphylococcus aureus endocarditis: a 10-year experience in Denmark. Arch Intern Med 1999; 159:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/28\">",
"      Figueiredo LT, Ruiz-Junior E, Schirmbeck T. Infective endocarditis (IE) first diagnosed at autopsy: analysis of 31 cases in Ribeir&atilde;o Preto, Brazil. Rev Inst Med Trop Sao Paulo 2001; 43:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/29\">",
"      Marantz PR, Linzer M, Feiner CJ, et al. Inability to predict diagnosis in febrile intravenous drug abusers. Ann Intern Med 1987; 106:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/30\">",
"      Fowler VG Jr, Li J, Corey GR, et al. Role of echocardiography in evaluation of patients with Staphylococcus aureus bacteremia: experience in 103 patients. J Am Coll Cardiol 1997; 30:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/31\">",
"      Sullenberger AL, Avedissian LS, Kent SM. Importance of transesophageal echocardiography in the evaluation of Staphylococcus aureus bacteremia. J Heart Valve Dis 2005; 14:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/32\">",
"      Abraham J, Mansour C, Veledar E, et al. Staphylococcus aureus bacteremia and endocarditis: the Grady Memorial Hospital experience with methicillin-sensitive S aureus and methicillin-resistant S aureus bacteremia. Am Heart J 2004; 147:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/33\">",
"      Kaasch AJ, Fowler VG Jr, Rieg S, et al. Use of a simple criteria set for guiding echocardiography in nosocomial Staphylococcus aureus bacteremia. Clin Infect Dis 2011; 53:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/34\">",
"      Rasmussen RV, H&oslash;st U, Arpi M, et al. Prevalence of infective endocarditis in patients with Staphylococcus aureus bacteraemia: the value of screening with echocardiography. Eur J Echocardiogr 2011; 12:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/35\">",
"      Jensen AG, Espersen F, Skinh&oslash;j P, Frimodt-M&oslash;ller N. Bacteremic Staphylococcus aureus spondylitis. Arch Intern Med 1998; 158:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/36\">",
"      Danner RL, Hartman BJ. Update on spinal epidural abscess: 35 cases and review of the literature. Rev Infect Dis 1987; 9:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/37\">",
"      Darouiche RO, Hamill RJ, Greenberg SB, et al. Bacterial spinal epidural abscess. Review of 43 cases and literature survey. Medicine (Baltimore) 1992; 71:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/38\">",
"      Jernigan JA, Farr BM. Short-course therapy of catheter-related Staphylococcus aureus bacteremia: a meta-analysis. Ann Intern Med 1993; 119:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/39\">",
"      Chang FY, MacDonald BB, Peacock JE Jr, et al. A prospective multicenter study of Staphylococcus aureus bacteremia: incidence of endocarditis, risk factors for mortality, and clinical impact of methicillin resistance. Medicine (Baltimore) 2003; 82:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/40\">",
"      Valente AM, Jain R, Scheurer M, et al. Frequency of infective endocarditis among infants and children with Staphylococcus aureus bacteremia. Pediatrics 2005; 115:e15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/41\">",
"      Fang G, Keys TF, Gentry LO, et al. Prosthetic valve endocarditis resulting from nosocomial bacteremia. A prospective, multicenter study. Ann Intern Med 1993; 119:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/42\">",
"      El-Ahdab F, Benjamin DK Jr, Wang A, et al. Risk of endocarditis among patients with prosthetic valves and Staphylococcus aureus bacteremia. Am J Med 2005; 118:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/43\">",
"      Hill EE, Vanderschueren S, Verhaegen J, et al. Risk factors for infective endocarditis and outcome of patients with Staphylococcus aureus bacteremia. Mayo Clin Proc 2007; 82:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/44\">",
"      Nadji G, R&eacute;madi JP, Coviaux F, et al. Comparison of clinical and morphological characteristics of Staphylococcus aureus endocarditis with endocarditis caused by other pathogens. Heart 2005; 91:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/45\">",
"      John MD, Hibberd PL, Karchmer AW, et al. Staphylococcus aureus prosthetic valve endocarditis: optimal management and risk factors for death. Clin Infect Dis 1998; 26:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/46\">",
"      Rohmann S, Erbel R, G&ouml;rge G, et al. Clinical relevance of vegetation localization by transoesophageal echocardiography in infective endocarditis. Eur Heart J 1992; 13:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/47\">",
"      Chambers HF, Korzeniowski OM, Sande MA. Staphylococcus aureus endocarditis: clinical manifestations in addicts and nonaddicts. Medicine (Baltimore) 1983; 62:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/48\">",
"      Hedstr&ouml;m SA, Christensson B. Staphylococcus aureus septicaemia and endocarditis at the University Hospital in Lund 1976-1980. Scand J Infect Dis Suppl 1983; 41:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/49\">",
"      Korzeniowski O, Sande MA. Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts: A prospective study. Ann Intern Med 1982; 97:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/50\">",
"      Le Cam B, Guivarch G, Boles JM, et al. Neurologic complications in a group of 86 bacterial endocarditis. Eur Heart J 1984; 5 Suppl C:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/51\">",
"      R&oslash;der BL, Wandall DA, Espersen F, et al. Neurologic manifestations in Staphylococcus aureus endocarditis: a review of 260 bacteremic cases in nondrug addicts. Am J Med 1997; 102:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/52\">",
"      Chamis AL, Peterson GE, Cabell CH, et al. Staphylococcus aureus bacteremia in patients with permanent pacemakers or implantable cardioverter-defibrillators. Circulation 2001; 104:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/53\">",
"      Murdoch DR, Roberts SA, Fowler Jr VG Jr, et al. Infection of orthopedic prostheses after Staphylococcus aureus bacteremia. Clin Infect Dis 2001; 32:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/54\">",
"      Zimmerli W, Widmer AF, Blatter M, et al. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA 1998; 279:1537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/55\">",
"      Brandt CM, Sistrunk WW, Duffy MC, et al. Staphylococcus aureus prosthetic joint infection treated with debridement and prosthesis retention. Clin Infect Dis 1997; 24:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/56\">",
"      Yu VL, Fang GD, Keys TF, et al. Prosthetic valve endocarditis: superiority of surgical valve replacement versus medical therapy only. Ann Thorac Surg 1994; 58:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/57\">",
"      Chua JD, Wilkoff BL, Lee I, et al. Diagnosis and management of infections involving implantable electrophysiologic cardiac devices. Ann Intern Med 2000; 133:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/58\">",
"      Adem PV, Montgomery CP, Husain AN, et al. Staphylococcus aureus sepsis and the Waterhouse-Friderichsen syndrome in children. N Engl J Med 2005; 353:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/59\">",
"      Herold BC, Immergluck LC, Maranan MC, et al. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA 1998; 279:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/60\">",
"      Centers for Disease Control and Prevention (CDC). Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus &mdash; Minnesota and North Dakota, 1997-1999. MMWR Morb Mortal Wkly Rep 1999; 48:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/61\">",
"      Mongkolrattanothai K, Boyle S, Kahana MD, Daum RS. Severe Staphylococcus aureus infections caused by clonally related community-acquired methicillin-susceptible and methicillin-resistant isolates. Clin Infect Dis 2003; 37:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/62\">",
"      Eftychiou C, Samarkos M, Golfinopoulou S, et al. Henoch-Schonlein purpura associated with methicillin-resistant Staphylococcus aureus infection. Am J Med 2006; 119:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/63\">",
"      Espersen F, Frimodt-M&oslash;ller N, Thamdrup Rosdahl V, et al. Changing pattern of bone and joint infections due to Staphylococcus aureus: study of cases of bacteremia in Denmark, 1959-1988. Rev Infect Dis 1991; 13:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/64\">",
"      Jensen AG, Espersen F, Skinh&oslash;j P, et al. Increasing frequency of vertebral osteomyelitis following Staphylococcus aureus bacteraemia in Denmark 1980-1990. J Infect 1997; 34:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/65\">",
"      Dubost JJ, Fis I, Denis P, et al. Polyarticular septic arthritis. Medicine (Baltimore) 1993; 72:296.",
"     </a>",
"    </li>",
"    <li>",
"     Gentry LO. Osteomyelitis and other infections of bones and joints. In: The staphylococci in human disease, Crossley KB, Archer GL (Eds), Churchill Livingstone, New York 1997. p.455.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/67\">",
"      Robinson SL, Saxe JM, Lucas CE, et al. Splenic abscess associated with endocarditis. Surgery 1992; 112:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/68\">",
"      Ting W, Silverman NA, Arzouman DA, Levitsky S. Splenic septic emboli in endocarditis. Circulation 1990; 82:IV105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/69\">",
"      Johnson JD, Raff MJ, Barnwell PA, Chun CH. Splenic abscess complicating infectious endocarditis. Arch Intern Med 1983; 143:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/70\">",
"      Ebright JR, Alam E, Ahmed H, et al. Splenic infarction and abscess in the setting of infective endocarditis. Infect Dis Clin Pract 2007; 15:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/71\">",
"      Weinstein L. Life-threatening complications of infective endocarditis and their management. Arch Intern Med 1986; 146:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/72\">",
"      Pintado V, Meseguer MA, Fort&uacute;n J, et al. Clinical study of 44 cases of Staphylococcus aureus meningitis. Eur J Clin Microbiol Infect Dis 2002; 21:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/73\">",
"      Jensen AG, Espersen F, Skinh&oslash;j P, et al. Staphylococcus aureus meningitis. A review of 104 nationwide, consecutive cases. Arch Intern Med 1993; 153:1902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/74\">",
"      Miller LG, Perdreau-Remington F, Rieg G, et al. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl J Med 2005; 352:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/75\">",
"      Lee BK, Crossley K, Gerding DN. The association between Staphylococcus aureus bacteremia and bacteriuria. Am J Med 1978; 65:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/76\">",
"      Sheth S, DiNubile MJ. Clinical significance of staphylococcus aureus bacteriuria without concurrent bacteremia. Clin Infect Dis 1997; 24:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/77\">",
"      Ekkelenkamp MB, Verhoef J, Bonten MJ. Quantifying the relationship between Staphylococcus aureus bacteremia and S. aureus bacteriuria: a retrospective analysis in a tertiary care hospital. Clin Infect Dis 2007; 44:1457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/78\">",
"      Muder RR, Brennen C, Rihs JD, et al. Isolation of Staphylococcus aureus from the urinary tract: association of isolation with symptomatic urinary tract infection and subsequent staphylococcal bacteremia. Clin Infect Dis 2006; 42:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/79\">",
"      Anderson DJ, Kaye KS, Sexton DJ. Methicillin-resistant Staphylococcus aureus bacteremia after isolation from urine. Clin Infect Dis 2006; 42:1504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/80\">",
"      Skinner, D, Keefer, CS. Significance of bacteremia caused by Staphylococcus aureus. A study of 122 cases and a review of the literature concerned with experimental infection in animals. Arch Intern Med 1941; 68:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/81\">",
"      Mylotte JM, McDermott C, Spooner JA. Prospective study of 114 consecutive episodes of Staphylococcus aureus bacteremia. Rev Infect Dis 1987; 9:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/82\">",
"      Wyllie DH, Crook DW, Peto TE. Mortality after Staphylococcus aureus bacteraemia in two hospitals in Oxfordshire, 1997-2003: cohort study. BMJ 2006; 333:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/83\">",
"      Bryan CS, Kirkhart B, Brenner ER. Staphylococcal bacteremia: current patterns in nonuniversity hospitals. South Med J 1984; 77:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/84\">",
"      Lesens O, Methlin C, Hansmann Y, et al. Role of comorbidity in mortality related to Staphylococcus aureus bacteremia: a prospective study using the Charlson weighted index of comorbidity. Infect Control Hosp Epidemiol 2003; 24:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26649/abstract/85\">",
"      Marra AR, Edmond MB, Forbes BA, et al. Time to blood culture positivity as a predictor of clinical outcome of Staphylococcus aureus bloodstream infection. J Clin Microbiol 2006; 44:1342.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2135 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-956556EC73-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_1_26649=[""].join("\n");
var outline_f26_1_26649=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Community acquisition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Prosthetic device",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Underlying medical conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      No identifiable focus of bacteremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PREDICTING COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Time to positive blood cultures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      APACHE II score",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIAGNOSTIC DIFFICULTIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Endocarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Other metastatic infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Prosthetic device infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Waterhouse-Friderichsen syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Henoch-Schonlein purpura",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Metastatic seeding",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Vertebral osteomyelitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Septic arthritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Splenic abscess",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Thrombophlebitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Central nervous system",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Pulmonary infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Soft tissue infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Bacteriuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/34/34346?source=related_link\">",
"      Approach to the adult patient with splenomegaly and other splenic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40729?source=related_link\">",
"      Clinical manifestations and diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18249?source=related_link\">",
"      Complications and outcome of infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/1/10263?source=related_link\">",
"      Epidemiology of Staphylococcus aureus bacteremia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37464?source=related_link\">",
"      Epidemiology, pathogenesis, and microbiology of intravascular catheter infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44345?source=related_link\">",
"      Infections involving cardiac implantable electronic devices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/17/40215?source=related_link\">",
"      Infective endocarditis in injection drug users",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31094?source=related_link\">",
"      Infective endocarditis: Historical and Duke criteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/22/362?source=related_link\">",
"      Necrotizing soft tissue infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/34/38439?source=related_link\">",
"      Overview of pulmonary disease in injection drug users",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32950?source=related_link\">",
"      Pyomyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11049?source=related_link\">",
"      Septic arthritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/0/2055?source=related_link\">",
"      Suppurative (septic) thrombophlebitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24249?source=related_link\">",
"      Treatment of Staphylococcus aureus bacteremia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36858?source=related_link\">",
"      Treatment of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/19/6457?source=related_link\">",
"      Treatment of prosthetic joint infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/24/44422?source=related_link\">",
"      Urinary tract infection associated with urethral catheters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/28/22985?source=related_link\">",
"      Vertebral osteomyelitis and discitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_1_26650="Epidemiology of cardiovascular disease and risk factors in HIV-infected patients";
var content_f26_1_26650=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology of cardiovascular disease and risk factors in HIV-infected patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/1/26650/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/1/26650/contributors\">",
"     Judith S Currier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/1/26650/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/1/26650/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/1/26650/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/1/26650/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/1/26650/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;For those who have access to potent antiretroviral therapy (ART), the overall incidence of AIDS or death related to infection by HIV has decreased dramatically [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/1\">",
"     1",
"    </a>",
"    ]. Prior to 1996, the annual mortality rate among individuals with HIV-1 infection exceeded 20 percent; after a decade of effective treatment, annual mortality has declined to less than 2 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As patients are living longer with HIV, new concerns have arisen among individuals taking combination ART, including increased prevalence of fat redistribution, lipoatrophy, fat accumulation, or a mixed picture of both [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. In addition to the changes in fat distribution, other metabolic abnormalities observed in patients on combination ART include dyslipidemia, diabetes mellitus, insulin resistance, and hepatic steatosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/5\">",
"     5",
"    </a>",
"    ]. There is concern that these metabolic disturbances, along with other factors, lead to an increased risk for cardiovascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will address the epidemiology of cardiovascular morbidity and mortality and cardiovascular risk factors in the setting of HIV infection and treatment. The incidence of subclinical atherosclerosis and the pathogenesis of cardiovascular disease in HIV-infected patients are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/28/40392?source=see_link\">",
"     \"Pathogenesis and biomarkers of cardiovascular disease in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Management of dyslipidemia in HIV-infected patients, HIV lipodystrophy, and HIV-associated cardiac complications, such as pericarditis, myocarditis, pulmonary hypertension, and cardiomyopathy, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/3/49?source=see_link\">",
"     \"Management of dyslipidemia and cardiovascular risk in the HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/40/25226?source=see_link\">",
"     \"Cardiac involvement in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/43/26298?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of HIV-associated lipodystrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     CARDIOVASCULAR DISEASE ASSOCIATED WITH HIV INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;With more effective and widespread treatment of HIV in resource-rich settings, morbidity and mortality from non-AIDS-related events have surpassed those from AIDS-related events [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. In particular, cardiovascular disease has emerged as an important cause of death in HIV-infected patients relative to the decreasing incidence of opportunistic disease. Several lines of evidence, from modeling of calculated cardiovascular risk to clinical studies evaluating such hard endpoints as stroke, myocardial infarctions (MIs), and sudden cardiac death have cumulatively supported this finding [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/10-14\">",
"     10-14",
"    </a>",
"    ]. The data evaluating the rate of cardiovascular disease in HIV-infected patients compared with uninfected populations and its association with antiretroviral therapy (ART) and HIV disease state are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14700934\">",
"    <span class=\"h2\">",
"     Incidence compared with uninfected populations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have analyzed large clinical databases and cohorts in the United States, Canada, and Europe to compare the incidence of cardiovascular disease in patients with and without HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/15-23\">",
"     15-23",
"    </a>",
"    ]. Although these studies are limited by low number of events, short follow-up, and incomplete assessments of other cardiac risk factors, they overall suggest an increased rate of cardiovascular events in HIV-infected individuals. One of the largest of these studies evaluated California state-sponsored health insurance claims data, which included 28,513 HIV-infected and 3,054,696 uninfected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/17\">",
"     17",
"    </a>",
"    ]. The incidence of coronary heart disease (including acute MI, other ischemic heart disease, and coronary atherosclerosis) in patients between the ages of 18 and 24 years was low overall but increased in those infected with HIV compared with the uninfected (relative risk [RR] 6.76, 95% CI 3.36&ndash;13.58 for men and 2.47, 95% CI 1.23&ndash;4.95, for women). The relative risk of coronary heart disease was the not increased in HIV-infected patients over the age of 45 years compared with uninfected populations.",
"   </p>",
"   <p>",
"    In contrast, other analyses have found that the risk of MI alone is elevated in all HIV-infected patients, regardless of age. In a cohort from Kaiser Permanente Northern California, the age-adjusted rate of hospitalization for MI was 4.3 versus 2.9 events per 1000 person years in HIV-infected and uninfected men, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/15\">",
"     15",
"    </a>",
"    ]. A slightly higher overall rate was observed from two tertiary care hospitals in Massachusetts, with 11 versus 7 acute MIs per 1000 person years in HIV-infected and uninfected patients, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/18\">",
"     18",
"    </a>",
"    ]. Even when adjusted for age, gender, race, hypertension, diabetes mellitus, and cholesterol, HIV infection remained associated with a significantly higher incidence of MI (RR 1.75, 95% CI 1.51&ndash;2.02). Similar findings were reported from cohorts in France and Denmark [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14700942\">",
"    <span class=\"h2\">",
"     Effect of antiretroviral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The degrees to which HIV infection itself, increases in traditional risk factors in the HIV-infected population, and ART each contribute to the elevated risk of cardiovascular disease in the HIV-infected population are unknown. However, the preponderance of data suggests that ART is associated with cardiac events. Most studies that show an association between ART and cardiovascular events implicate protease inhibitor (PI) use. (See",
"    <a class=\"local\" href=\"#H742255\">",
"     'Protease inhibitors'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group prospectively studied the incidence of MI in 23,468 HIV-positive patients residing in Australia, Europe, and the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. The overall incidence was low at 3.5 events per 1000 person years, but the incidence increased with cumulative exposure to ART (age adjusted RR 1.26, 95% CI 1.12&ndash;1.41, for each additional year of exposure). The association between MI and ART persisted in models that controlled for total cholesterol and triglyceride levels, suggesting that ART may negatively affect cardiovascular risk independent of its effects on lipid profile. (See",
"    <a class=\"local\" href=\"#H2957201\">",
"     'Effects of antiretroviral therapy on lipid levels'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Subgroup analyses of other retrospective database and cohort studies similarly demonstrated that the relative risk of cardiovascular disease compared with HIV-uninfected patients was greater in HIV-infected patients on ART than those not on therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/17,20,26\">",
"     17,20,26",
"    </a>",
"    ]. One notable exception is the United States Veterans Study that retrospectively evaluated 36,766 HIV-seropositive veterans for risk of cardiovascular or cerebrovascular events [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/27\">",
"     27",
"    </a>",
"    ]. Between 1995 and 2001, the overall mortality decreased by more than 75 percent. The rates of hospital admissions related to cardiovascular or cerebrovascular disease remained constant over time and were comparable between ART treated and untreated patients. These findings persisted in a follow-up study that extended the evaluation period from 1993 to 2003 and included 41,213 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/28\">",
"     28",
"    </a>",
"    ]. Compared with no therapy, there was no significant difference in the rate of serious cardiovascular events after 24, 28, and 72 months of exposure to ART. The reasons for the discrepancy between this and other studies of cardiovascular risk with ART are unknown, although the veteran population may represent a group with higher cardiovascular risk at baseline.",
"   </p>",
"   <p>",
"    The full extent of cardiovascular risk in treated HIV-infected patients will become more discernible as many of the initial cohorts continue to follow patients over time. Since the HIV-infected population is relatively young and actual cardiovascular events are infrequent, many investigators have used surrogate measures of coronary artery disease, such as intima media thickening of the carotid and coronary arteries, as indirect endpoints. The effect of ART on these markers of cardiovascular disease is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/28/40392?source=see_link&amp;anchor=H10000548#H10000548\">",
"     \"Pathogenesis and biomarkers of cardiovascular disease in HIV-infected patients\", section on 'Subclinical atherosclerosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H742255\">",
"    <span class=\"h3\">",
"     Protease inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some, but not all, studies show an association between PIs and cardiovascular events [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/15,21,24,29,30\">",
"     15,21,24,29,30",
"    </a>",
"    ]. In the studies that show a positive association, the PIs evaluated were largely agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/57/20378?source=see_link\">",
"     lopinavir-ritonavir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/62/19433?source=see_link\">",
"     nelfinavir",
"    </a>",
"    , which are no longer considered preferred first-line agents. Furthermore, specific evaluation of individual PIs suggests that the increased risk of cardiovascular disease is not a class effect. Protease inhibitors currently recommended as first-line therapy may not have the increased risk of cardiovascular disease seen with other agents from this class.",
"   </p>",
"   <p>",
"    The following studies illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a follow-up analysis of the D:A:D study, PI use was associated with an increased risk of MI [",
"      <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/24\">",
"       24",
"      </a>",
"      ]. The incidence increased from 1.5 to 6 events per 1000 person years in HIV-infected patients with zero compared with six years of PI exposure, with an adjusted relative risk of 1.16 (95% CI 1.10&ndash;1.23) for every year of PI exposure. Evaluation of the specific drugs in this class suggested that cumulative exposure to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/36/25161?source=see_link\">",
"       indinavir",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/57/20378?source=see_link\">",
"       lopinavir-ritonavir",
"      </a>",
"      was associated with an increased risk of MI, while cumulative exposure to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/62/19433?source=see_link\">",
"       nelfinavir",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3482?source=see_link\">",
"       saquinavir",
"      </a>",
"      was not [",
"      <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/30\">",
"       30",
"      </a>",
"      ]. As noted in the previous D:A:D study, the increased risk of MI in association with lopinavir-",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"       ritonavir",
"      </a>",
"      or indinavir was not fully explained by an increased risk of dyslipidemia in patients with longer exposure to these drugs.",
"     </li>",
"     <li>",
"      After accruing 37,005 person years of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"       atazanavir",
"      </a>",
"      use, the D:A:D study did not show an increased risk of MI or stroke among patients with greater than three years of atazanavir exposure compared with atazanavir-na&iuml;ve individuals [",
"      <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/29\">",
"       29",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link\">",
"       \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In a subset analysis of a French Hospital Database on HIV (34,766 HIV-infected men followed from 1996 to 1999), individuals receiving PIs for more than 18 months had twice the risk of myocardial infarction than those with a shorter exposure to PIs. In a nested case-control study of the same database at a later time, 423 patients who had a MI were matched for age and gender with 884 controls [",
"      <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/31\">",
"       31",
"      </a>",
"      ]. Cumulative exposure to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/57/20378?source=see_link\">",
"       lopinavir-ritonavir",
"      </a>",
"      and amprenavir or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/11/44217?source=see_link\">",
"       fosamprenavir",
"      </a>",
"      was associated with increased risk of MI. One limitation of these studies was an inability to adjust for classic cardiovascular risk factors, including smoking and hypertension.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H742816\">",
"    <span class=\"h3\">",
"     Abacavir",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some studies have evaluated whether the risk of cardiovascular disease may be related to particular agents within the nucleoside reverse transcriptase inhibitor (NRTI) class, specifically",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    . The data surrounding abacavir and myocardial infarction (MI) risk are conflicting without clear conclusion. As an example, in sequential analyses of the D:A:D cohort evaluating 580 events over 178,835 person years, there was an increased risk of MI in those exposed to abacavir and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    within the six months prior to the MI [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/30,32\">",
"     30,32",
"    </a>",
"    ]. This increased risk was not seen with other NRTIs, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    . Criticisms of these studies suggested that abacavir may have been preferentially prescribed to those patients with metabolic syndrome and renal disease, reflecting prescriber bias [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a secondary analysis of the Strategies for Management of Antiretroviral Therapy (SMART) study, a randomized controlled trial to compare continuous versus interrupted ART administration, patients on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    or didanosine without abacavir were compared with patients on all other NRTIs [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/34\">",
"     34",
"    </a>",
"    ]. Preliminary results demonstrated a fourfold risk of MI and a significant increase in other coronary artery disease events, such as stroke, peripheral vascular disease, and congestive heart failure, in association with abacavir use compared with other NRTIs. No such association was found with didanosine. Other studies, including a randomized controlled trial and several observational cohorts also found increased cardiovascular risk with abacavir [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/20,35,36\">",
"     20,35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, not all studies consistently show risk of MI with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    use [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/37-41\">",
"     37-41",
"    </a>",
"    ]. A pooled analysis evaluated the results of 52 industry-sponsored studies in the drug manufacturer's database of HIV trials, which included 9502 patients who received abacavir and 4672 who took other antiretroviral medications [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/38\">",
"     38",
"    </a>",
"    ]. Baseline demographics, including lipids and glucose values, were similar between both groups. Rates of myocardial infarction were comparable among patients exposed or not to an abacavir-containing regimen. Other analyses of data from randomized controlled HIV drug trials arrived at similar conclusions [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/37,39,41\">",
"     37,39,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies evaluating changes in inflammatory or coagulopathic biomarkers upon initiation or discontinuation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    similarly have demonstrated conflicting results [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/34,42\">",
"     34,42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/28/40392?source=see_link&amp;anchor=H25650733#H25650733\">",
"     \"Pathogenesis and biomarkers of cardiovascular disease in HIV-infected patients\", section on 'Pathogenesis of vascular disease in HIV infection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H743048\">",
"    <span class=\"h2\">",
"     Effect of ART interruption",
"    </span>",
"    &nbsp;&mdash;&nbsp;The above studies suggest that longer duration of use of ART, and particularly of some protease inhibitors, is associated with an increased risk of cardiovascular events. However, in the SMART study, a large international study of CD4 cell count-guided antiretroviral treatment interruption, the 2720 patients randomly assigned to the drug interruption arm had an increased risk of major cardiovascular events compared with the 2752 patients in the continuous treatment arm [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/43\">",
"     43",
"    </a>",
"    ]. After approximately 3700 person years of follow-up (median 16 months), there were 79 fatal and nonfatal myocardial infarctions; the event rate in the interruption group was 1.3 per 100 person years compared with 0.8 per 100 person years in the continuous therapy group. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/51/10039?source=see_link&amp;anchor=H9#H9\">",
"     \"Structured treatment interruptions in the HIV-infected patient\", section on 'SMART trial'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, despite evidence that use of ART may be associated with cardiovascular risks, its discontinuation may result in an even greater risk of disease. One possible explanation for this finding is that suppression of HIV itself may be cardioprotective, possibly by reducing proinflammatory cytokines (eg, IL-6) that may play a role in arterial inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/24,44\">",
"     24,44",
"    </a>",
"    ]. Additionally, discontinuation of ART may impact the lipid profile, leading to a reduction in high-density lipoprotein (HDL) cholesterol, a finding that was associated with MI in a case control analysis of SMART study participants [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/28/40392?source=see_link&amp;anchor=H1593221#H1593221\">",
"     \"Pathogenesis and biomarkers of cardiovascular disease in HIV-infected patients\", section on 'Inflammation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24755939\">",
"    <span class=\"h2\">",
"     Effects of CD4 cell count and viral load",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of CD4 cell count and viral load on cardiovascular morbidity is uncertain. In the large D:A:D study, there was no association between nadir CD4 cell count (lowest recorded value) or peak HIV viral load and incidence of myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/24\">",
"     24",
"    </a>",
"    ]. However, other studies have suggested that lower CD4 cell counts and higher HIV viral loads confer greater cardiovascular risk [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/46-48\">",
"     46-48",
"    </a>",
"    ]. In a nested case-control study within the French Hospital Database on HIV, 289 HIV-infected cases who had a prospectively recorded first-time myocardial infarction (MI) were age, gender, and site-matched to 884 HIV-infected controls with no history of MI [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/47\">",
"     47",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cases had a lower mean CD4 cell count nadir than controls (135 versus 177",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"       )",
"      </span>",
"      but current CD4 counts were similar between the two groups.",
"     </li>",
"     <li>",
"      Lower nadir CD4 cell count and higher plasma viral load were associated with a small but statistically significant increased rate of MI, independent of exposure to ART and presence of traditional risk factors.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Furthermore, in a retrospective analysis of 3068 HIV-infected patients in the Netherlands, 57 patients experienced a cardiovascular event (MI, stroke, need for coronary artery intervention) during the nearly 11,000 patient years of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/46\">",
"     46",
"    </a>",
"    ]. Those patients with poor immunological recovery (ie, CD4 cell counts remained &lt;200",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    two years following initiation of ART) had higher estimated five-year cardiovascular event rates (4.7 percent) than those with better CD4 cell count improvements (2 to 2.6 percent). This associated cardiovascular risk was attenuated after adjusting for variables such as age, gender, and prior history of an event.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Asymptomatic myocardial ischemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with HIV infection also appear to have a high rate of silent myocardial ischemia, as detected through electrocardiograms (ECG). In 4841 HIV-infected patients without known coronary artery disease from the SMART study, baseline resting 12-lead ECGs were evaluated for the presence of asymptomatic Q-waves or ST segment depression [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/49\">",
"     49",
"    </a>",
"    ]. The following was found:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ECG evidence for asymptomatic ischemic heart disease was present in 10.9 percent of the participants. The prevalence of symptomatic ischemic heart disease was 3.9 percent.",
"     </li>",
"     <li>",
"      Risk factors for asymptomatic ischemic heart disease were age &ge;60 years, current antihypertensive treatment, and location of study site. European participants and possibly Asian participants were significantly more likely to have asymptomatic ECG changes.",
"     </li>",
"     <li>",
"      Smoking and dyslipidemia were not associated with asymptomatic ischemic heart disease. This suggests that factors in addition to dyslipidemia contribute to increased cardiovascular risk in HIV-infected individuals.",
"     </li>",
"     <li>",
"      There was no clear association between antiretroviral therapy type or duration and ECG evidence of asymptomatic ischemic heart disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2957187\">",
"    <span class=\"h1\">",
"     PREVALENCE OF TRADITIONAL CARDIOVASCULAR RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overall, the classic cardiovascular risk factors of dyslipidemia, hypertension, diabetes, and smoking are common among HIV-infected populations, although the frequency of these comorbidities is not sufficient to explain the overall increased incidence of cardiovascular disease observed in the setting of HIV infection.",
"   </p>",
"   <p>",
"    The presence of major risk factors for cardiovascular disease were evaluated among 1455 women and 931 men participating in two United States-based cohorts of HIV-infected patients (the Women's Interagency HIV Study [WIHS] and the Multicenter AIDS Cohort Study [MACS]) and compared with HIV-uninfected controls [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/50\">",
"     50",
"    </a>",
"    ]. The 10-year risk of developing coronary heart disease (CHD) was estimated using the Framingham risk score equations (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39048?source=see_link&amp;anchor=H9#H9\">",
"     \"Estimation of cardiovascular risk in an individual patient without known cardiovascular disease\", section on 'Framingham risk scores'",
"    </a>",
"    ). This cross-sectional study demonstrated the following results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compared with uninfected controls, HIV-infected individuals more frequently had low high-density lipoprotein cholesterol (HDL-c) and elevated triglycerides.",
"     </li>",
"     <li>",
"      Among HIV-infected men, 2 percent had moderate and 17 percent had high predicted CHD risk, in contrast with HIV-uninfected men (5 and 11 percent, respectively).",
"     </li>",
"     <li>",
"      Among HIV-infected women, 2 percent had moderate and 12 percent had high predicted CHD risk, similar to HIV-uninfected women.",
"     </li>",
"     <li>",
"      The risk of CHD was significantly lower in patients who were treatment-naive compared with those patients taking protease inhibitors (odds ratio 0.57).",
"     </li>",
"     <li>",
"      Predictors of elevated risk also included low income status and elevated body mass index.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A high prevalence of modifiable risk factors was present in the study participants. For example, 40 percent were current smokers. In addition, &gt;40 percent of HIV-infected men and &gt;60 percent of HIV-infected women met criteria for being overweight or obese. However, rates of obesity were less than in HIV-uninfected individuals.",
"   </p>",
"   <p>",
"    A similar study in France had comparable findings. To calculate a predicted risk for myocardial infarction (MI) and CHD, a cohort of HIV-positive individuals using protease inhibitors (APROCO) was compared with a cohort of HIV-negative individuals (WHO MONICA) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/51\">",
"     51",
"    </a>",
"    ]. Compared with the 1038 age-matched HIV-negative individuals, the 274 patients with HIV were more likely to be thin, have elevated triglyceride levels, and low HDL-c levels. The HIV-seropositive individuals were also more likely to smoke. The predicted five-year risk of coronary heart disease was greater among HIV-infected men and women compared with the WHO MONICA cohort (relative risk [RR] 1.20 and 1.59 for men and women, respectively). Of note, only 51 HIV-infected women were included in this study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2957194\">",
"    <span class=\"h2\">",
"     Dyslipidemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies have consistently shown a high prevalence of dyslipidemia among HIV-infected patients, with and without antiretroviral therapy (ART). Abnormalities of lipid metabolism were originally reported in patients with advanced AIDS during the era prior to the introduction of combination ART [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. HIV-infected patients tend to develop decreases in high-density lipoprotein cholesterol (HDL-c) and low-density lipoprotein cholesterol (LDL-c) levels, followed by an increase in plasma triglyceride levels prior to developing AIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/54\">",
"     54",
"    </a>",
"    ]. The degree of viremia may correlate to the amount of triglyceridemia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/54\">",
"     54",
"    </a>",
"    ]. In one prospective study of 50 men from MACS, significant declines in mean serum Total cholesterol (TC), HDL-c, and LDL-c were observed for a mean of eight years after HIV infection when compared to preseroconversion levels [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/55\">",
"     55",
"    </a>",
"    ]. Subsequent initiation of ART was associated with increases in TC and LDL-c, but little change in HDL-c.",
"   </p>",
"   <p>",
"    It is not understood why HIV infection causes a shift in the lipid profile. One postulated mechanism links HIV inhibition of cholesterol efflux from human macrophages [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/56\">",
"     56",
"    </a>",
"    ]. Accumulation of lipids within macrophages occurs via HIV impairment of the ATP-binding cassette transporter A1 (ABCA1)-dependent cholesterol efflux.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2957201\">",
"    <span class=\"h3\">",
"     Effects of antiretroviral therapy on lipid levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;ART contributes to many of the metabolic disturbances seen in HIV-infected patients, in particular lipid abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. There has been great interest in defining which class of antiretroviral agents may be the greatest contributors to dyslipidemia. It is also prudent to distinguish between agents within each class as important differences have emerged with newer agents. The impact of drugs on lipid profiles must be analyzed carefully since elevations of certain fractions (such TC, LDL-c, and triglycerides) are considered unfavorable, whereas elevations in the HDL-c fraction are considered cardioprotective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2957264\">",
"    <span class=\"h4\">",
"     Protease inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dyslipidemia, including hypercholesterolemia and hypertriglyceridemia, develops with the use of most protease inhibitors (PIs), although the effect will vary with the individual PI [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/59\">",
"     59",
"    </a>",
"    ]. Overall, the newer PI regimens that require a lower dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    for boosting (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36473?source=see_link\">",
"     darunavir",
"    </a>",
"    ) tend to have less unfavorable effects on the lipid profile.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2957271\">",
"    <span class=\"h5\">",
"     Ritonavir",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertriglyceridemia is particularly common and may be severe with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. Even the low dose of ritonavir that is used for &ldquo;pharmacokinetic boosting&rdquo; of concurrently used PIs has been associated with lipid abnormalities, although these are less pronounced in regimens that minimize the dose of ritonavir.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"       ritonavir",
"      </a>",
"      (100 mg twice daily) to 20 HIV-seronegative individuals led to significantly increased concentrations of TC (10 percent), LDL-c (16 percent), triglycerides (27 percent), and total HDL-c (17 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A randomized cross-over study compared the effect of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"       ritonavir",
"      </a>",
"      100 mg daily with 100 mg twice daily in 20 HIV-seronegative individuals [",
"      <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/63\">",
"       63",
"      </a>",
"      ]. While both doses were associated with small but significant decreases in HDL-c levels, only the twice-daily ritonavir dose was associated with a significant increase in serum triglycerides.",
"     </li>",
"     <li>",
"      In a cross-sectional analysis that evaluated 7483 HIV-infected individuals participating in the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study who took protease inhibitors, triglyceride levels and the proportion of patients with TC &ge;6.2",
"      <span class=\"nowrap\">",
"       mmol/L",
"      </span>",
"      (approximately 239",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"      were highest in those receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"       ritonavir",
"      </a>",
"      alone or in combination with other protease inhibitors [",
"      <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2957278\">",
"    <span class=\"h5\">",
"     Lopinavir-ritonavir",
"    </span>",
"    &nbsp;&mdash;&nbsp;The addition of lopinavir 400 mg twice daily to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    100 mg twice daily in HIV-seronegative adults did not further exacerbate triglyceride and LDL levels, but did cause additional increases of TC and HDL-c without affecting the",
"    <span class=\"nowrap\">",
"     TC/HDL-c",
"    </span>",
"    ratio. [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2957285\">",
"    <span class=\"h5\">",
"     Atazanavir-ritonavir",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the CASTLE study,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    -",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    compared favorably to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/57/20378?source=see_link\">",
"     lopinavir-ritonavir",
"    </a>",
"    with a backbone of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    among treatment-naive patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/64\">",
"     64",
"    </a>",
"    ]. At 48 weeks, the estimated differences between the two arms (percent change from baseline) were: -9.5 (TC), -11.6 (non-HDL cholesterol), and -25.2 (triglycerides), all statistically significant favoring atazanavir-ritonavir versus lopinavir-ritonavir.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"     Atazanavir",
"    </a>",
"    was also associated with declines in cholesterol and triglyceride levels in treatment-experienced patients who switched to an atazanavir-containing regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/65-67\">",
"     65-67",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/3/49?source=see_link&amp;anchor=H30236047#H30236047\">",
"     \"Management of dyslipidemia and cardiovascular risk in the HIV-infected patient\", section on 'Treatment-experienced patients'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2957292\">",
"    <span class=\"h5\">",
"     Darunavir-ritonavir",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the pooled subgroup analysis of the clinical trials of boosted",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36473?source=see_link\">",
"     darunavir",
"    </a>",
"    (POWER 1 and POWER 2), 15 percent of patients developed elevated triglyceride levels (&gt;8.4",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    compared with seven percent in the comparator PI arms [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/68\">",
"     68",
"    </a>",
"    ]. However, in a head-to-head comparison of darunavir-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    (800",
"    <span class=\"nowrap\">",
"     mg/100",
"    </span>",
"    mg every day) to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/57/20378?source=see_link\">",
"     lopinavir-ritonavir",
"    </a>",
"    dosed either once or twice daily (ie, the ARTEMIS trial), darunavir-ritonavir patients had smaller median increases in triglycerides and total cholesterol than lopinavir-ritonavir patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/69\">",
"     69",
"    </a>",
"    ]. Lipid levels remained below National Cholesterol Education Program cut-offs for darunavir-ritonavir-treated patients during 96 weeks of follow-up.",
"   </p>",
"   <p>",
"    Preliminary data suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36473?source=see_link\">",
"     darunavir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    have clinically comparable effects on lipids. In a trial of 65 treatment-na&iuml;ve patients with normal baseline lipid levels, those randomly assigned to a boosted darunavir-based or a boosted atazanavir-based regimen had similar small increases in triglycerides, TC, and LDL levels after 48 weeks of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2957299\">",
"    <span class=\"h5\">",
"     Other protease inhibitors",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When administered with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"       ritonavir",
"      </a>",
"      (200 mg daily) for pharmacokinetic boosting,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/11/44217?source=see_link\">",
"       fosamprenavir",
"      </a>",
"      is associated with similar lipid profile changes as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/57/20378?source=see_link\">",
"       lopinavir-ritonavir",
"      </a>",
"      in HIV-infected patients [",
"      <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/71\">",
"       71",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/33/19992?source=see_link\">",
"       Tipranavir",
"      </a>",
"      , which requires higher dosing of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"       ritonavir",
"      </a>",
"      (200 mg twice daily) is associated with less favorable lipid profiles than drugs that can be dosed with as little as 100 mg ritonavir daily [",
"      <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/72\">",
"       72",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2957307\">",
"    <span class=\"h4\">",
"     Nonnucleoside reverse transcriptase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonnucleoside reverse transcriptase inhibitor (NNRTI) use is associated with an increase in LDL-c and TC levels compared with the lipid profiles of treatment-na&iuml;ve individuals. However, this increase is counterbalanced by an increase in HDL-c during treatment with NNRTI therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/59\">",
"     59",
"    </a>",
"    ]. The favorable overall lipid profile with NNRTI therapy is particularly pronounced with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    , which is also associated with a decline in triglycerides levels [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/73,74\">",
"     73,74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This superiority of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    among NNRTIs was well illustrated in a large prospective trial (2NN trial) of 706 patients that compared the lipid profiles in patients assigned to either nevirapine or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    , each in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    , for 48 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/75\">",
"     75",
"    </a>",
"    ]. At the end of the treatment period, the increase in HDL-c was significantly higher in the nevirapine arm (43 versus 34 percent). Furthermore, there was a relatively lower increase in TC levels in the nevirapine arm that resulted in a more favorable",
"    <span class=\"nowrap\">",
"     TC/HDL-c",
"    </span>",
"    ratio.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13320?source=see_link\">",
"     Etravirine",
"    </a>",
"    , a newer generation NNRTI, was comparable to placebo in terms of any induced lipid abnormalities in the DUET 1 and 2 trials [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9287?source=see_link\">",
"     \"Clinical trials of HIV antiretroviral therapy: Non-nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2957314\">",
"    <span class=\"h4\">",
"     Nucleoside reverse transcriptase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;First line nucleoside reverse transcriptase inhibitors (NRTIs), such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    , do not have an adverse effect on lipid profiles. In an observational cohort of 2267 patients who started their first ART regimen, tenofovir, in combination with either emtricitabine or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    , was associated with lower levels of TC, LDL-c, and triglycerides compared with other nucleoside reverse transcriptase inhibitors (NRTIs); however, there was no associated benefit on HDL-c levels [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/78\">",
"     78",
"    </a>",
"    ]. Similarly, in an open-label trial of 311 patients with viral suppression on a regimen of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/4/3141?source=see_link\">",
"     abacavir-lamivudine",
"    </a>",
"    with a boosted protease inhibitor, modestly more favorable changes in the total cholesterol (median change of -21 versus -3",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    and LDL cholesterol (median change of -7 versus 2",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    levels were observed among those randomly assigned to switch to a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    backbone compared with those assigned to continue the regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Abnormal lipid profiles have been associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    use, which is no longer a preferred agent for the treatment of HIV infection, although it is still used in resource-limited settings [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. Improvements in hypertriglyceridemia and hypercholesterolemia levels have been demonstrated in patients taking stavudine who subsequently switched to alternative nucleoside analogs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/3/49?source=see_link\">",
"     \"Management of dyslipidemia and cardiovascular risk in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2957328\">",
"    <span class=\"h4\">",
"     Integrase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overall, integrase inhibitors are associated with favorable lipid profiles. A multicenter, randomized, double-blind study of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    , both combined with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    -",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    , was performed in 198 treatment-na&iuml;ve HIV-infected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/82\">",
"     82",
"    </a>",
"    ]. Lipid profiles were basically unchanged in patients randomly assigned to the raltegravir arm. Furthermore, switching from a boosted PI to a raltegravir-based regimen has been associated with decreases in TC, non-HDL-c, and triglycerides in several randomized controlled trials [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/3/49?source=see_link&amp;anchor=H30236047#H30236047\">",
"     \"Management of dyslipidemia and cardiovascular risk in the HIV-infected patient\", section on 'Treatment-experienced patients'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/34/7720?source=see_link&amp;anchor=H27660883#H27660883\">",
"     \"Clinical trials of HIV antiretroviral therapy: Integrase inhibitors\", section on 'Switching from a protease inhibitor to raltegravir'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1726345\">",
"    <span class=\"h4\">",
"     CCR5 antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few data on CCR5 antagonists. In a study of 721 treatment-na&iuml;ve patients who were randomly assigned to take",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    and either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/45/20182?source=see_link\">",
"     maraviroc",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    , fewer patients assigned to maraviroc had grade 3 or 4 laboratory abnormalities, including dyslipidemia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2957342\">",
"    <span class=\"h2\">",
"     Insulin resistance and diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exposure to ART is associated with an increased incidence of insulin resistance and diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/86,87\">",
"     86,87",
"    </a>",
"    ]. In the Multicenter AIDS Cohort Study (MACS), for example, the rate of incident diabetes was 4.7 cases per 100 person years among HIV-infected men using ART compared with 1.4 cases per 100 person years among HIV-seronegative men during the four-year period of observation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/86\">",
"     86",
"    </a>",
"    ]. These metabolic abnormalities can develop independent of changes in body composition [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/88\">",
"     88",
"    </a>",
"    ]. Other cohorts have reported incident diabetes rates among treated HIV-infected patients ranging from 4.4 per 1000 person years to 5 per 100 person years, although these studies have differed in definition of diabetes, ART regimens commonly used, and underlying prevalence of obesity [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/89-92\">",
"     89-92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antiretroviral agents from several classes have been implicated in insulin resistance. In vitro models, animal models, studies of HIV-negative volunteers given protease inhibitors, and clinical trials of protease inhibitors have all demonstrated insulin resistance with these agents [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/93\">",
"     93",
"    </a>",
"    ]. One possible explanation for the association is the observation that protease inhibitors can direct down-regulation of the glucose transporter isoform GLUT4, the major transporter of glucose into fat cells and cardiac and skeletal muscle [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/87\">",
"     87",
"    </a>",
"    ]. Several studies have also noted an association between cumulative exposure to nucleoside reverse transcriptase inhibitors (NRTIs) and an increased risk of insulin resistance and diabetes compared with no NRTI exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/94-96\">",
"     94-96",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/43/26298?source=see_link&amp;anchor=H18#H18\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of HIV-associated lipodystrophy\", section on 'Insulin resistance'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most of these studies evaluated patients using older antiretroviral agents, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/36/25161?source=see_link\">",
"     indinavir",
"    </a>",
"    , which are no longer commonly used in resource-rich settings. It is unclear whether there is a significant risk of diabetes with newer antiretroviral drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H368411\">",
"    <span class=\"h2\">",
"     Hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV-infected patients may have higher rates of hypertension compared with the uninfected. In a study that analyzed billing codes from two large hospitals in Massachusetts, the diagnosis of hypertension was recorded more frequently among patients with HIV infection (21 versus 16 percent in those without HIV infection) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/18\">",
"     18",
"    </a>",
"    ]. This higher prevalence of hypertension may be related to ART, as illustrated by findings of MACS, which followed 5578 HIV-infected men over 19 years and observed a significantly higher systolic blood pressure in those using ART for greater than five years [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/97\">",
"     97",
"    </a>",
"    ]. This increase was not noted if ART was used for less than two years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2957349\">",
"    <span class=\"h2\">",
"     Smoking",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reported rates of current or former smoking among patients with HIV infection from various countries range from 57 to 72 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/18,24,98\">",
"     18,24,98",
"    </a>",
"    ]. These are considerably higher than those seen in the general population.",
"   </p>",
"   <p>",
"    As in the general population, smoking is a major risk factor for cardiovascular disease in HIV-infected individuals. In a cohort study of 2921 HIV-infected patients with free access to antiretroviral therapy who did not use injection drugs, current compared with never smoking was associated with increased mortality from both cardiovascular and all causes (relative risks 4.3, 95% CI 1.4-13.1, and 4.4, 95% CI 3.0-6.7, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/98\">",
"     98",
"    </a>",
"    ]. This translated into a loss of 12.3 years of life among smokers with HIV compared with nonsmokers with HIV, more than double the 5.1 years of life lost attributable to HIV alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H367874\">",
"    <span class=\"h1\">",
"     OTHER CLINICAL RISK MODIFIERS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H367855\">",
"    <span class=\"h2\">",
"     Lipodystrophy syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lipodystrophy syndrome refers to abnormal fat redistribution with lipoatrophy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lipohypertrophy that can occur in HIV-infected patients on antiretroviral therapy (ART). The exact prevalence of this phenomenon is unclear, and there may be different risks for fat atrophy versus accumulation, suggesting discrete processes. Nevertheless, although HIV-infected patients with abnormal fat redistribution may not have overt obesity, it is often associated with significant metabolic abnormalities, including dyslipidemia and insulin resistance, and thus increased cardiovascular risk. As an example, 10-year coronary heart disease (CHD) risk estimates were compared between 91 HIV-infected patients and HIV-seronegative controls from the Framingham Offspring Study who were matched for age, gender, and body mass index [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/99\">",
"     99",
"    </a>",
"    ]. The risk estimates were significantly higher in HIV-infected patients with evidence of fat redistribution. However, when these patients were matched to controls based on waist-to-hip ratio measurements, the CHD risk was similar. Furthermore, HIV-infected patients without evidence of fat redistribution did not have an increased CHD risk compared with controls. These data suggest that increased cardiovascular risk in HIV-seropositive patients may be associated with fat redistribution itself.",
"   </p>",
"   <p>",
"    The epidemiology of lipodystrophy and its association with dyslipidemia and insulin resistance are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/43/26298?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of HIV-associated lipodystrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H368450\">",
"    <span class=\"h3\">",
"     Metabolic syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Not surprisingly, since treatment of HIV infection is associated with central fat accumulation, dyslipidemia, and insulin resistance, studies that evaluate HIV-infected populations for the presence of metabolic syndrome have found high rates [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/100-102\">",
"     100-102",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32954?source=see_link&amp;anchor=H2#H2\">",
"     \"The metabolic syndrome (insulin resistance syndrome or syndrome X)\", section on 'Definition'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the INITIO trial, a study of 881 HIV-infected patients who initiated ART, the prevalence of metabolic syndrome at baseline was approximately 8 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/89\">",
"     89",
"    </a>",
"    ]. During three years of follow-up, the incidence of metabolic syndrome was 8 to 12",
"    <span class=\"nowrap\">",
"     cases/100",
"    </span>",
"    person years, depending on the criteria used. Both baseline and incident metabolic syndrome were associated with the development of diabetes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2959230\">",
"    <span class=\"h2\">",
"     Hepatitis C virus coinfection",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a few studies that suggest that elevations in cholesterol levels may be blunted in patients co-infected with hepatitis C virus (HCV); however, it is not clear whether this has a direct bearing on rates of cardiovascular disease in HIV-positive individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/103-107\">",
"     103-107",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective study of 357 HIV-infected patients and 115",
"      <span class=\"nowrap\">",
"       HIV/HCV-coinfected",
"      </span>",
"      patients taking ART, the mean changes in cholesterol were significantly lower in coinfected patients than in patients with HIV alone [",
"      <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/104\">",
"       104",
"      </a>",
"      ]. Eight percent of HIV-infected patients had to initiate lipid-lowering agents while none of the",
"      <span class=\"nowrap\">",
"       HIV/HCV-coinfected",
"      </span>",
"      patients started treatment.",
"     </li>",
"     <li>",
"      Another retrospective study evaluated the incidence and risk factors associated with the development of lipid abnormalities in 282 patients initiating ART [",
"      <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/105\">",
"       105",
"      </a>",
"      ]. No differences were noted between patients who were exposed to nonnucleoside reverse transcriptase inhibitors versus protease inhibitors; however, a protective effect against developing hypercholesterolemia was seen among patients who were HCV-seropositive.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The mechanism for these observations is unclear but may be related to impaired cholesterol synthesis in patients with HCV coinfection. Nevertheless, any benefit to the lipid profile may be offset by modulation of other risk factors. As an example, among 19,424 HIV-infected patients retrospectively analyzed in the Veterans Administration HIV Clinical Case Registry from 1996 to 2005, those with HCV coinfection were less likely to have abnormal lipid profiles but more likely to be smokers and to have hypertension and diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/106\">",
"     106",
"    </a>",
"    ]. Furthermore, in an analysis of data prospectively collected from 32,395 HIV-positive individuals in the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study, the risk for development of myocardial infarction was similar for",
"    <span class=\"nowrap\">",
"     HIV/HCV-coinfected",
"    </span>",
"    patients compared to HIV-monoinfected patients after adjusting for potential confounders [",
"    <a class=\"abstract\" href=\"UTD.htm?26/1/26650/abstract/107\">",
"     107",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With more effective and widespread treatment of HIV in resource-rich settings, the overall incidence of AIDS or death related to infection by HIV has decreased dramatically. However, as patients are living longer, cardiovascular disease has emerged as an important cause of death in HIV-infected patients. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The incidence of coronary artery disease, specifically myocardial infection, in HIV-infected patients is low overall, but it is higher than that seen in HIV-uninfected patients matched for age and gender. (See",
"      <a class=\"local\" href=\"#H14700934\">",
"       'Incidence compared with uninfected populations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The degrees to which HIV infection itself, increases in traditional risk factors in the HIV-infected population, and antiretroviral therapy (ART) each contribute to the elevated risk of cardiovascular disease in the HIV-infected population are unknown. The preponderance of data suggest that ART, particularly protease inhibitor use, is significantly associated with cardiac events. Protease inhibitors currently recommended as first-line therapy, however, may not increase the risk of cardiovascular disease as do other agents from this class. Some data suggest an increased risk of myocardial infarction with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"       abacavir",
"      </a>",
"      (a nucleoside reverse transcriptase inhibitor) use, although this is not consistent across studies. (See",
"      <a class=\"local\" href=\"#H14700942\">",
"       'Effect of antiretroviral therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Despite the apparent negative impact of ART on cardiovascular risk, discontinuation of ART is associated with an even greater risk of cardiovascular events, suggesting a protective effect of suppression of HIV replication. (See",
"      <a class=\"local\" href=\"#H743048\">",
"       'Effect of ART interruption'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HIV-infected patients tend to develop decreases in high-density lipoprotein cholesterol (HDL-c) and low-density lipoprotein cholesterol (LDL-c) levels, followed by an increase in plasma triglyceride levels, independent of any exposure to ART. Certain antiretroviral agents, particularly",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"       ritonavir",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"       stavudine",
"      </a>",
"      , can exacerbate these unfavorable changes in lipid profile. Protease inhibitor regimens that require a lower dose of ritonavir for boosting (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"       atazanavir",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36473?source=see_link\">",
"       darunavir",
"      </a>",
"      ) tend to have less unfavorable effects on the lipid profile. Treatment with nonnucleoside reverse transcriptase inhibitors, particularly",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"       nevirapine",
"      </a>",
"      , is associated with increases in the HDL-c and decreases in the triglyceride level. (See",
"      <a class=\"local\" href=\"#H2957194\">",
"       'Dyslipidemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Exposure to ART is associated with an increased incidence of insulin resistance, in isolation and in association with other metabolic abnormalities seen in the lipodystrophy syndrome. (See",
"      <a class=\"local\" href=\"#H2957342\">",
"       'Insulin resistance and diabetes'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H367855\">",
"       'Lipodystrophy syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is a high prevalence of other traditional cardiovascular risk factors among this patient population, such as hypertension and smoking. (See",
"      <a class=\"local\" href=\"#H368411\">",
"       'Hypertension'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2957349\">",
"       'Smoking'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some studies have demonstrated that coinfection with hepatitis C may be associated with a lower risk of developing hypercholesterolemia during antiretroviral therapy, although it does not appear that this affects overall cardiovascular risk. (See",
"      <a class=\"local\" href=\"#H2959230\">",
"       'Hepatitis C virus coinfection'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/1\">",
"      Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/2\">",
"      May MT, Sterne JA, Costagliola D, et al. HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet 2006; 368:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/3\">",
"      Dub&eacute; MP, Johnson DL, Currier JS, Leedom JM. Protease inhibitor-associated hyperglycaemia. Lancet 1997; 350:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/4\">",
"      Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12:F51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/5\">",
"      Barbaro G. Highly active antiretroviral therapy-associated metabolic syndrome: pathogenesis and cardiovascular risk. Am J Ther 2006; 13:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/6\">",
"      Stein JH, Hsue PY. Inflammation, immune activation, and CVD risk in individuals with HIV infection. JAMA 2012; 308:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/7\">",
"      Neuhaus J, Angus B, Kowalska JD, et al. Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV. AIDS 2010; 24:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/8\">",
"      Antiretroviral Therapy Cohort Collaboration. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 2010; 50:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/9\">",
"      Mocroft A, Reiss P, Gasiorowski J, et al. Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. J Acquir Immune Defic Syndr 2010; 55:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/10\">",
"      Grinspoon SK, Grunfeld C, Kotler DP, et al. State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary. Circulation 2008; 118:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/11\">",
"      Kamin DS, Grinspoon SK. Cardiovascular disease in HIV-positive patients. AIDS 2005; 19:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/12\">",
"      Grover SA, Coupal L, Gilmore N, Mukherjee J. Impact of dyslipidemia associated with Highly Active Antiretroviral Therapy (HAART) on cardiovascular risk and life expectancy. Am J Cardiol 2005; 95:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/13\">",
"      Currier JS, Lundgren JD, Carr A, et al. Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation 2008; 118:e29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/14\">",
"      Tseng ZH, Secemsky EA, Dowdy D, et al. Sudden cardiac death in patients with human immunodeficiency virus infection. J Am Coll Cardiol 2012; 59:1891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/15\">",
"      Klein D, Hurley LB, Quesenberry CP Jr, Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr 2002; 30:471.",
"     </a>",
"    </li>",
"    <li>",
"     Klein D, Hurley L, Sidney S, et al. Hospitalizations for CHD and MI among Northern California HIV + and HIV - Men: Additional Follow-up, Changes in Practice and Framingham Risk Scores. Presented at the Thirteenth Conference on Retroviruses and Opportunistic Infections, Denver, CO February 5-8, 2006, Abstract 737.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/17\">",
"      Currier JS, Taylor A, Boyd F, et al. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr 2003; 33:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/18\">",
"      Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007; 92:2506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/19\">",
"      Lang S, Mary-Krause M, Cotte L, et al. Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population. AIDS 2010; 24:1228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/20\">",
"      Obel N, Thomsen HF, Kronborg G, et al. Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population-based cohort study. Clin Infect Dis 2007; 44:1625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/21\">",
"      Durand M, Sheehy O, Baril JG, et al. Association between HIV infection, antiretroviral therapy, and risk of acute myocardial infarction: a cohort and nested case-control study using Qu&eacute;bec's public health insurance database. J Acquir Immune Defic Syndr 2011; 57:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/22\">",
"      Chow FC, Regan S, Feske S, et al. Comparison of ischemic stroke incidence in HIV-infected and non-HIV-infected patients in a US health care system. J Acquir Immune Defic Syndr 2012; 60:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/23\">",
"      Freiberg MS, Chang CC, Kuller LH, et al. HIV Infection and the Risk of Acute Myocardial Infarction. JAMA Intern Med 2013; :1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/24\">",
"      DAD Study Group, Friis-M&oslash;ller N, Reiss P, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356:1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/25\">",
"      Friis-M&oslash;ller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349:1993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/26\">",
"      Mary-Krause M, Cotte L, Simon A, et al. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003; 17:2479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/27\">",
"      Bozzette SA, Ake CF, Tam HK, et al. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003; 348:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/28\">",
"      Bozzette SA, Ake CF, Tam HK, et al. Long-term survival and serious cardiovascular events in HIV-infected patients treated with highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2008; 47:338.",
"     </a>",
"    </li>",
"    <li>",
"     d'Arminio Monforte A, Reiss P, Ryom L, et al. ATV-containing ART is not associated with an increased risk of cardio- or cerebro-vascular events in the D:A:D study. Presented at the 19th annual Conference on Retroviruses and Opportunistic Infections, Seattle, WA, March 5-8, 2012; abstract #823.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/30\">",
"      Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis 2010; 201:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/31\">",
"      Lang S, Mary-Krause M, Cotte L, et al. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med 2010; 170:1228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/32\">",
"      D:A:D Study Group, Sabin CA, Worm SW, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008; 371:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/33\">",
"      Aberg JA, Ribaudo H. Cardiac risk: not so simple. J Infect Dis 2010; 201:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/34\">",
"      Strategies for Management of Anti-Retroviral Therapy/INSIGHT, DAD Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008; 22:F17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/35\">",
"      Martin A, Bloch M, Amin J, et al. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial. Clin Infect Dis 2009; 49:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/36\">",
"      Choi AI, Vittinghoff E, Deeks SG, et al. Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons. AIDS 2011; 25:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/37\">",
"      Ribaudo HJ, Benson CA, Zheng Y, et al. No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT. Clin Infect Dis 2011; 52:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/38\">",
"      Brothers CH, Hernandez JE, Cutrell AG, et al. Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects. J Acquir Immune Defic Syndr 2009; 51:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/39\">",
"      Cruciani M, Zanichelli V, Serpelloni G, et al. Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data. AIDS 2011; 25:1993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/40\">",
"      Bedimo RJ, Westfall AO, Drechsler H, et al. Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era. Clin Infect Dis 2011; 53:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/41\">",
"      Ding X, Andraca-Carrera E, Cooper C, et al. No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis. J Acquir Immune Defic Syndr 2012; 61:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/42\">",
"      Martin A, Amin J, Cooper DA, et al. Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trial. AIDS 2010; 24:2657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/43\">",
"      Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren J, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/44\">",
"      Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5:e203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/45\">",
"      Duprez DA, Kuller LH, Tracy R, et al. Lipoprotein particle subclasses, cardiovascular disease and HIV infection. Atherosclerosis 2009; 207:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/46\">",
"      van Lelyveld SF, Gras L, Kesselring A, et al. Long-term complications in patients with poor immunological recovery despite virological successful HAART in Dutch ATHENA cohort. AIDS 2012; 26:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/47\">",
"      Lang S, Mary-Krause M, Simon A, et al. HIV replication and immune status are independent predictors of the risk of myocardial infarction in HIV-infected individuals. Clin Infect Dis 2012; 55:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/48\">",
"      Bucher HC, Richter W, Glass TR, et al. Small dense lipoproteins, apolipoprotein B, and risk of coronary events in HIV-infected patients on antiretroviral therapy: the Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 2012; 60:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/49\">",
"      Carr A, Grund B, Neuhaus J, et al. Asymptomatic myocardial ischaemia in HIV-infected adults. AIDS 2008; 22:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/50\">",
"      Kaplan RC, Kingsley LA, Sharrett AR, et al. Ten-year predicted coronary heart disease risk in HIV-infected men and women. Clin Infect Dis 2007; 45:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/51\">",
"      Sav&egrave;s M, Ch&ecirc;ne G, Ducimeti&egrave;re P, et al. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis 2003; 37:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/52\">",
"      Grunfeld C, Kotler DP, Shigenaga JK, et al. Circulating interferon-alpha levels and hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1991; 90:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/53\">",
"      Shor-Posner G, Basit A, Lu Y, et al. Hypocholesterolemia is associated with immune dysfunction in early human immunodeficiency virus-1 infection. Am J Med 1993; 94:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/54\">",
"      Grunfeld C, Pang M, Doerrler W, et al. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992; 74:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/55\">",
"      Riddler SA, Smit E, Cole SR, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA 2003; 289:2978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/56\">",
"      Mujawar Z, Rose H, Morrow MP, et al. Human immunodeficiency virus impairs reverse cholesterol transport from macrophages. PLoS Biol 2006; 4:e365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/57\">",
"      Dube M, Fenton M. Lipid abnormalities. Clin Infect Dis 2003; 36:S79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/58\">",
"      Pujari SN, Dravid A, Naik E, et al. Lipodystrophy and dyslipidemia among patients taking first-line, World Health Organization-recommended highly active antiretroviral therapy regimens in Western India. J Acquir Immune Defic Syndr 2005; 39:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/59\">",
"      Fontas E, van Leth F, Sabin CA, et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis 2004; 189:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/60\">",
"      Sullivan AK, Nelson MR. Marked hyperlipidaemia on ritonavir therapy. AIDS 1997; 11:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/61\">",
"      Danner SA, Carr A, Leonard JM, et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. N Engl J Med 1995; 333:1528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/62\">",
"      Shafran SD, Mashinter LD, Roberts SE. The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations. HIV Med 2005; 6:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/63\">",
"      Collot-Teixeira S, De Lorenzo F, Waters L, et al. Impact of different low-dose ritonavir regimens on lipids, CD36, and adipophilin expression. Clin Pharmacol Ther 2009; 85:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/64\">",
"      Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 2008; 372:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/65\">",
"      M&ouml;bius U, Lubach-Ruitman M, Castro-Frenzel B, et al. Switching to atazanavir improves metabolic disorders in antiretroviral-experienced patients with severe hyperlipidemia. J Acquir Immune Defic Syndr 2005; 39:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/66\">",
"      Johnson M, Grinsztejn B, Rodriguez C, et al. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS 2006; 20:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/67\">",
"      Gatell J, Salmon-Ceron D, Lazzarin A, et al. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results. Clin Infect Dis 2007; 44:1484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/68\">",
"      Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007; 369:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/69\">",
"      Mills AM, Nelson M, Jayaweera D, et al. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS 2009; 23:1679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/70\">",
"      Aberg JA, Tebas P, Overton ET, et al. Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks. AIDS Res Hum Retroviruses 2012; 28:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/71\">",
"      Eron J Jr, Yeni P, Gathe J Jr, et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet 2006; 368:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/72\">",
"      Gathe J, Cooper DA, Farthing C, et al. Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial. Clin Infect Dis 2006; 43:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/73\">",
"      van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004; 363:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/74\">",
"      Maggi P, Bellacosa C, Carito V, et al. Cardiovascular risk factors in patients on long-term treatment with nevirapine- or efavirenz-based regimens. J Antimicrob Chemother 2011; 66:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/75\">",
"      van Leth F, Phanuphak P, Stroes E, et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med 2004; 1:e19.",
"     </a>",
"    </li>",
"    <li>",
"     Haubrich R, Cahn P, De Smedt G, et al and the DUET-1 study group. DUET-1: Week 48 results of a Phase III randomized double-blind trial to evaluate the efficacy and safety of etravirine (ETR; TMC 125) versus placebo in 612 treatment-experienced HIV-1-infected patients. Presented at the 15th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 3-6, 2008; abstract #790.",
"    </li>",
"    <li>",
"     Johnson M, Campbell T, De Smedt G, and the DUET-2 study group. DUET-2: Week 48 results of a Phase III randomized double-blind trial to evaluate the efficacy and safety of etravirine (ETR; TMC 125) versus placebo in 591 treatment-experienced HIV-1-infected patients. Presented at the 15th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 3-6, 2008; abstract #791.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/78\">",
"      Crane HM, Grunfeld C, Willig JH, et al. Impact of NRTIs on lipid levels among a large HIV-infected cohort initiating antiretroviral therapy in clinical care. AIDS 2011; 25:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/79\">",
"      Campo R, Dejesus E, Bredeek UF, et al. SWIFT: Prospective 48-Week Study to Evaluate Efficacy and Safety of Switching to Emtricitibine/Tenofovir From Lamivudine/Abacavir in Virologically Suppressed HIV-1 Infected Patients on a Boosted Protease Inhibitor Containing Antiretroviral Regimen. Clin Infect Dis 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/80\">",
"      Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/81\">",
"      Galli M, Ridolfo AL, Adorni F, et al. Body habitus changes and metabolic alterations in protease inhibitor-naive HIV-1-infected patients treated with two nucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 2002; 29:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/82\">",
"      Markowitz M, Nguyen BY, Gotuzzo E, et al. Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr 2007; 46:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/83\">",
"      Mart&iacute;nez E, Larrousse M, Llibre JM, et al. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. AIDS 2010; 24:1697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/84\">",
"      Eron JJ, Young B, Cooper DA, et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet 2010; 375:396.",
"     </a>",
"    </li>",
"    <li>",
"     Saag M, Ive P, Heera J, et al. A multicenter, randomized, double-blind, comparative trial comparing novel CCR5 antagonist, maraviroc versus efavirenz, both in combination with zidovudine and lamivudine in the treatment of antiretroviral naive subjects with HIV: week 48 of the MERIT study. 4th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention: July 22-25, 2007, Sidney, Australia.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/86\">",
"      Brown TT, Cole SR, Li X, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med 2005; 165:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/87\">",
"      Rudich A, Ben-Romano R, Etzion S, Bashan N. Cellular mechanisms of insulin resistance, lipodystrophy and atherosclerosis induced by HIV protease inhibitors. Acta Physiol Scand 2005; 183:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/88\">",
"      Mulligan K, Grunfeld C, Tai VW, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 2000; 23:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/89\">",
"      Wand H, Calmy A, Carey DL, et al. Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. AIDS 2007; 21:2445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/90\">",
"      Markovic O, J&ouml;rnvall H. Tomato and Aspergillus niger pectinesterases. Correlation of differences in existing reports: large species variations. Protein Seq Data Anal 1990; 3:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/91\">",
"      De Wit S, Sabin CA, Weber R, et al. Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetes Care 2008; 31:1224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/92\">",
"      Ledergerber B, Furrer H, Rickenbach M, et al. Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study. Clin Infect Dis 2007; 45:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/93\">",
"      Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005; 352:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/94\">",
"      Tien PC, Schneider MF, Cole SR, et al. Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study. AIDS 2007; 21:1739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/95\">",
"      Brown TT, Li X, Cole SR, et al. Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study. AIDS 2005; 19:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/96\">",
"      Butt AA, McGinnis K, Rodriguez-Barradas MC, et al. HIV infection and the risk of diabetes mellitus. AIDS 2009; 23:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/97\">",
"      Seaberg EC, Mu&ntilde;oz A, Lu M, et al. Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003. AIDS 2005; 19:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/98\">",
"      Helleberg M, Afzal S, Kronborg G, et al. Mortality attributable to smoking among HIV-1-infected individuals: a nationwide, population-based cohort study. Clin Infect Dis 2013; 56:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/99\">",
"      Hadigan C, Meigs JB, Wilson PW, et al. Prediction of coronary heart disease risk in HIV-infected patients with fat redistribution. Clin Infect Dis 2003; 36:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/100\">",
"      Wu PY, Hung CC, Liu WC, et al. Metabolic syndrome among HIV-infected Taiwanese patients in the era of highly active antiretroviral therapy: prevalence and associated factors. J Antimicrob Chemother 2012; 67:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/101\">",
"      Sobieszczyk ME, Hoover DR, Anastos K, et al. Prevalence and predictors of metabolic syndrome among HIV-infected and HIV-uninfected women in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr 2008; 48:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/102\">",
"      Worm SW, Friis-M&oslash;ller N, Bruyand M, et al. High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome. AIDS 2010; 24:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/103\">",
"      Lapadula G, Torti C, Paraninfo G, et al. Influence of hepatitis C genotypes on lipid levels in HIV-positive patients during highly active antiretroviral therapy. Antivir Ther 2006; 11:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/104\">",
"      Cooper CL, Mills E, Angel JB. Mitigation of antiretroviral-induced hyperlipidemia by hepatitis C virus co-infection. AIDS 2007; 21:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/1/26650/abstract/105\">",
"      Patroni A, Torti C, Tomasoni L, et al. Effect of highly active antiretroviral therapy (HAART) and hepatitis C Co-infection on hyperlipidemia in HIV-infected patients: a retrospective longitudinal study. HIV Clin Trials 2002; 3:451.",
"     </a>",
"    </li>",
"    <li>",
"     Bedimo RJ, Westfall A, Saag M, et al. HCV is an Independent Risk Factor for Acute Myocardial Infarction among HIV-Infected Veterans. Presented at the 15th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 3-6, 2008; abstract #1083.",
"    </li>",
"    <li>",
"     Weber R, Sabin C, Lundgren J, et al and the D:A:D study group. Hepatits Virus Co-infections and Risk of Diabetes Mellitus and Myocardial Infartion in HIV-infected Persons: The D:A:D Study. Presented at the 15th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 3-6, 2008; abstract #1082.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3734 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-201.248.109.99-8AB70CBFC1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_1_26650=[""].join("\n");
var outline_f26_1_26650=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H41\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      CARDIOVASCULAR DISEASE ASSOCIATED WITH HIV INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14700934\">",
"      Incidence compared with uninfected populations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14700942\">",
"      Effect of antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H742255\">",
"      - Protease inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H742816\">",
"      - Abacavir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H743048\">",
"      Effect of ART interruption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24755939\">",
"      Effects of CD4 cell count and viral load",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Asymptomatic myocardial ischemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2957187\">",
"      PREVALENCE OF TRADITIONAL CARDIOVASCULAR RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2957194\">",
"      Dyslipidemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2957201\">",
"      - Effects of antiretroviral therapy on lipid levels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2957264\">",
"      Protease inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H2957271\">",
"      - Ritonavir",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H2957278\">",
"      - Lopinavir-ritonavir",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H2957285\">",
"      - Atazanavir-ritonavir",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H2957292\">",
"      - Darunavir-ritonavir",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H2957299\">",
"      - Other protease inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2957307\">",
"      Nonnucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2957314\">",
"      Nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2957328\">",
"      Integrase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1726345\">",
"      CCR5 antagonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2957342\">",
"      Insulin resistance and diabetes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H368411\">",
"      Hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2957349\">",
"      Smoking",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H367874\">",
"      OTHER CLINICAL RISK MODIFIERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H367855\">",
"      Lipodystrophy syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H368450\">",
"      - Metabolic syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2959230\">",
"      Hepatitis C virus coinfection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/40/25226?source=related_link\">",
"      Cardiac involvement in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/34/7720?source=related_link\">",
"      Clinical trials of HIV antiretroviral therapy: Integrase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9287?source=related_link\">",
"      Clinical trials of HIV antiretroviral therapy: Non-nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/43/26298?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of HIV-associated lipodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39048?source=related_link\">",
"      Estimation of cardiovascular risk in an individual patient without known cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/3/49?source=related_link\">",
"      Management of dyslipidemia and cardiovascular risk in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/28/40392?source=related_link\">",
"      Pathogenesis and biomarkers of cardiovascular disease in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=related_link\">",
"      Selecting antiretroviral regimens for the treatment naive HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/51/10039?source=related_link\">",
"      Structured treatment interruptions in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32954?source=related_link\">",
"      The metabolic syndrome (insulin resistance syndrome or syndrome X)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_1_26651="Differentiation of Uhl anomaly from ARVC";
var content_f26_1_26651=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F66378&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F66378&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differentiation of Uhl anomaly from arrhythmogenic right ventricular cardiomyopathy (ARVC)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Uhl anomaly",
"       </td>",
"       <td class=\"subtitle1\">",
"        ARVC",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Family history",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Yes (some patients)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gender, ratio M:F",
"       </td>",
"       <td>",
"        1.3:1",
"       </td>",
"       <td>",
"        2.9:1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Age at presentation",
"       </td>",
"       <td>",
"        Infancy + childhood",
"       </td>",
"       <td>",
"        Adolescence + older",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Usual mode of presentation",
"       </td>",
"       <td>",
"        Heart failure",
"       </td>",
"       <td>",
"        Arrhythmia, syncope, or sudden death",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Exercise-induced deaths",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        Uncommon",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pathology",
"       </td>",
"       <td>",
"        Areas of complete absence of myocardium of parietal wall of RV: endocardial and epicardial layers are directly opposed",
"       </td>",
"       <td>",
"        Localized patchy replacement of the parietal wall of RV by fibrous and fatty tissue",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ARVC: Arrhythmic right ventricular cardiomyopathy.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_1_26651=[""].join("\n");
var outline_f26_1_26651=null;
var title_f26_1_26652="Rx syphilis";
var content_f26_1_26652=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F50435&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F50435&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatment options for syphilis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Early (primary, secondary, or latent less than one year)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Drugs of choice",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Penicillin G benzathine 2.4 million units IM once*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Alternatives",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Doxycycline",
"        <sup>",
"         &bull;",
"        </sup>",
"        100 mg oral twice daily for 14 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Late (more than one year's duration, cardiovascular, gumma, late-onset)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Drugs of choice",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Penicillin G benzathine 2.4 million units IM weekly for three weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Alternatives",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Doxycycline",
"        <sup>",
"         &bull;",
"        </sup>",
"        100 mg oral twice daily for four weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Neurosyphilis",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Drugs of choice",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Penicillin G 3 to 4 million units IV every four hours or 24 million units continuous IV infusion for 10 to 14 days",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Penicillin G procaine 2.4 million units IM daily",
"        <strong>",
"         plus",
"        </strong>",
"        probenecid 500 mg four times daily oral, both for 10 to 14 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Alternatives",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ceftriaxone 2 g IV once daily for 10 to 14 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Congenital",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Drugs of choice",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Penicillin G 50,000 units/kg every 8 to 12 hours for 10 to 14 days",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Penicillin G procaine 50,000 units/kg IM daily for 10 to 14 days",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Some experts recommend a repeat dose after seven days, especially in patients with HIV infection or pregnant women.",
"     <br>",
"      &bull; Not recommended in pregnancy.",
"      <br>",
"       &Delta; Patients allergic to penicillin should be desensitized and treated with penicillin.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Drugs for sexually transmitted diseases. Treat Guidel Med Lett 2004; 2:67.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_1_26652=[""].join("\n");
var outline_f26_1_26652=null;
var title_f26_1_26653="Findings cyanotic heart disease";
var content_f26_1_26653=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F79941&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F79941&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Typical physical examination, chest radiography, and electrocardiography findings in some forms of cyanotic heart disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Diagnosis",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Physical exam",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Chest radiography",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Electrocardiogram",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Incidence (100,00 live birth)*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        S2",
"       </td>",
"       <td class=\"subtitle2\">",
"        Murmur",
"       </td>",
"       <td class=\"subtitle2\">",
"        Heart size",
"       </td>",
"       <td class=\"subtitle2\">",
"        PBF",
"       </td>",
"       <td class=\"subtitle2\">",
"        Percent RAA",
"       </td>",
"       <td class=\"subtitle2\">",
"        QRS axis",
"       </td>",
"       <td class=\"subtitle2\">",
"        Hypertrophy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TGA",
"       </td>",
"       <td>",
"        single",
"       </td>",
"       <td>",
"        none",
"       </td>",
"       <td>",
"        &uarr;",
"       </td>",
"       <td>",
"        &uarr;",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        90-150",
"       </td>",
"       <td>",
"        nml",
"       </td>",
"       <td>",
"        21",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TOF",
"       </td>",
"       <td>",
"        single",
"       </td>",
"       <td>",
"        sys",
"       </td>",
"       <td>",
"        boot",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        90-150",
"       </td>",
"       <td>",
"        nml",
"       </td>",
"       <td>",
"        20-26",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HLHS",
"       </td>",
"       <td>",
"        single",
"       </td>",
"       <td>",
"        sys",
"       </td>",
"       <td>",
"        &uarr;",
"       </td>",
"       <td>",
"        vc",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        90-150",
"       </td>",
"       <td>",
"        &darr; LV forces",
"       </td>",
"       <td>",
"        16",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PA-IVS",
"       </td>",
"       <td>",
"        single",
"       </td>",
"       <td>",
"        sys",
"       </td>",
"       <td>",
"        &uarr;&uarr;",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        30-90",
"       </td>",
"       <td>",
"        LVH, RAE",
"       </td>",
"       <td>",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PS",
"       </td>",
"       <td>",
"        single",
"       </td>",
"       <td>",
"        sys",
"       </td>",
"       <td>",
"        &uarr;",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        30-90",
"       </td>",
"       <td>",
"        LVH, RAE",
"       </td>",
"       <td>",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TAPVC",
"       </td>",
"       <td>",
"        split",
"       </td>",
"       <td>",
"        sys",
"       </td>",
"       <td>",
"        &uarr;, nl",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        &uarr;, vc",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        90-150",
"       </td>",
"       <td>",
"        RAE",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tricuspid atresia",
"       </td>",
"       <td>",
"        single",
"       </td>",
"       <td>",
"        sys",
"       </td>",
"       <td>",
"        &uarr;",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        -30- -90",
"       </td>",
"       <td>",
"        LVH, RAE",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Truncus arteriosus",
"       </td>",
"       <td>",
"        single",
"       </td>",
"       <td>",
"        sys/&plusmn;dias",
"       </td>",
"       <td>",
"        &uarr;",
"       </td>",
"       <td>",
"        &uarr;",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        90-150",
"       </td>",
"       <td>",
"        nml",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ebstein's",
"       </td>",
"       <td>",
"        split",
"       </td>",
"       <td>",
"        sys",
"       </td>",
"       <td>",
"        &uarr;&uarr;",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        90-150",
"       </td>",
"       <td>",
"        RAE",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Note: This table represents the common presentation of each lesion. Variations do occur. For example, tricuspid atresia usually is associated with a small ventricular septal defect and pulmonary stenosis; some patients with this diagnosis can have a large ventricular septal defect, no pulmonary stenosis, and increased pulmonary blood flow.",
"    <div class=\"footnotes\">",
"     dias: diastolic; HLH: hypoplastic left heart syndrome; LV: left ventricular; LVH: left ventricular hypertrophy; nl: normal; nml: normal for neonate (right ventricular predominance); PA-IVS: pulmonary atresia intact ventricular septum; PBF: pulmonary blood flow; PS: pulmonary stenosis; RAA: right aortic arch; RAE: right atrial enlargement; sys: systolic; TAPVC: total anomalous pulmonary venous connection; TGA-IVS: d-transposition of the great arteries, intact ventricular septum; TOF: tetralogy of Fallot; vc: venous congestion.",
"     <br>",
"      * Incidence from report of New England Regional Infant Cardiac Program. Pediatrics 1980; 65:375.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       Patients with TAPVC associated with pulmonary venous observation have normal heart size and venous congestion on the chest radiography while those without obstruction usually have cardiomegaly and increased pulmonary blood flow.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_1_26653=[""].join("\n");
var outline_f26_1_26653=null;
var title_f26_1_26654="Iron deficiency anemia and RA";
var content_f26_1_26654=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F56354&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F56354&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 487px\">",
"   <div class=\"ttl\">",
"    Identification of iron deficiency anemia in rheumatoid arthritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 467px; height: 387px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Mulherin D, Skelle M, Saunders A, et al. J Rheumatol 1996; 23:237.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_1_26654=[""].join("\n");
var outline_f26_1_26654=null;
var title_f26_1_26655="Plain abdominal film of retained surgical sponge";
var content_f26_1_26655=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F64696&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F64696&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Plain abdominal film of retained surgical sponge",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 301px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_1_26655=[""].join("\n");
var outline_f26_1_26655=null;
